 
CLINICAL STUDY PROTOCOL : Randomized, Double -Blind, Placebo -Controlled, Three -
Arm, 12 -Month, Safety and  Efficacy Study of Hydromethylthionine Mesylate (LMTM) 
Monotherapy in Subjects with  Alzheimer’s Disease Followed by a 12 -Month Open -Label 
Treatment  
Study N umber : [STUDY_ID_REMOVED]  
Date: 16-Jun-2023  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol: TRx -237-[ADDRESS_977529] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 1 of 145   
 
CLINICAL STUDY PROTOCOL  
 
Randomiz ed, Double -Blind, Placeb o-Control led, Three -Arm, 12-Month, Safety and 
Efficacy Study of  Hydromethylthionine Mesylate  (LMTM) Monotherapy in Sub jects wi th 
Alzheimer’s D isease  Followed by a 12 -Month Open -Label Treatment  
 
STUDY  CODE: TRx -237-039 
 
STUDY PHASE: 3 
 
VERSION 7.1 DATED 16 JUNE 2023 
 
 
Previous Version s: 
VERSION 7.[ADDRESS_977530] -04 
Shenton House  
Singapore 068805  
Republic of Singapore   Operational Location:  
[ADDRESS_977531]  
Aberdeen AB2 4 5RP 
Scotland, [LOCATION_006]  
Tel: +44 (0) [ADDRESS_977532] party without 
written authorization  from TauRx.  
Protocol: TRx -237-[ADDRESS_977533] -[ADDRESS_977534] ENROLLMENT AND WITHDRAWAL  ................................ ................... 54 
11.1  Inclusion Criteria  ................................ ................................ ................................ ...54 
11.2  Exclusion Criteria  ................................ ................................ ................................ ..56 
11.3  Re-screening  ................................ ................................ ................................ .......... 59 
Protocol: TRx -237-[ADDRESS_977535] -003558 -17  
TABLE OF CONTENTS - continued  
  PAGE  
Protocol Version 7.1 CONFIDENTIAL  Page 3 of 145 11.4  Discontinuations / Withdrawals  ................................ ................................ ............. 60 
11.4.1  Handling of Subjects Who Discontinue Study Drug  ........................... 60 
11.4.2  Handling of Study Discontinuation / Withdrawal  ............................... 60 
11.4.3  Replacements  ................................ ................................ ....................... 61 
12 STUDY DRUG  ................................ ................................ ................................ ................. 61 
12.1  Treatments Administered: Form, Dosage and Administration  ............................... [ADDRESS_977536] RESTRICTIONS  .................. 66 
13.1  AChEI and/or Memantine  ................................ ................................ ...................... 66 
13.2  Drugs with Serotonergic Potential  ................................ ................................ ......... 67 
13.3  CYP and P -gp Substrates  ................................ ................................ ....................... 67 
13.4  Drugs Used to Manage Behavioral Disturbance  ................................ .................... 67 
13.5  Other Medications  ................................ ................................ ................................ ..68 
13.6  Dietary Tyramine  ................................ ................................ ................................ ...68 
13.7  Contraceptive Measures  ................................ ................................ ......................... 68 
13.8  Folate and Vitamin B 12 ................................ ................................ ........................... 69 
14 TERMINATION OF THE STUDY  ................................ ................................ ............... 70 
15 STUDY ASSESSMENTS  ................................ ................................ ................................ 70 
15.1  Demographic Data/Medical History  ................................ ................................ ......70 
15.2  Assessment of Efficacy  ................................ ................................ .......................... 70 
15.2.1  Raters  ................................ ................................ ................................ ...70 
15.2.2  Instruments  ................................ ................................ ........................... 72 
15.3  Imaging Assessments and Procedures  ................................ ................................ ...75 
15.3.1  General Considerations  ................................ ................................ ........ 75 
15.3.2  Site Selection and Qualification ................................ ........................... 76 
15.3.3  Imaging Methods for Efficacy  ................................ ............................. 76 
15.4  Safety Assessments and Procedures ................................ ................................ .......78 
15.5  Other Assessments  ................................ ................................ ................................ .79 
15.5.1  MT Concentration  ................................ ................................ ................ 79 
15.5.2  Genotypi[INVESTIGATOR_007]  ................................ ................................ ........................... 80 
Protocol: TRx -237-[ADDRESS_977537] -003558 -17  
TABLE OF CONTENTS - continued  
  PAGE  
Protocol Version 7.1 CONFIDENTIAL  Page 4 of 145 16 ADVERSE EVENTS AND SAFETY  ................................ ................................ ............. 80 
16.1  Definition of AEs, Period of Observation, and Recording of AEs  ........................ 80 
16.2  Eliciting Adverse Event Information  ................................ ................................ .....81 
16.3  Categorizing Intensity  ................................ ................................ ............................ 81 
16.4  Investigator’s Brochure  ................................ ................................ .......................... [ADDRESS_977538] Abnormalities  ................................ ................................ ................... 86 
16.11.1  Hemolytic Anemia  ................................ ................................ ............... 86 
16.11.2  Lens Discoloration  ................................ ................................ ............... 86 
16.11.3  Other Safety Reasons Requiring Discontinuation of Study 
Drug  ................................ ................................ ................................ .....86 
16.12  Urgent Safety Measures  ................................ ................................ ......................... 87 
17 STATISTICAL ANALYSIS  ................................ ................................ ........................... 87 
17.1  Efficacy Endpoints  ................................ ................................ ................................ .88 
17.1.1  Primary Efficacy Endpoints for Double -Blind Treatment 
Period  ................................ ................................ ................................ ...88 
17.1.2  Secondary Efficacy Endpoints for Double -Blind Treatment 
Period  ................................ ................................ ................................ ...89 
17.1.3  Secondary Endpoint for Open -Label, Delayed -Start Phase  ................. 89 
17.2  Number of Subjects and Sample Size Calculation  ................................ ................ 89 
17.3  Analysis Populations  ................................ ................................ .............................. 90 
17.4  Clinical Efficacy and Imaging Analysis  ................................ ................................ 91 
17.4.1  Hypothesis ................................ ................................ ............................ 91 
17.4.2  MITT (FDA) Analysis  ................................ ................................ ......... 92 
17.4.3  ITT (EMA) Analysis  ................................ ................................ ............ 93 
17.4.4  Estimands  ................................ ................................ ............................. 93 
17.4.5  Handling of Missing and Incomplete Data  ................................ .......... 95 
17.4.6  Open -Label, Delayed -Start Analysis  ................................ ................... 96 
17.4.7  Dose Response Analyses  ................................ ................................ .....96 
17.4.8  Responder Analyses  ................................ ................................ ............. 96 
17.4.9  Time -to-Event Analyses  ................................ ................................ ......97 
17.4.10  Subgroup Analyses  ................................ ................................ .............. 98 
17.4.11  Sensitivity Analyses  ................................ ................................ ............. 98 
17.5  Exploratory Analyses  ................................ ................................ ........................... 100 
17.6  Demographic and Baseline Characteristics  ................................ ......................... 102 
17.7  Safety Analysis ................................ ................................ ................................ .....102 
Protocol: TRx -237-[ADDRESS_977539] -[ADDRESS_977540] Procedures ................................ ................................ ............................. 108 
21.2  COVID -19 Risk Assessment ................................ ................................ ................ 109 
22 DOCUMENTATION  ................................ ................................ ................................ .....110 
23 PUBLICATION  ................................ ................................ ................................ ............. 111 
24 INDEMNITY, INSURANCE, AND COMPENSATION  ................................ ........... 111 
25 ADMINISTRATIVE AND FINANCIAL AGREEMENT  ................................ ......... 111 
26 STUDY ADMINISTRATION  ................................ ................................ ...................... 111 
27 REFERENCES  ................................ ................................ ................................ ............... 113 
28 APPENDICES  ................................ ................................ ................................ ................ 117 
28.1  Disallowed Treatments and Windows  ................................ ................................ .. 117 
28.1.1  Disallowed Medical Food / Medications Beginning 90 Days 
Before Baseline and During the Study ................................ ............... 117 
28.1.2  Disallowed Medications Beginning 60 Days Before Baseline 
and During the Study  ................................ ................................ ......... 117 
28.1.3  Disallowed Treatments Beginning 28 Days Before Baseline 
and During the Study  ................................ ................................ ......... 117 
28.2  Study Blood Assessments  ................................ ................................ ....................  118 
28.3  Education / Occupation  ................................ ................................ ........................  119 
28.3.1  Education  ................................ ................................ ........................... 119 
28.3.2  Occupation  ................................ ................................ ......................... 119 
28.4  Summary of Changes to the Protocol  ................................ ................................ ..120 
28.4.1  Protocol Version 2.0  ................................ ................................ .......... 120 
28.4.2  Protocol Version 2.1  ................................ ................................ .......... 121 
28.4.3  Protocol Version 3.0  ................................ ................................ .......... 122 
28.4.4  Protocol Version 4.0  ................................ ................................ .......... 127 
28.4.5  Protocol Version 4.1  ................................ ................................ .......... 129 
28.4.6  Protocol Version 5.0  ................................ ................................ .......... 130 
28.4.7  Protocol Version 5.1  ................................ ................................ .......... 137 
Protocol: TRx -237-[ADDRESS_977541] -003558 -17  
TABLE OF CONTENTS - continued  
  PAGE  
Protocol Version 7.1 CONFIDENTIAL  Page 6 of 145 28.4.8  Protocol Version 6.0  ................................ ................................ .......... 138 
28.4.9  Protocol Version 7.0  ................................ ................................ .......... 142 
Protocol: TRx -237-[ADDRESS_977542] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 7 of 145  
2 GCP COMPLIANCE STATEMENT  
This study will be conducted in compliance with the protocol, the principles contained in the 
Declaration of Helsinki , International Council for  Harmonisation  of Technical Requirements 
for Pharmaceuticals for Human Use  (ICH)  Integrated Addendum to ICH E6(R 1): Guideline 
for Good Clinical Pra ctice  (GCP)  E6(R2) (or ICH  E6(R1) in those juri sdictions where ICH 
E6(R2) is not yet implemented by [CONTACT_50756]), and the applicable regulat ory 
requirement(s).  
 
  
Protocol: TRx -237-[ADDRESS_977543] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 8 of 145 3 PROTOCOL APPROVAL  
 
Sponsor Signatory  
 
 
 
 
 
 
 
 
 
  
 
 
 Signature [CONTACT_717327]: TRx -237-[ADDRESS_977544] -[ADDRESS_977545] Lead(s)  
 
TauRx Therapeutics Ltd.  
[ADDRESS_977546]:  
Emergency Scientific and Medical Services Global 
(ESMS  Global)  
A current list of contact [CONTACT_717165]/Pharmacovigilance Department  
Farnborough Business Park – [ADDRESS_977547],  
Farnborough,  
Hampshire, GU14 7BF  
[LOCATION_008]  
Fax: +[PHONE_3639]  
Email: [EMAIL_1604]  
Investigational Medicinal Product Manufacturer 
(including packaging, labelling and distribution)  
Pi[INVESTIGATOR_717123].  
Pi[INVESTIGATOR_717124], Northumberland  NE61 3YA  
[LOCATION_008]  
Tel: [PHONE_14937]  Rater Training and  Approval, Scale Management,  
Electronic Capture of Clinical Efficacy Data, Central 
Review of Assessments   
MedAvante -ProPhase Inc.  
[ADDRESS_977548]  
Hamilton, New Jersey [ZIP_CODE]  
[LOCATION_002]  
Tel.: +[PHONE_14930]   
Data Management  
Synteract, Inc.  
[ADDRESS_977549]  
Carlsbad, C alifornia  [ZIP_CODE]  
[LOCATION_002]  
Tel: +[PHONE_14931]  Randomization and Trial Supply Management 
System  
Bioclinica, Inc.  
[ADDRESS_977550]  
Audubon, Pennsylvania [ZIP_CODE]  
[LOCATION_002]  
Tel: +[PHONE_14932]  
 

Protocol: TRx -237-[ADDRESS_977551] -[ADDRESS_977552]  
Indianapolis, Indiana [ZIP_CODE]  
[LOCATION_002]  
Tel: +[PHONE_14933]  
Fax: +[PHONE_14934]  
 
Europe  
   Labcorp Central Laboratory Services S.à r.l.  
7 Rue Moïse -Marcinhès  
Meyrin, Geneva 1217  
Switzerland  
Tel: [PHONE_9367]  
Fax: [PHONE_9368]  Magnetic Resonance Imaging (MRI)  Imaging   
 
 
Suitably Qualified Vendor  
 
 
Positron Emission Tomography (PET)  
Invicro  
[ADDRESS_977553], Suite 8A  
New Haven, Connecticut [ZIP_CODE]  
[LOCATION_002]  
Tel: +[PHONE_14935]  
Fax: +[PHONE_14936]  
Methylthioninium (MT) Concentrations  
Charles River Laboratories Edinburgh Ltd.  
(cross -validation purposes only)  
Elphinstone Research Centre  
Tranent, East Lothian, EH33 2NE  
[LOCATION_008]  
Tel: +44 (0) [ADDRESS_977554] 110, 104EJ Amsterdam,  
The Netherlands  
Tel: +31 (0)88 101 2450  
 
 
Statistics  
Cytel Inc  
Geneva Branch  
Route de Prebois 20  
1215 Geneva  
Switzerland  
Tel: [PHONE_14938]  
  

Protocol: TRx -237-[ADDRESS_977555] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 11 of 145 5 INVESTIGATOR SIGNATURE [CONTACT_717328] [CONTACT_31300], I agree to the conditions relating to this study as set out in this protocol 
(TRx -237-039 Version 7.1 dated  XX June 2023 ). 
 
I agree to conduct this study according to the principles contained in the Declaration of 
Helsinki , International Council for  Harmonisation  of Technical Requirements for 
Pharmaceuticals for Human Use  (ICH ) Integrated Addendum to ICH E6(R 1): Guideli ne for 
Good Clinical Practice ( GCP ) E6(R2)  (or ICH E6(R1) in those juri sdictions where ICH 
E6(R2) is not yet implemented by [CONTACT_50756]) , the National Institute on Aging 
(NIA), the Alzheimer’s Association (AA),  and the applicable regulatory requirement (s). 
 
I fully understand that any changes instituted by [CONTACT_717166] a deviation  from  the 
protocol.  
 
I agree to adhere to the protocol in all circumstances other than where necessary to protect the 
well-being of the subject.  
 
I will ensure that the drugs supplied by [CONTACT_717167].  
 
 
Study Site Principal Investigator’s Name, Title, Address and Contact [CONTACT_7171]:  
 
______________________________________ _____________________  
_______________________________________ ____________________  
_______________________________________ ____________________  
_______________________________________ ____________________  
_______________________________________ ____________________  
_______________________________________ ____________________  
_______________________________________ ____________________  
_______________________________________ ____________________  
_______________________________________ ____________________  
 
 
Signature: [CONTACT_1782]:  
 
 
  
Protocol: TRx -237-[ADDRESS_977556] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 12 of 145 6 SYNOPSIS  
Name [CONTACT_790] / Company: TauRx Therapeutics Ltd (TauRx)  
Name [CONTACT_2756]:  LMTM  (TRx0237) Film -coated Tablets, 4 mg  
Name [CONTACT_3261] (Drug Substance): Hydromethylthionine Mesylate  
Number and Title of Study: TRx-237-039: Randomized,  Double-Blind, Placebo-Controlled, Three -Arm, 
12-Month, Safety and Efficacy Study of Hydromethylthionine Mesylate  (LMTM)  Monotherapy in Subjects with 
Alzheimer’s Disease Followed by a 12 -Month Open -Label Treatment  
Study Site(s): Sites  in North America ([LOCATION_002] and Canada)  and Europe  
Study Duration: The total duration of participation for an individual 
subject will be up to 120 weeks, including a Screening period of up to 
16 weeks (112 days), a double -blind t reatment period  of [ADDRESS_977557] open -label 
visit may be subsequently offered an oppo rtunity to receive treatment 
with LMTM in a separate Expanded  Access Program (EAP).  Phase of Development:  
Phase 3 
Objectives  
The primary objectives of the study pertain to the randomized, double -blind treatment period , listed below. The 
secondary objectives are presented separately for the double -blind treatment period  and the  open -label,  delayed -
start phase . 
 
Primary (double -blind treatment period) : 
1. To compare the LMTM dose of 16 mg/day  with the placebo group on the following co -primary 
endpoints:  
a. Alzheimer’s Disease Assessment Scale, 11 -item version ( ADAS -cog 11) 
b. Alzheimer’s Disease Cooperative Study - Activities of Daily Living, 23 -item version 
(ADCS -ADL 23)  
2. To assess the safety and tolerability of LMTM 16 mg/day given for up to 52 weeks 
 
Secondary (double -blind treatment period):  
3. To compare the LMTM dose of 16 mg/day with the placebo group in annualized rate of whole brain  
atrophy over 52 weeks  as measured by [CONTACT_458626] (MRI ) and quantified using the 
Boundary Shift Integral (BSI)  
4. To compare the LMTM dose of 16 mg/day with the placebo group  in temporal lobe 
18F-fluorodeoxyglucose positron emission tomography (18F-FDG -PET) change in Standardized Uptake 
Value Ratio (SUVR) (normalized to pons) over 52 week s, restricted to subjects with Clinical Dementia 
Rating (CDR ) 0.5 at Screening , if a predefined threshold is reached for a sufficient number of subjects 
providing data  
5. To compare the LMTM dose of 8 mg/day with the placebo group  in temporal lobe 18F-FDG -PET change 
in SUVR (normalized to pons) over [ADDRESS_977558] 0.5  at Screening , if a 
predefined threshold is reached for a sufficient number of subjects providing data  
6. To compare the LMTM dose of 8 mg/day with the placebo group  on the co -primary endpoints ( ADAS -
cog 11 and ADCS -ADL 23)  
7. To compare the LMTM doses of 8 and 16 mg/day with the placebo group in annualized rate of temporal 
and parietal lobe atrophy over 52 weeks  as measured by [CONTACT_717168]  
8. To assess the safety and tolerability of LMTM 8 mg/day given for up to 52 weeks 
 
Secondary (open-label , delayed -start p hase) : 
9. To determine if there is a difference in disease progression on the co -primary clinical endpoints and the 
MRI imaging endpoint for subjects who started treatment in the double -blind treatment phase and those 
who started treatment in the open -label, delayed -start phase (referred to as “early” and “late” LMTM 
starters, respectively)  
a. Only ADAS -cog 11 will serve as a secondary endpoint ; ADCS -ADL 23 and other imaging 
endpoints are exploratory with the aim to be directionally supportive  
Protocol: TRx -237-[ADDRESS_977559] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 13 of 145 Name [CONTACT_790] / Company: TauRx Therapeutics Ltd (TauRx)  
Name [CONTACT_2756]:  LMTM  (TRx0237) Film -coated Tablets, 4 mg  
Name [CONTACT_3261] (Drug Substance): Hydromethylthionine Mesylate  
10. To evaluate safety and tolerability of LMTM given for up to 104 weeks  
 
Sensitivity analyses, including the evaluation of the secondary imaging endpoints to  confirm the absence  of 
treatment unblinding , are described in  the protocol and Statistical Analysis Plan (SAP).  
 
Population Pharmacokinetic (PK) analyses will be performed to estimate PK exposure in each subjec t for use in 
the evaluation of exposure -response relationship s; these will be defined in a separate Population PK SAP or a 
dedicated section of the main SAP.  
 
Additional exploratory analyses are described in the protocol and SAP. These include analyses of:  
1. ADAS -cog 13 
2. A new composite endpoint /composite endpoints  based on selected item of the Alzheimer’s Disease 
Assessment Scale, 13 -item version (ADAS -cog 13) and the ADCS -ADL 23, analy zed at 9 months and 12 
months to evaluate its usefulness for future studies  (for all subjects and also separately for subjects with 
CDR 0.[ADDRESS_977560] 1 -2 at Screening) .  
3. MMSE  
4. CDR sum of boxes  
5. Influence of Apolipoprotein E ( ApoE ) genotype  
Study Design  
This is a two -phase outpatient study of LMTM administered as monotherapy in 500 subjects with early to mild -
moderate Alzheimer’s disease (AD): a r andomized, double -blind, placebo -controlled, 52-week treatment period 
followed by a 52 -week  open -label  phase that represents a modified delayed start of treatment. Subjects who are 
not receiving concomitant AChEI and/or memantine, for whom legally acceptable  informed consent has been 
obtained and who are found eligible on the basis of screening evaluations, will be randomly assigned at Baseline 
to receive either LMTM 16 mg/day, LMTM 8  mg/day , or placebo;  the drug supplies for the placebo group will 
include tablets containing a urinary dis colorant, methylthioninium chloride (MTC), 4 mg. T he primary treatment 
group comparisons during the double -blind treatment phase are of LMTM 16 mg/day and placebo. Following 
completion of the 52 -week treatment period, all subjects (regardless of randomized treatment assignment or 
response) will continue o pen-label treatment with LMTM 16 mg/day for a further 52 weeks ; prior treatment 
assignment will not be unbl inded . 
 
The Screening period is to be up to 9 weeks  for subjects who are not receiving an AChEI and/or memantine at 
the time of signing the consent (Initial Screening Visit, Visit 1) . For subjects who are receiving an AChEI and/or 
memantine, the Screening period may be extended for up to a further 6 weeks , 15 weeks in total  (+7 days at 
Sponsor discretion),  to allow for the performance of the necessary screening tests prior to the discontinuation of 
an AChEI and/or memantine and to permit a washout of at least [ADDRESS_977561] dose prior to the baseline  
assessments  (inclu sive of  the baseline 18F-FDG -PET scan in subjects who have a screening CDR of 0.5) . 
 
A sufficient number of  subjects will be recruited from sites in North America  and Europe such that 
approximately 500 subjects are enrolled . Beginning with Protocol Version  5.0, approximately 450 subjects are to 
be enrolled and randomized  at the Baseline/Randomization Visit (Visit 2)  to the LMTM 16mg/day 
(200 subjects), LMTM 8mg/day (50 subjects), or placebo  (200 subjects) groups . Randomization will be  stratified 
by [CONTACT_926] ( Mini -Mental State Examination [ MMSE ] 16-19, 20-25, or 26 -27 at study level for those randomized 
to Protoc ol Version  5.0 and above ), by [CONTACT_717169]/or memantine, and by [CONTACT_11338] (grouped into 
North America  or Europe ). Subjects will be assigned to the MMSE severity groups based on screening MMSE 
score with a target ratio of approximately 2:3:1 (MMSE 16 -19, 20 -25, 26-27, respectively)  for those randomized 
to Protocol Version 5.0 and above ; to achieve this target, enrollment will be monitored and controlled at the site 
level for high recruiting sites (i.e., sites projected to recruit more than 10% of the subjects) and capped as needed 
at the stud y level . 
 
Eight post-Baseline visits are scheduled : five during the double -blind  treatment period  (Visit 3: safety , and Visits 
4, 5, 6 , and 7 : imaging, efficacy, and safety ) and three during the open -label, delayed -start phase (Visits 8 
[telephone contact [INVESTIGATOR_13701]], 9, and 10) . A summary of modifications to the post -Baseline visits that may be 
implemented in response to the Coronavirus Disease 2019  Public Health Emergency (hereafter referred to as 
COVID -19) is described in the body of the protocol. Unscheduled visits may occur as needed for assessment, or 
Protocol: TRx -237-[ADDRESS_977562] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 14 of 145 Name [CONTACT_790] / Company: TauRx Therapeutics Ltd (TauRx)  
Name [CONTACT_2756]:  LMTM  (TRx0237) Film -coated Tablets, 4 mg  
Name [CONTACT_3261] (Drug Substance): Hydromethylthionine Mesylate  
upon early termination . In addition, subjects are to be followed as needed for the resolution or stabilization of an 
adverse event (AE), including following the last dose, consistent with the investigator’s medical judgement .   
 
Subjects who drop out after randomization will not be replaced  (however, the study partner may be replaced  if 
the current one withdraws/drops out ); subjects will be encouraged to continue with study visits until the 
scheduled completion  of the double -blind treatment period (Visit 7) . Only subjects who continue in the study 
and receive LMTM treatment  up to and including the last visit (Visit 10) without the addition of concomitant 
AChEIs and/or memantine may be eligible for a separate  EAP . 
Sample Size  
Sample size estimations to achieve 90% power (two -sided alpha = 0.05) to detect a difference between LMTM 
16 mg/day and placebo, the primary treatment group comparison in the double -blind treatment period, have been 
performed for the two co -primary clinical endpoints. These assume a withdrawal rate of  20% to 25% over 
52 weeks. The study sample size of approximately 450  subjects enrolled under Protocol Version 5.0 and above 
(200 subjects in each treatment group, with a further 50  subjects for secondary analyses of an LMTM 8 -mg/day 
group) is based on the ADCS -ADL 23, since a larger sample size is required  for this rating scale  to achieve the 
target power.  
 
Based on  an estimated decline in ADCS -ADL [ADDRESS_977563] deviation (SD) of 8.[ADDRESS_977564] >90% power to detect a reduction in decline of 3.[ADDRESS_977565] of 5. 0 ± 1.6 (mean ±  standard error) units 
in the pooled studies TRx -237-005/TRx -237-015.  
 
Based on an estimated decline in ADAS -cog 11 over 52 weeks  based on pooled information from studies 
TRx-237-005/TRx -237-015 in the control arm of 6.5 units with an estimated SD of 5.9 units, 200 subjects per 
treatment arm provide > 90% power to detect a reduction in decline of 2. [ADDRESS_977566] based on pooled studies TRx -237-005/TRx -237-015 is 
5.2 ± 1.3 (mean ±  standard error) units.  
 
With 200 subjects randomized to the primary comparison in the double -blind treatment period  under Protocol 
Version 5.0 and above , 160 to 170 subjects  per arm will enter the  open -label, delayed -start treatment phase 
assuming the 20-25% drop-out rates mentioned above. Assuming a further 10% drop out in  the delayed -start 
phase , the key secondary  analysis to demonstrate disease modification by [CONTACT_717170]  a 
non-inferiority margin of -2 ADAS -cog 11 units has approximately 80% power.  
Subject Population  
Inclusion Criteria:  
1. AD, encompassing probable AD and mild cognitive impairment  due to AD (MCI -AD) based on  2011  
National Institute on Aging  (NIA) / Alzheimer’s Association  (AA) criteria: 
• All cause dementia and probable AD  (probable AD)  
In brief, subjects with probable AD dementia must have insidious onset, worsening impairment in 
at least two cognitive areas (learning and recall, language, executive function, visuospatial skills), 
sufficient to significantly interfere with work or usual activities, that is not explained by [CONTACT_477883], 
drugs, major psychiatric disorder, medical illness, cerebrovascular disease, other forms of 
dementia, or neurological disorder. The accuracy of the diagnosis will be confirmed independently  
by [CONTACT_717171] 
• MCI -AD 
In subjects with MCI -AD, there should be evidence of concern about a change in cognition, in 
comparison with the person’s previous level verified by a knowledgeable informant or clinician. 
Other mild cognitive deficits may also be present, but there must b e preservation of independence 
in functional abilities. Subjects should not meet the criteria for dementia. The cognitive changes 
must be mild and there must be no evidence of a significant impairment in social or occupational 
functioning. Impairmen ts must not be explained by [CONTACT_477883], drugs, major psychiatric disorder, 
medical illness, cerebrovascular disease, other forms of dementia, or neurological disorder.  
2. Documented PET scan that is positive for amyloid; if most recent PET scan was performed >3 years 
prior to Screening and was negative, it may be repeated ( a negative amyloid PET scan within the 
3 years prior to Screening is exclusionary ) 
Protocol: TRx -237-[ADDRESS_977567] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 15 of 145 Name [CONTACT_790] / Company: TauRx Therapeutics Ltd (TauRx)  
Name [CONTACT_2756]:  LMTM  (TRx0237) Film -coated Tablets, 4 mg  
Name [CONTACT_3261] (Drug Substance): Hydromethylthionine Mesylate  
3. MMSE  score of 16-27 (inclusive) at Screening , subject to stratification requirements  
4. Global CDR  score of 0.5 to 2 at Screening  (if 0.5, including a score of > 0 in one of the functional 
domains : Community Affairs, Home and Hobbies, or Personal Care)  
5. Age < [ADDRESS_977568] meet one of the following: 
• Surgically sterile (hysterectomy, bilateral salpi[INVESTIGATOR_1656] / oophorectomy) for at least 6 months 
minimum 
• Have undergone  bilateral tubal occlusion / ligation at least 6 months prior 
• Post-menopausal  for at least 1 year 
• Using adequate contraception (a barrier method [such as condo m, diaphragm or cervical/vault cap] 
with spermicidal foam, gel, film, cream, or suppository; intrauterine device [IUD] or system, or oral 
or long -acting  injected or implanted hormonal contraceptives for at least 90 days prior to Baseline; 
or vasect omized partner [with the appropr iate post-vasect omy documentation of the absence of 
spermatozoa in the ejaculate]) or true abstinence (when this is in line with the preferred and usual 
lifestyle of the subject); subjects must be competent to use adequate contraception and to agree to 
continue to maintain adequate contraception throughout participation in the study (including up to 
[ADDRESS_977569] dose of study drug)  
7. Subject and/or, in the case of reduced decision -making capacity, legally acceptable representative(s)  
(LAR(s) ), consistent with local and national law, is able to read, understand and provide written 
informed consent in the designated  language of the study site  
8. Has one (or more) identified  adult study partner  (i.e., a caregiver or informant)  who meets the following 
criteria: 
• Either lives with the subject, or in the investigator’s opi[INVESTIGATOR_1649], the extent of contact [CONTACT_717172] ( e.g., sees the subject on average for ≥1  hour/day 
≥3 days/week ) 
• Is willing to provide written informed consent for his/her own participation  
• Is able to read, understand , and speak the designated language at the study site  
• Agrees to accompany the subject to each study visit  
• Is able to verify compliance with study drug  
9. The subject must not have been taking either an AChEI , i.e., donepezil, galantamine, or rivastigmine, 
and/or memantine, for at least 60 days  at the time of the baseline  assessment s 
• Subjects never previously treated with an AChEI and/ or memantine may be enrolled if initiation of 
treatment with these medications is not planned for the time period during which the subject will be 
participating in this study 
10. Able to comply with the study procedures in the view of the investigator 
Exclusion Criteria:  
1. Significant central nervous system (CNS) disorder other than probable AD or MCI -AD, e.g., Lewy 
body dementia, Parkinson’s disease, multiple sclerosis, progressive supranuclear palsy, 
hydrocephalus, Huntington’s disease, any condition directly or indirectly caused by [CONTACT_717173] (TSE), Creutzfeldt -Jakob Disease (CJD),  variant Creutzfeldt -Jakob 
Disease (vCJD), or new variant Creutzfeldt -Jakob Disease (nvCJD)  
2. Significant intracranial focal or vascular pathology seen on brain MRI scan that would, based on the 
independent reviewer imaging evaluation, lead to a diagnosis other than probable AD  or MCI -AD, 
including but not limited to:  
• Large confluent white matter hyperintense lesio ns (i.e., Fazekas score of 3)  
• Other focal brain lesions judged clinically relevant by [CONTACT_093]  
• Evidence of a prior or current macrohemorrhage  
3. Clinical evidence or history of any of the following (within specified period prior to Baseline): 
• Cerebrovascular accident (2 years)  
• Transient ischemic attack (6 months)  
• Significant head injury , for example,  associated loss of consciousness, skull fracture or persisting 
cognitive impairment (2 years)  
Protocol: TRx -237-[ADDRESS_977570] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 16 of 145 Name [CONTACT_790] / Company: TauRx Therapeutics Ltd (TauRx)  
Name [CONTACT_2756]:  LMTM  (TRx0237) Film -coated Tablets, 4 mg  
Name [CONTACT_3261] (Drug Substance): Hydromethylthionine Mesylate  
• Other unexplained or recurrent loss of consciousness (2 years)  
4. Diagnosed with epi[INVESTIGATOR_002] (a single prior seizure  >6 months prior to Screening,  is considered acceptable)  
5. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria met (for any of the 
following within specified period):  
• Major depressive disorder (current)  
• Schizophrenia (lifetime)  
• Other psychotic disorders, bipolar disorder (within the past 5 years)  
• Substance (including alcohol) related disorders ( within the past 2 years ) 
6. Metal implants in the head (except dental), pacemaker, cochlear implants, or any other non -removable 
items that are contraindications to MRI. MRI compatible prosthetics, clips, stents, or any other device 
proven to be compatible are allowed  
7. Resides in hospi[INVESTIGATOR_717125] (residence in low grade 
assisted living facility where there is sufficient autonomy to permit valid evaluation of activities of 
daily living is allowed so long as it is not mandate d by [CONTACT_717174])  
8. Any physical disability that would prevent completion of study procedures or assess ments ( e.g., 
blindness or significant uncorrected visual impairment, deafness or significant hearing loss not 
corrected by [CONTACT_148289], non -AD-related speech impairment)  
9. History of swallowing difficulties (note: study drug should be swallowed whole and MUST NOT be 
broken, crushed, chewed, or dissolved in fluids prior to ingestion)  
10. Pregnant or breastfeeding  
11. Glucose -6-phosphate dehydrogenase (G6PD) deficiency based on World Health Organization 
classification (<60% of normal, i.e., <6.1 U/g hemoglobin [Hgb])  
12. History of significant hematological abnormality or current acute or chronic clinically significant 
abnormality, including:  
• History of hemoglobinopathy, myelodysplastic syndrome, hemolytic anemia, or splenectomy  
• Screening Hgb value (confirmed upon repeat) below age/sex appropriate lower limit of the central 
laboratory normal range  
Subjects in whom folate is <4.0 ng/mL may be entered into the study provided folate supplementation 
(approximately 1 mg/day) is initiated and maintained for the duration of the study . 
Subjects in whom vitamin B 12 is <150 pg/mL can be allowed if the investigator confirms that it does 
not affect the cognitive state of the subject and that the subject is supplemented as appropriate prior to 
the initiation of study drug  
13. Abnormal se rum chemistry laboratory value at Screening deemed to be clinically significant  by [CONTACT_1275] . In addition, subjects with either of the following abnormalities must be excluded:  
• Creatinine clearance <30 mL/min, estimated by [CONTACT_717175]  
• Thyroid stimulating hormone (TSH) above laboratory normal range (subject may be treated [if 
clinically indicated based on further laboratory testing] and re -screened after 90 days)  
14. Clinically significant cardiovascular disease or abnormal assessments (based on the investigator’s 
interpretation of the locally obtained electrocardiogram [ECG]) such as:  
• Hospi[INVESTIGATOR_252671] (acute myocardial infarction or unstable angina) or 
symptoms consistent with angina pectoris, within the 12  months preceding Baseline  
• Signs or symptoms of clinical heart failure  within the 12 months preceding Baseline  
• Atrial fibrillation on screening ECG or history of atrial fibrillation that is not currently controlled 
(heart rate ≥ 85 bpm and/or inappropriate anticoagulation)  
• QTcF (QT corrected for heart rate using Fridericia’s formula) at Screening >460 msec in males or 
> 470 msec in females, or low or flat T waves making measurement of QT interval unreliable  
• Recent history of poorly controlled hypertension, systolic blood pressure >180  mmHg, or diastolic 
blood pressure >100 mmHg, after 5 minutes in a seated position at Screening  
• Hypotension: systolic blood pressure <100 mmHg after 5 minutes in a seated position at Screening  
Protocol: TRx -237-[ADDRESS_977571] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 17 of 145 Name [CONTACT_790] / Company: TauRx Therapeutics Ltd (TauRx)  
Name [CONTACT_2756]:  LMTM  (TRx0237) Film -coated Tablets, 4 mg  
Name [CONTACT_3261] (Drug Substance): Hydromethylthionine Mesylate  
• Heart rate <48 bpm or >96 bpm by [CONTACT_717176] (after 5 minutes in a seated position) 
or by [CONTACT_717177]  
15. Pre-existing or current signs or symptoms of respi[INVESTIGATOR_213156] e, e.g., caused by [CONTACT_717178], bronchial asthma, lung fibrosis, or other disease  
• Subjects with currently  diagnosed moderate to severe sleep apnea should be excluded ; the 
definition of moderate to severe includes oxygen supplementation, e.g., nasal prongs or Continuous 
Positive Airway Pressure (CPAP)  
16. Concurrent acute or chronic clinically significant (in the opi[INVESTIGATOR_871]) immunologic, 
hepatobiliary (such as presence of encephalopathy or ascites), or endocrine disease (not adequately 
treated) , and/or other unstable or major disease other than probable AD or MCI -AD; the following are 
specifically excluded:  
• Active hepatitis or primary biliary cirrhosis  
• Active Human T -Cell Lymphocytic Virus Type III (HTLV -III), Lymphadenopathy Associated 
Virus (LAV), any mutants or derivatives of HLTV -III or LAV, any condition associated with 
active Acquired Immunodeficiency Syndrome or similar condition however named  
17. Diagnosis of cancer (excluding basal cell carcinoma, squamous cell carcinoma, or prostate carcinoma in 
situ [Stage 1 ]) meeting either of the following criteria:  
• Newly diagnosed within past 2 years  
• Previous (>2 years) diagnosis of cancer that has required any form of intervention or treatment 
within the past 2 years, e.g., chemotherapy, radiotherapy, hormonal therapy, or surgery  
18. Prior intolerance or hypersensitivity to MT -containing drug or methemoglobinemia induced by [CONTACT_134206] -
containing drug, similar organic dyes, or any of the excipi[INVESTIGATOR_840]  
19. Treatment currently or within 90 days before Baseline with any of the following:  
• Souvenaid® 
• Antipsychotics  
o Clozapi[INVESTIGATOR_050] (and there is no intent to initiate therapy during the course of the study)  
o Other antipsychotics are allowable provided they have not been initiated within 90 days before 
Baseline and preferably at a stable dose and regimen  
• Carbamazepi[INVESTIGATOR_050], primidone, valproate  
• Drugs for which there is a warning or precaution in the labeling about methemoglobinemia at 
approved doses ( e.g., dapsone, local anesthetics such as benzocaine used chronically, primaquine 
and related antimalarials)  
20. Current or prior participation in a clinical trial as follows:  
• Any clinical trial of LMTM  
• Clinical trial of a product for cognition prior to Baseline  in which the last dose was received within 
[ADDRESS_977572] been randomized to placebo  
• A clinical trial of a ny other investigational  drug, biologic, device, or medical food in which the last 
dose was received within 28 days prior to Baseline  
Dose/Route/Regimen  
Throughout the study, a ll subjects will receive four tablets orally per day ( two in the morning and two in the 
evening ), to be taken at the same time (and same meal condition) to the extent possible. Study drug should be 
swallowed whole and MUST NOT be broken, crushed, chewed, or dissolved in fluids prior to ingestion.  
 
For the 52 -week, double -blind treatment period, s ubjects will be randomized  4:1:4  (beginning with Protocol 
Version 5.0 ) to one of the following treatment groups:  
• LMTM 16-mg/day group : Two 4-mg tablet s in the morning and two 4-mg tablet s in the evening  
• LMTM 8-mg/day group : One 4-mg table t and one  placebo tablet in the morning, and one 4-mg 
tablet and one placebo tablet in the evening  
• Placebo group: Two “dummy”  tablet s in the morning and two “dummy ” tablet s in the evening , one 
of which may be replaced by a 4 -mg MTC tablet to maintain the treatment blind (the remainder 
being placebo tablets)  
 
Protocol: TRx -237-[ADDRESS_977573] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 18 of 145 Name [CONTACT_790] / Company: TauRx Therapeutics Ltd (TauRx)  
Name [CONTACT_2756]:  LMTM  (TRx0237) Film -coated Tablets, 4 mg  
Name [CONTACT_3261] (Drug Substance): Hydromethylthionine Mesylate  
The first dose of study drug (Visit 2)  and the morning dose at Visit 3 (after 4 weeks of study drug) , Visit 7 (after 
52 weeks of study drug) , and Visit 10 (after 104 weeks of study drug)  will be administered in the clinic. These 
visits should be scheduled to occur in the morning and s ubjects will be required to remain at the site for at least 
[ADDRESS_977574] -dose on each occasion . Alternative arrangements for dosing and dispensing study drug supplies due 
to COVID -19 may be permitted and are further described i n the body of the protocol.  
 
Interruption of dosing for up to a maximum of 14 consecutive days may be allowed if the investigator 
determines this is indicated  (e.g., due to an AE or any other reported change in the subject’s physical condition 
in the judgment of the investigator) on a  maximum of two occasions. Dose reduction is not permitted.  The 
reason for dose inter ruption should be recorded in the sour ce documen tation.  
 
After the completion of the 52-week double -blind treatment period, beginning with supplies dispensed at Visit 7  
(Baseline/Day 1 for the open -label  phase) , all subjects will receive LMTM 16 mg/day (two 4 -mg tablets in the 
morning and two 4 -mg tablets in the evening) from a newly dispensed open -label study kit for an additional 
[ADDRESS_977575] been completed  (refer to Table 10-[ADDRESS_977576] -dose assessments 
to be performed at Visit 7 ). 
Methodology  
All subjects should have a likely diagnosis of probable AD or MCI -AD prior to being offered the consent forms , 
on the basis of investigator interview and examination . Subjects currently using an AChEI and/or memantine 
must be willing to discontinue such medication before continuing with screening  (for timing of withdrawal 
reference Table 10-1). 
 
Following provision of written informed consent by [CONTACT_70579] t (and/or legal representative [s]) and study 
partner (s), consistent with national and/or local law, eligibility for enrollment will be assessed initially during the 
Screening period which may require multiple visits ( collectively designated Visit 1). These  will occur no earlier 
than 63 days before Visit  2 for subjects not using an AChEI and/or memantine. F or subjects  using an AChEI  
and/or memantine at the time of signing the consent document or who have recently discontinued use, Screening 
visits can occur no earlier than 105 days before Visit 2.  
 
The diagnosis of probable A D or MCI -AD should be confirmed per the 2011 NIA/AA criteria, documented in 
the subject’s medical records and independently confirmed  by [CONTACT_717179] . MMSE and CDR will 
then be completed at Screening for eligibility assessment. Note that MMSE should be conducted first, followed 
by [CONTACT_717180].  If the subject does not qualify 
with either of these scales, no further assessments should be performed  and the subj ect should be considered a 
screen failure.  If, however , the subject meets the MMSE and CDR inclusion criteria, a  blood sample for clinical 
laboratory testing should be obtained and medical screening assessment s performed.  
 
In subjects for whom it is appropriate to proceed with further screening, a  PET scan that is positive for amyloid 
and an MRI scan that excludes other CNS  pathology are required at Screening to confirm subject eligibility. The 
amyloid PET scan can have been documented previously as positive  or, alternatively, be based on the local read   
(or central for those sites not able to read locally)  of a PET scan using an approved amyloid ligand  and according 
to criteria recommended as standard by [CONTACT_717181] . All images (including prior images with 
subject consent) will be sent to an imaging core laboratory, either as a repository (amyloid PET) or for 
evaluation by a trained technologist for acceptable quality (MRI). MRIs will be reviewed by [CONTACT_717182] (reader) who is trained in the evaluations and is not involved in the clinical conduct of  the study 
to confirm eligibility of the subject. The reader’s MRI assessment will be communicated to the site within 
5 business days of image transfer to the imaging core laboratory (or of resolution of any quality issues).  
 
Subjects willing to discontinue AChEI and/or memantine in order to take part in the study must be documented 
to be eligible according to clinical inclusion / exclusion criteria, screening MRI and amyloid positive PET scan , 
before these drugs are discontinued.  
 
Only s ubjects  with a CDR 0.5  will undergo 18F-FDG -PET. 18F-DG-PET images are to be obtained prior to 
Visit  2 (and at least [ADDRESS_977577] dose of A ChEI and/or memantine) for purposes of establishing the 
baseline assessment . Completion of this scan must be confirmed prior to randomization ; other than confirmation 
of acceptable quality, the results per se are not considered  for eligibility at the Screening visit. The baseline 
Protocol: TRx -237-[ADDRESS_977578] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 19 of 145 Name [CONTACT_790] / Company: TauRx Therapeutics Ltd (TauRx)  
Name [CONTACT_2756]:  LMTM  (TRx0237) Film -coated Tablets, 4 mg  
Name [CONTACT_3261] (Drug Substance): Hydromethylthionine Mesylate  
18F-FDG -PET image will be sent to a core imaging laboratory and will be reviewed by [CONTACT_10981], 
appropriately trained nuclear medicine reader. Imaging receipts will be sent in all cases; only in those instances 
where the scan is deemed unacceptable will the site and imaging laboratory be  further  notified.  
 
At the Baseline/Randomization visit (Visit 2), eligibility will be confirmed, subjects will be randomized , and 
baseline safety and efficacy assessments will be completed. Subjects will be treated with study drug for 
[ADDRESS_977579] -Baseline  study 
visits will occur at time points approximately 4, 13, 26, 39 , and 52 weeks after Baseline. All subjects will receive 
a supply of study drug according to their randomization , to take home for us e until Visit 4 (13 weeks after 
Baseline). Study drug will be resupplied at Visits 4, 5, and 6 (13, 26, and 39 weeks after Baseline). Visit 7 (the 
final visit in the double -blind treatment period) will serve as the open -label Baseline. During the open -label, 
delayed -start phase , study visits will occur at approximately 4 weeks (by [CONTACT_756]), 26 weeks , and 52 weeks 
after the open -label Baseline (Visits 8, 9, and 10), with a supply of open -label study drug from a newly 
dispensed study kit provided at Visits [ADDRESS_977580] (DSMB) throughout its duration.  
Assessments  
Efficacy:  
Imaging assessments will be made by [CONTACT_717183]:  
• Brain MRI will be evaluated for temporal, parietal, whole brain, lateral ventricular, hippocampal, 
putamen, nucleus accumbens , and nucleus basalis volumes at Screening and after 13, 26, 39 , and 
52 weeks, or upon early termination . Change in MRI volumetric parameters will be quantified at the 
imaging core laboratory.  The image hyperintensities will also be quantified. MRIs will also be obtained 
and evaluated after the additional 26 and 52 weeks of open -label treatment.  
• Brain 18F-FDG -PET will be evaluated in subjects with CDR 0.[ADDRESS_977581] 
will also be examined including, but not restricted to, inferior temporal gyrus, angular gyrus, anterior 
and posterior cingulate gyrus, and cerebellum. Change in SUVR parameters will be quantified by [CONTACT_272737].  
 
Two primary clinical efficacy scales will be  used, ADAS -cog 13 and ADCS -ADL 23. Clinical assessments will be 
made by [CONTACT_717184], using the instruments on an 
electronic tablet (and captured via an audio recording of the assessment for independent evaluation) . The 
following will be assessed at Baseline ; after 13, 26, 39, and 52 weeks  during the double -blind treatment period; 
and after the additional 26 and 52 weeks of open -label treatment , or upon  early termination : 
• ADAS -cog 13  
o As the primary endpoint is ADAS -cog 11, in order to  be able to link the results of this study to the 
recently completed Phase 3 studies TRx -237-005 and TRx -237-015, an ADAS -cog 11 will be 
derived from the ADAS -cog 13. 
• ADCS -ADL [ADDRESS_977582] will be repeated at the final double -blind treatment period visit (Visit 7) and the final 
open -label visit (Visit 10)  or upon early termination .  
 
The clinical e fficacy scale assessments should be performed at approximately the same time of day throughout 
the study for a given subject, to the greatest extent possible . 
 
Safety and Tolerability:  
Safety assessments will be performed during Screening to assess subject eligibility for enrollment. All safety 
assessments will be performed by [CONTACT_717185]; where 
specified below, the assessments must be made by a medical assessor ( physician, doctor of medicine [MD] , or 
doctor of osteopath ic medicine  [DO]) . For enrolled subjects, safety assessments will be made at Baseline and at 
each clinic visit ( i.e., after 4, 13, 26, 39, and 52 weeks during the double -blind treatment period as well as after 
26 and 52 weeks in the open -label, delayed -start phase ); during a telephone contact  [CONTACT_3435] 4 weeks in the open -
label, delayed -start phase ; when needed to follow up on an AE ; and upon early termination. All AEs, vital signs, 
Protocol: TRx -237-[ADDRESS_977583] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 20 of 145 Name [CONTACT_790] / Company: TauRx Therapeutics Ltd (TauRx)  
Name [CONTACT_2756]:  LMTM  (TRx0237) Film -coated Tablets, 4 mg  
Name [CONTACT_3261] (Drug Substance): Hydromethylthionine Mesylate  
ECG, clinical laboratory findings, physical and neurological examinations, and ophthalmological examinations 
(as applicable) will be assessed according to the following:  
• AEs will be recorded from the time informed consent is signed and recording will continue throughout 
the study  and, if pertinent, until resolution of the event; AEs with an onset after the first dose of study 
drug or that worsen in intensity or treatment relationship after the first dose will be considered 
treatment -emergent  (and must be reviewed by a medical assessor) . 
• Blood pressure and pulse will be obtained at Screening, on Day 1 (pre -dose and approximately [ADDRESS_977584]-dose), and at each clinic visit thereafter or upon early termination. Blood pressure and pulse will be 
measured after the subject has been in a seated position for at least 5 minutes.  
• Height will be measured at Screening only. Body weight will be measured at Screening and at each 
clinic visit thereafter or upon early termination.  
• A 12 -lead ECG will be obtained at Screening , with the site assessing eligibility based on the local 
clinical interpretation  by a medical assessor . 
• TSH, vitamin B 12, folate, haptoglobin, and G6PD will be measured at Screening; a thyroid panel may be 
obtained in response to an elevated TSH. Standard clinical laboratory testing, including hematology and 
blood chemistry, will be performed at Screening and each subsequent clinic visit (or upon early 
termination ). Testing may also be performed as needed in response to an AE.  All laboratory testing 
results must be reviewed by a medical assessor.  
• A blood sample for a serum pregnancy test will be collected f rom all women of childbearing potential at 
Screening and at each subsequent clinic visit (or upon early termination ). 
• Complete physical and neurological assessments will be performed at Screening. Targeted 
examinations will be performed pre -dose and approximately [ADDRESS_977585] 
dose of study drug (Visit 2). Thereafter, targeted examinations are to be performed at each subsequent 
clinic visit (or upon early termination ). At a minimum, targeted examinations should include heart and 
lung auscultation and brief neurological assessment guided by [CONTACT_717186]/symptoms/AEs  (e.g., 
evaluating subjec ts for potential serotonin toxicity ). These examinations are to be performed by a 
medical assessor.  
• Ophthalmological examination (slit lamp) of subjects with history of lens implants will be performed by 
a licensed  optometrist, ophthalmologist, or other suitably qualified medical ass essor prior to the first 
dose of study drug (during the  Screening  procedures or as part of the baseline assessments) , at Visit 7 , 
and at Visit 10 / early termination (after completion of efficacy assessments) , to assess whether the lens 
has been discolored during the trial.  A slit lamp examination should also be performed if a  subject has 
cataract surgery /lens implantation  at any point during his or her  study participation  (as soon as possible 
after the surgery), as well as in response to visual complaints if suggestive of lens discoloration . 
• At Screening, medications administered within the last 90 days will be recorded ; the exception is for 
anti-dementia medications, where lifetime use ( as far as possible) is to be recorded. Changes in 
concomitant medications and any new medications will be recorded at all subsequent visits , including 
the telephone contact , and reviewed by a medical assessor .  
Other Assessments:  
• At Visit 2 , Visit 3 , Visit 7, and Visit 10,  blood will be collected  on the same day on  three occasions  for 
determination of plasma MT and whole blood concentrations (parent MT /LMT , N-desmethyl MT , and 
total MT , to the extent possible ); these visits should be scheduled to occur in the morning. Samples will 
be collected  prior to dosing (in the clinic) and again approximately [ADDRESS_977586] -dose; a third 
sample will be collected approximately 4 hours after the dose.  Times of dose  and blood sampling  (and 
at Visits 3, 7, and 10, times of the prior dose taken on the preceding day) will be recorded.  At any early 
termination visit, if the subject has not yet discontinued study drug and is willing to take a final in -clinic 
dose, three blood samples will be collected as described above. If, however, the subject has already 
discontinued study drug or is u nwilling to take a final in -clinic dose, a single blood sample only for 
determination of MT concentrations will be collected, irrespective of the date or time of the last dose of 
study drug. The date and time of the last dose will be collected and recorded.  For subjects who continue 
in the study off -treatment ( the off-treatment -on-study [TOTOS]  group), blood samples will not continue 
to be collected for the determination of MT concentrations.  
• A single blood sample for ApoE will be obtained from  subjects  who provide legally acceptable 
informed consent ; the blood sample may be collected any time after eligibility for randomization and 
continued participation in the study has been confirmed  but prior to Visit 7 (end of the double -blind 
treatment period) . 
Protocol: TRx -237-[ADDRESS_977587] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 21 of 145 Name [CONTACT_790] / Company: TauRx Therapeutics Ltd (TauRx)  
Name [CONTACT_2756]:  LMTM  (TRx0237) Film -coated Tablets, 4 mg  
Name [CONTACT_3261] (Drug Substance): Hydromethylthionine Mesylate  
Statistical Analys es 
Double -blind Treatment Period : 
The primary target of estimation is the difference in ADAS -cog 11 and ADCS -ADL 23 over 52 weeks in subjects 
receiving LMTM in a dose of 16  mg/day as compared to placebo.  
 
The primary efficacy analyses for FDA  will be performed on the Efficacy  Modified Intent -to-Treat ( E-MITT)  
which will include all randomized subjects who took at least one dose of study drug and have a baseline and  a 
valid post -baseline efficacy assessment , and for EMA on the Intent -to-Treat (ITT) population with conservative 
assumptions about disease progression made for subjects who have missing post -baseline assessments . Subjects 
will be analyzed in the treatment group and according to the stratification variables to which they were 
randomized.  
 
Changes from baseline to Week 52 on the co -primary efficacy endpoints and other modalities with repeated 
measures such as MRI will be analyzed using a linear mixed model for repeated measures with unstructured 
covariance matrix. The linear mixed model will contain fixed effects for time, treatment, and a treatment -by-
time interaction; additionally, the baseline value of the corresponding endpoint will be included as a covariate 
and the randomization stratification variables of prior usage of AChEIs and/or m emantine , severity based on 
MMSE (16 -19, 20-25, or 26 -27) as  determined at Screening,  and region will be included as fixed effects  in the 
model . 18F-FDG -PET and other modalities with only one planned post -baseline assessment will be analyzed 
using an ANCOVA ; the covariates for th is model will be adjusted accordingly by [CONTACT_717187].   
 
More details about the exact contrast statements  used for these tests as well as further sensitivity analyses, 
additional analyses of the primary variables (such as responder analyses and subgroup analyses), analyses of the 
secondary and exploratory endpoints , and  modifications to be implemented regarding sensitivity analys es due to 
COVID -19 are described in the body of the protocol and SAP.  
 
Open -Label, Delayed -Start Phase : 
“Late”  starters, i.e., subjects originally randomized to placebo, will be compared to “early ” starters, i.e., those 
originally randomized to LMTM 16 mg/day or 8  mg/day  (pooled,  and individually for both groups as a 
sensitivity  analysis ). The last assessment prior to start of  open -label treatment (Visit 7)  will serve as the baseline 
assessment for these comparisons. The analyses will be based on a similar linear mixed model for repeated 
measures  with the aim to investigate whether there is a difference in ch ange in primary and MRI imaging 
endpoints  dependent on LMTM treatment  history. The comparison  will be implemented through a non -
inferiority test. The non-inferiority margin for the primary endpoint of ADAS -cog [ADDRESS_977588] of > 5 units (~40% of this effect 
size). Margins for other endpoints which are exploratory to support a disease modifying argument will be 
defin ed in the SAP. The results will also be presented with the Visit 2 Baseline as baseline and treatment visits 
Week 26 and Week 52 in the open -label, delayed -start phase  as Week 78 and Week 104.  
Protocol: TRx -237-[ADDRESS_977589] -003558 -17  
Protocol Version 7.0 CONFIDENTIAL  Page 22 of 145 7 ABBREVIATIONS  
 
Abbreviations  Definitions  
AA Alzheimer’s Association  
AChEI  acetylcholinesterase inhibitor  
AD Alzheimer’s Disease  
ADAS -cog 11 Alzheimer's Disease Assessment Scale – Cognitive Subscale (11-item)  
ADAS -cog 13 Alzheimer's Disease Assessment Scale – Cognitive Subscale (1 3-item)  
ADCS -ADL 23 Alzheimer's Disease Cooperative Study – Activities of Daily Living 
(23-item)  
ADNI  Alzheimer's Disease Neuroimaging Initiative  
ADR  Adverse Drug Reaction  
AE adverse event  
AESI  adverse event of special interest  
ApoE  Apolipoprotein E  gene  
ATC  Anatomical Therapeutic Classification  
AUC  area under the plasma concentration versus  time curve  
BCRP  breast cancer resistance protein  
bid twice daily  
BSI Boundary Shift Integral  
BSA  body surface area  
bvFTD  behavioral variant frontotemporal dementia  
CDR  Clinical Dementia Rating  
CJD Creutzfeldt -Jakob Disease  
CL/F  apparent plasma clearance  
Cmax peak plasma concentration  
Cmax, ss  peak steady -state plasma concentration  
CMP  Clinical Monitoring Plan  
CNS  central nervous system  
COVID -[ADDRESS_977590]  
EAP  Expanded Access Program  
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
EMA  European Medicines Agency  
E-MITT  Efficacy  Modified Intent -to-Treat  
eTMF  electronic Trial Master File  
EU European Union  
FDA  Food and Drug Administration ([LOCATION_002])  
18F-FDG -PET 18F-fluorodeoxyglucose positron emission tomography  
g, kg, mg , pg gram, kilogram, milligram , pi[INVESTIGATOR_167465]  
G6PD  glucose -6-phosphate dehydrogenase 
GCP  Good Clinical Practice  
GI gastrointestinal  
Protocol: TRx -237-[ADDRESS_977591] -[ADDRESS_977592]  
ITT Intent -To-Treat 
IUD intrauterine device  
L, mL, dL  liter, millilit er, decilit er 
LAR  Legally A cceptable  Representative  
LAV  Lymphadenopathy Associated Virus  
LDH  lactate dehydrogenase  
LMT  hydromethylthionine, leuco -methylthioninium  
LMTB  leuco -methylthioninium bis(hydrobromide)  
LMTM  hydromethylthionine mesylate, leuco -methylthioninium 
bis(hydromethanesulfonate)  
LSM  Least Square s Mean 
LVV  lateral ventricular volume  
MAO  monoamine oxidase  
MATE  Multidrug And Toxin Extrusion (protein)  
MCI -AD mild cognitive impairment  due to AD  
MD Doctor of Medicine  
MedDRA  Medical Dictionary for Regulatory Activities  
MHRA  Medicines and Healthcare products Regulatory Agency  
min, msec  minutes , millisecond  
MI-MITT  MRI Imaging Intent -to-Treat  
MMSE  Mini -Mental State Examination  
MRI  magnetic resonance imaging  
MT Methylthioninium  
MTC  methylthioninium chloride  
NIA National Institute on Aging  
NMDA  N-methyl -D-aspartate  
NOAEL  no-observed -adverse effect -level  
nvCJD new variant Creutzfeldt-Jakob Disease 
OAT  Organic Anion Transporter  
OCT  Organic Cation Transporter  
PET Positron Emission Tomography  
P-gp P-glycoprotein  
PHF paired helical filament  
PI [INVESTIGATOR_717126]-MITT  Imaging Modified Intent -to-Treat  
PK Pharmacokinetic  
PP Per Protocol  
Protocol: TRx -237-[ADDRESS_977593] -[ADDRESS_977594] Operating Procedure  
SPM  statistical parametric mappi[INVESTIGATOR_717127]  
T½ terminal  elimination half -life 
TEAE  treatment -emergent adverse event  
tid three times daily  
TOTOS  The-Off-Treatment -On-Study  (subjects)  
TSE Transmissible Spongiform Encephalopathy 
TSH  thyroid stimulating hormone 
UGT  UDP -glucuronosyltransferase  
[LOCATION_003]N  [LOCATION_002] Abbreviated Name  
[CONTACT_717329]-Jakob Disease 
WBC  white blood cell  
WHO  World Health Organization  
 
 
  
Protocol: TRx -237-[ADDRESS_977595] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 25 of 145 8 BACKGROUND AND RATIONALE  FOR THE STUDY  
Hydromethylthionine  (International Nonproprietary Name  [INN] and [LOCATION_002] 
Abbreviated Name  [[LOCATION_003]N] ), the reduced form of methylt hionin ium (MT) that is also known 
as leuco -methylthion inium (LMT) , is proposed for treatment of tauopathies and other protein 
misfolding disorders. Tauopathies are a class of neurodegenerative diseases associated with 
pathological aggregation of tau protein in the human brain. The tauopathies include diseases 
that primarily affect cognition such as Alzheimer’s disease (AD). AD is a severe irreversible 
neurodegenerative disease resulting in complete loss of mental faculties. In A D, the 
microtubule associated protein tau is  redistributed exponentially into paired helical filaments 
(PHF) forming neurofibrillary tangles that correlate with pyramidal cell destruction (Wischik 
et al., 1997). There is a robust clinico -pathological correlation between tau pathology, tau 
aggregation, and clinical measures of dementia (Bierer et al., 1995; Mukaetova -Ladinska et 
al., 2000). These relationships are maintained from the earliest detectable stages of dementia 
and progress in parallel with clinical deterioration  and are also seen by [CONTACT_340738] g using 
recently developed tau ligands (Lockhart et al., 2016; Xia et al., 2017; Pontecorvo et al., 
2017 . 
 
The repeat -domain tau fragment originally identified biochemically as a structural constituent 
of the tangle PHF core (Wischik et al., 1988a,b) has recently been confirmed using cryo -
electron  microscopy (Fitzpatrick et al., 2017). This fragment assembles spontaneously  in 
vitro  to form PHF -like filaments (Al -Hilaly et al., 201 7). The active moiety required both to 
block filament assembly and to disassemble formed filaments is the reduced LMT form of 
MT (Al-Hilaly et al. , 2018) .  
 
As of 2020, d rugs currently available to treat AD, such as acetylcholinesterase inhibitors 
(AChEIs) or memantine, are symptomatic treatments that address certain central neuronal 
dysfunctions associated with AD, but are not known to directly affect the neurofibrillary 
tangles in the brain that represent a core pathological component of AD. Controlled studies 
with the AChEIs donepezil, rivastigmine, and galantamine have demonstrated small 
improvements in cognitive tests and global measures of change in selec ted subjects with mild 
to moderate A D over 3 to 12 months (Birks and Harvey, 200 3; Olin and Schneider, 200 2). 
However, improvements in function and behavior have been demonstrated less reliably with 
AChEIs. Furthermore, although these medications provide benefits for some subjects, their 
effectiveness often is limited in duration and they do not affect the rate  of progression of the 
disease ( Courtney  et al. , 2004).  
 
Memantine is a noncompetitive, low -affinity, N -methyl -D-aspartate (NMDA) receptor 
antagonist that might prevent calcium -mediated glutamate excitatory toxicity in AD. Studies 
with memantine over [ADDRESS_977596] shown small 
benefits on cognition, global measures, daily living activities, and behavior (Reisberg et al., 
2003), but evidence for a benefit is lacking in mild AD (Schneider et al., 2011) . 
 
Aduhelm ™ (aducanumab), an amyloid beta -directed antibody, was recently granted 
accelerated approval by [CONTACT_620733]  2021 for early AD based on a biomarker (reduction of 
amyloid plaque). One particularly significant limitation in the widespread use of such drugs is 
the requirement for monthly intravenous infusions of the monoclonal antibody preparations 
that target aggregated forms of amy loid, which has a substantial impact on the costs of 
production, distribution, and administration of such treatments.  Based  on the clinical trials to 
date, there are uncertainties regarding the effectiveness of aducanumab on clinical outcomes .  
Protocol: TRx -237-[ADDRESS_977597] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 26 of 145 In addition , there is a significant risk of triggering amyloid -related imaging abnormalities , 
requiring regular monitoring by [CONTACT_9252] ( MRI ) scans  (summarized in the 
Aduhelm  FDA Drug Approval Package, June 2021 ). 
 
Therefore, an unmet need exists to develop new medications for AD that more directly 
modify the underlying disease pathology and offer longer -term and greater efficacy. LMTM, 
the investigational product, is believed to have the potential to confer benefits over existing 
treatments for AD due to its ability to affect the process of tau aggregation responsible for the 
underlying neurofibrillary pathology o f AD. Available non clinical  and clinical evidence 
supports the clinical evaluation of LMTM in A D. 
 
8.[ADDRESS_977598] is LMTM ( [LOCATION_003]N hydromethylthionine mesylate, also referred to 
as leuco -methylthioninium bis (hydromethanesulfonate ), hydromethylthionine 
bis(hydromesylate ), leucomethylene blue dimesylate, and its code name, TRx0237) . As a 
dihydromethanesulfonate salt (also known as mesylate), LMTM stabilizes the reduced 
crystalline form of the MT moiety in the solid state .  
 
LMTM is provided as 4 -mg, immediate -release  tablets, to be taken twice daily; the 
pharmacokinetics (PK) of LMTM 4 mg as a single dose and given twice daily at steady state 
(8 mg/day) are described in Section [IP_ADDRESS] . Following dissociation of the counter ions , the 
uncharged (reduced) LMT form , i.e., the active moiety,  is absorbed passively . The charged 
(MT+) form  does not have the conformation necessary to block filament assembly and to 
disassemble formed filaments  (Al-Hilaly et al., 2018) . When dosed as the charged (MT+) 
form  (as in methylthioninium chloride [MTC], also known as methylene blue) , it is 
postulated that MT+ requires an additional reduction step ( to LMT ) to be distributed to the 
brain . Within cells, MT exists  in equilibrium between the reduced (LMT) and oxidi zed (MT+) 
forms, the predominant form present depending on the cellular milieu, i.e., pH and r eductive 
capacity within that cell , with the LMT form predominating intracellularly (May et al. 2004) .  
 
Matching placebo tablets are provided. The drug supplies for the placebo group will include 
tablets containing a urinary dis colorant, MTC, 4 mg , in order to provide urinary discoloration  
and maintain the treatment blind . 
 
8.1.2 Nonclinical Data 
In cell models, LMT (including as LMTM) has  been shown to prevent aggregation and 
facilitate disaggregation of pre -existing oligomers and fibers . In transgenic mouse models, 
facilitation of clearance of tau aggregates and associated improvements in cognitive and 
motor learning abilities have been demonstrated. Tau pathology in these transgenic mouse 
models has been shown to be ameliorated in certa in brain regions ( e.g., entorhinal cortex, 
hippocampus, and neocortex) following treatment with LMTM.  
 
The primary toxicity of MT is hematological, manifesting as methemoglobinemia and a 
regenerative hemolytic anemia. Depending on the species, Heinz body formation also occurs. 
A no -observed -adverse effect -level (NOAEL) of 3 to 5 mg MT/kg/day was  established in 
rats, regardless of salt or duration, depending on the low dose in a given study ; the parent 
Protocol: TRx -237-[ADDRESS_977599] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 27 of 145 MT/LMT  plasma levels (exposure) at these doses are comparable to human exposure at an 
LMTM dose of 8 mg/day . In monkeys, the NOAEL  for hematological toxicity was 0.9 mg 
MT/kg/day in the 6 -month MTC phase (toxicokinetic data at this dose are not available); the 
NOAEL in the subsequent 9 -month LMTB phase in which higher doses were given was 
<20 mg MT/kg/day (the lowest dose studied). Hematological toxicity was seen in minipi[INVESTIGATOR_717128] ; therefore, the NOAEL is considered to be < 3 mg MT/ kg/day. 
The hematological effects in rats occur at exposure s that are 2.1-fold higher than in humans at 
an LMTM dose of  16 mg/day and in  minipi[INVESTIGATOR_717129] 1.2-fold higher . In rats 
and minipi[INVESTIGATOR_14107] (but not monkey s) at the hematologically toxic doses , myeloid generation is 
also affected , and extramedullary hematopoiesis  is seen . Pi[INVESTIGATOR_2517] (hemosiderin) deposition 
becomes evident in liver and renal cortical tubules (some lipofuscin is also present in 
minipi[INVESTIGATOR_14107]) with no adverse effect on either live r or kidney function evident.  At relatively high 
doses, effects on white blood cells (WBC s) are seen, but not consistently across species (seen 
only in rats, not monkeys or minipi[INVESTIGATOR_14107]). Decreases in circulating neutrophils occurred with an 
exposure -based safety margin of 8.9. 
 
The other potential significant toxicities observed include effects on the heart, described as 
myocardial necrosis, generally occurring at rapi[INVESTIGATOR_717130]. In the minipig, no cardiac t oxicity was observed at 
the highest dose administered chronically, providing safety margins of > 7.5-fold relative to 
an LMTM dose of 16 mg/day in humans. Gastric irritation is seen in rodents and urinary 
bladder irritation is seen in mice and minipi[INVESTIGATOR_14107] (with single cell necrosis in the latter species).  
 
MT is genotoxic in vitro  and damage s DNA  in vitro , but is not genotoxic in vivo . There is no 
evidence of an interaction with or damage to DNA in vivo , a difference which may be due to 
differences in the predominant redox state of MT in vitro  and in vivo . In addition, MT+, as a 
photosensitizer, is activated in vitro  by [CONTACT_717188] m utagenic  in vitro  only in the presence of light ; there is no 
evidence that MT administered orally  unde rgoes photo -oxidation. According to the 
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use  (ICH)1, “When a positive result occurs in an in vitro  mammalian cell assay, 
clearly negative results in two well -controlled in vivo assays, in appropriate tissues and with 
demonstrated adequate exposure, are considered sufficient evidence for lack of genotoxic 
potential in vivo .” Thus, MT (and by [CONTACT_717189] N-desmethyl MT) is 
considered to have no clinically relevant genotoxic potential . 
 
As reviewed by [CONTACT_941] U.S. National Toxicology Program, there is “some evidence of 
carcinogenic activity”2 of MTC in male rats based on increased incidences of pancreatic islet 
cell adenoma and adenoma or carcinoma (combined)  and in male mice based on increased 
incidences of carcinoma and of adenoma or carcinoma (combined) in the small intestine. 
When data are evaluated using the U.S. Food and Drug Administration (FDA) criteria for a 
positive response3, there were no statistically significant neoplastic findings in either species. 
However, FDA concluded that the combined incidence of pancreatic islet cell adenomas and 
carcinomas in male rats wa s higher than in historical controls , particularly at the mid -dose of 
 
1 ICH S2(R1): Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use 
(2012)  
2 Text in quotation marks refers to the interpretation of results provided by [CONTACT_941] U.S. National Toxicology 
Program, the sponsoring organization. These analyses were not consistent with FDA statistical guidelines.  
3 FDA Guidance for Industry: Statistical aspects of the design, analysis, and interpretation of chronic rodent 
carcinogenicity studies of pharmaceuticals (draft, May 2001).  
Protocol: TRx -237-[ADDRESS_977600] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 28 of 145 19 mg MT/kg/day , and thus caused by [CONTACT_134206] . At this dose, t he exposure -based safety margin 
relative to a human LMTM dose of 16 mg/day is 3.0-fold. 
 
MT has no effect on mating performance or pregnancy rate in rats when administered orally. 
The exposure -based safety margin  is >8.3-fold and >10.1-fold in males and females, 
respectively,  for an LMTM dose of 16 mg/day.  
 
Two embryo -fetal development studies have been performed by [CONTACT_717190]. There was no evidence of teratogenicity in rats (NOAEL safety 
margin of 92-fold relative to a human LMTM dose of 16 mg/day, adjusted for differences in 
body surface area [BSA]); evaluation of fetotoxicity was confounded by [CONTACT_717191]. In rabbits, the NOAEL for teratogenicity was the lowest dose studied, a 46-fold 
safety margin; feto toxicity  (abortions)  occurred at the lowest dose (a dose that was maternally 
toxic) . The observed malformations in rabbits, umbilical hernia, are of unclear relevance to 
humans. Thus, the nonclinical reproductive toxicity studies do not raise a strong suspi[INVESTIGATOR_717131]/fetotoxicity at clinical doses  of LMTM  to be studied.  Results of studies 
in other species and by [CONTACT_717192]’s 
Brochure. There have been no reports of human teratogenicity in early pregnancy . Thus, MT 
is considered to have “unlikely human terotogenicity/fetotoxicity in early pregnancy”4.  
 
In a standard study performed in male Long -Evans pi[INVESTIGATOR_14922], MT does not cause 
phototoxicity.  
 
Additional details regarding findings from nonclinical studies with various salt forms of MT 
(LMTM, leuco -methylthioninium bis(hydrobromide) [ LMTB ], and MTC) are described in 
the Investigator’s Brochure.  
 
8.1.3 Clinical Dat a 
[IP_ADDRESS]  Pharmacokinetics  
A single - and multiple -dose pharmacokinetic study has been completed in older (≥50 years ), 
healthy, male and female volunteers (TRx -237-036). Following a single 4 -mg dose, the mean 
peak (C max) plasma parent MT /LMT  concentration is 0.1 ng/mL, occurring approximately [ADDRESS_977601] 12 hours following dosing 
in the majority of subjects , consistent with a possible biliary recirculation .  
 
Following a single 125 -mg dose of LMTM, the presence of food delays absorption by [CONTACT_2902] 
1 hour. C max of parent MT /LMT  increases , but not to a clinically meaningful  extent; t here is 
no difference in area under the plasma concentration versus  time curve ( AUC ). 
 
There is evidence of a possible saturation of absorption with increasing doses. With single -
dose administration  beginning with a dose of 75 mg , plasma concentrations increase 
proportionally until a dose of 500 mg. At higher doses  up to 1000 mg , there is a delay in C max 
and plateau in AUC.  
 
MT is not highly protein bound: 69.1 % to 74.9% in human blood.  
 
4 Clinical Trials Facilitation Group : Recommendations related to contraception and pregnancy testing in clinical 
trials (Version 1.1, September 2020)  
Protocol: TRx -237-[ADDRESS_977602] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 29 of 145  
Hepatic  metabolism to N-desmethyl MT , an active metabolite,  occurs , mediated primarily by 
[CONTACT_9058] P450 isoenzyme ( CYP ) 1A2 and , to a minor  extent , by [CONTACT_097]3A4 . Plasma levels 
of this metabolite  are approximately 10% to 30% of parent MT/LMT  based on Cmax and AUC 
following single or multiple doses (however, plasma concentrations could not be reliably 
measured).   
 
Conjugation to the inactive N-glucuronide is the primary route of metabolism of LMTM. The 
primary UDP -glucuronosyltransferase (UGT ) isoform responsible is UGT1A4; UGT1A7 and 
UGT1A9 may contribute, as well as UGT1A8 and UGT1A10 to a lesser extent.  “Total” MT, 
i.e., predominantly LMT -glucuronide(s), is present in concentrations that are >1000 -fold 
higher than th ose of parent MT /LMT  in plasma , whether based on C max or AUC following a 
single 4-mg dose or 8 mg/day . This is consistent with extensive first pass me tabolism 
(particularly  glucuronidation) and rapid distribution of MT  from the central compartment, as 
MT is  absorbed and pas sed through the intestine and liver to the systemic circulation  and 
deep compartments .  
 
Steady -state plasma concentrations of parent MT /LMT  are achieved within 10  days of dosing  
(the first timepoint at which trough plasma concentrations were measured  in TRx -237-036). 
At an LMTM  dose of 8 mg/day (given daily as two divided doses), plasma parent MT /LMT  
Cmax is 0.3  ng/mL . Based on C max and AUC, t here is no unexpected accumulation with 
multiple dosing. At steady state, t he mean terminal  elimination half -life ( T½) of parent 
MT/LMT  is 35.6 hours; mean T½ of total MT is shor ter (19.1 hours) . 
 
At the higher doses (150 and 250 mg/day  dosed to steady state ), there is a linear but greater 
than proportional increase in parent MT /LMT  exposure and a less than proportional increase 
in total MT. As a result, at steady state, total MT -to-parent MT /LMT  ratios are 243 - to 388-
fold for C max and 249 - to 291-fold for AUC  0-τ over the dosing interval , suggesting either a 
saturation in formation of the glucuronide conjugate or proportionately more extensive 
distribution into deep compartments at high doses.  
 
LMT is not a substrate of either P-glycoprotein ( P-gp) or breast cancer resistance protein 
(BCRP ) transporters. MT+ (but not LMT) is a substrate of the hepatic uptake  transporter,  
organic cation transporter  1 (OCT1 ); the renal uptake transporter , organic cation transporter 2  
(OCT2 ); and the renal/hepatic efflux transporters , multidrug and toxin extrusion proteins  1 
and 2 K (MATE1 and MATE2 K). Neither LMT nor MT+ is a substrate of  the other 
transporters tested ( organic anion transporters 1 and 3 [ OAT1  and OAT3 ], or organic anion 
transporting polypeptides 1B1and 1B3 [OATP1B1 and OATP1B3] ). 
 
There are n o clinically meaningful differences in apparent clearance  (CL/F) between men and 
women (adjusted for differences in body weight) or between Caucasians and non -Caucasians.   
 
In cross study comparisons, the CL/F of parent MT /LMT  is lower in older subjects, possibly 
attributable to renal and/or hepatic impairment of varying degrees. The mean  T½ of parent 
MT/LMT  after a single oral dose  in healthy older subjects is 20.7 hours as compared to 
approxi mately 15 .8 hours in younger  healthy volunteers5.  
 
 
5 Average based on Studies TRx -237-019, TRx -237-021, and TRx -237-024. 
Protocol: TRx -237-[ADDRESS_977603] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 30 of 145 Renal clearance of parent MT/LMT in healthy volunteers represents 13% of CL/F . Most of a 
radiolabeled dose (7 2%) is recovered in the urine, with 24% as unchanged drug and the 
remainder as metabolites, primarily LMT -glucuronide (28% of the dose). Apparent c learance 
of parent MT /LMT  and total MT is decreased in subjects with renal impairment; 
correspondingly, AUC increases and T ½ is prolonged. AUC  for parent MT/LMT  increases by 
1.5-fold in subjects with mild impairment to 4.8 -fold in subjects with severe impa irment; in 
subjects with severe impairment , Cmax is also affected (1.7 -fold increase) . T½ of parent 
MT/LMT  after a single dose increases with worsening degree of impairment ( mean 
24.4 hours, 29.3 hours, and 46.2 hours  in mildly, moderately, and severely impaired subjects, 
respectively ), relative to a mean T½ of 15.7 hours  in generally young er healthy controls  [and 
in a cross -study comparison,  21.3 hours in older healthy volunteers ]); the longest T ½ was 
81.[ADDRESS_977604] with severe impairment . 
 
Apparent c learance of parent MT /LMT  (but not total MT) is decreased in subjects with mild 
to moderate hepatic impairment; some of the subjects with mild to moderate hepatic 
impairment also had markedly elevated bilirubin (including due to Gilbert’s syndrome) 
and/or history of cholecystectomy. When compared to control subjects with normal hepatic 
function, Cmax was 2.1 - to 3.2-fold higher with mild and moderate impairment, respectively; 
AUC was 1.4 - to 2.1 -fold higher, respectively . Mean T ½ was prolonged 54% to 87% relative 
to a mean T½ of 15 .2 hours  in generally young er healthy controls  (and in a cross -study 
comparison, 21.3 hours in older healthy volunteers as noted above ); the longest T½ was 50.[ADDRESS_977605] with mild impairment . 
 
Approximately 23% of a n orally administered dose is recovered from the feces ( primarily as 
parent MT /LMT ). The observation of secondary peaks in plasma concentrations  (and the 
demonstrated excretion into bile of bile duct -cannulated rats) is consiste nt with biliary 
recirculation , indicating that the fecal excretion cannot be attributed solely to unabsorbed 
drug. 
 
Results of a drug -drug interaction study in healthy volunteers given LMTM (225  mg twice 
daily [ bid]) for 3  days or 10 days indicate that MT is a weak inhibitor of CYP3A4, CYP2C8, 
and CYP2C19. LMTM is also a weak inducer of CYP2B6 and P -gp. These data indicate that 
MT may also increase exposure to other co -administered drugs that are substrates of 
CYP3A4, CYP2C8, or CYP2C19, and decrease exposure to substrates of CYP2B6 or P -gp. 
However, the extent to which this occurs at the lower LMTM doses of 8 or 16  mg/d ay is not 
known. LMTM is not an inducer or inhibitor of CYP1A2, CYP2C9, CYP2D6, or CYP2E1.  
 
When evaluated  in vitro , neither the reduced form ( LMT ) nor the oxidized form (MT+) 
inhibits UGT enzyme activity or  the OCT1, OCT2, OAT1, OAT3, OATP1B1, OATP1B3, 
MATE1, MATE2k, or the bile salt export pump  (BSEP)  transporter s at clinically relevant test 
concentrations . LMT (but not MT+) inhibits BCRP at clinically relevant test concentrations.  
 
[IP_ADDRESS]  Cardiac Pharmacodynamics  
LMTM given in single, supra -therapeutic doses of 250 and 875  mg (62.5 - and 2 18.8-fold 
higher than an LMTM 4 -mg dose administered at one time) does not prolong the QT interval 
and is not associated with any other abnormalities of cardiac repolarization . 
 
Protocol: TRx -237-[ADDRESS_977606] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 31 of 145 [IP_ADDRESS]  Efficacy  
In a double -blind, placebo -controlled Phase 2 study (TRx -014-001) of male and female 
subjects with mild or moderate AD (AChEIs and memantine excluded), MTC was 
administered orally at doses of 30 mg three times daily ( tid), 60 mg tid, and 100  mg tid (total 
doses of 69  mg/day, 138 mg/day, and 228  mg/day MT base equivalents, respectively). 
MT 138 mg MT/day appeared to slow the clinical rate of decline on the Alzheimer’s Disease 
Assessment Scale – cognitive subscale (ADAS -cog) and the Mini -Mental State Examinat ion 
(MMSE) measured over [ADDRESS_977607] s and the benefit on the ADAS -cog, Alzheimer’s 
Disease Cooperative Study -Clinical Global Impression of Change, and MMSE scales were  
already evident in subjects  with moderate disease at Baseline  within the first 6  months in an 
analysis of the entire population with severity as an interaction term. The 6 -month analysis 
and methodology were pre -specified as part of the primary analysis. The result in subjects  
with moderate disease severity at 6  months remained significant after correction for multiple 
comparisons. Longer term efficacy was confirmed in mixed mild/moderate subjects by [CONTACT_717193] 50 weeks and 102 weeks, and efficacy was also confirmed in analyses of a 
variety of secondary end points (Wischik et al., 2015). The lower dose (69 mg  MT/day) was 
below the minimally effective dose. The capsule formulation used limited the absorption of 
MT at the 228 mg  MT/day dose due to a combination of dose -dependent delay in dissolution 
of the 100-mg MTC capsules used in the study and a formulation -independent limitation in 
the ability to absorb MT at the highest dose in the presence of food when administered as 
MTC. When both of these factors were taken into account, the clinically effective dose 
available for release within 60  minutes in subjects receiving a nominal dose of 228 mg  
MT/day was equivalent to approximately 69 mg  MT/day (Baddeley et al., 2015), and the 
total available dose was equivalent to 109 mg  MT/day (Wischik et al., 2015).  
 
Evidence of clinical efficacy was supported by [CONTACT_717194] [ADDRESS_977608] a nalysis and 
was particularly marked in the inferior medial temporal and temporo -parietal regions of the 
neocortex on the statistical parametric mappi[INVESTIGATOR_007] (SPM) analysis, areas characteristically 
affected by [CONTACT_717195] (Braak and Braak, 1991). MTC at a dose of 138 mg MT/day was found 
to eliminate this decline entirely (Wischik et al., 2015). A similar effect was seen in a smaller 
group of 2 0 subjects imaged by 18F-fluorodeo xyglucose positron emission tomography  (18F-
FDG-PET) to measure neuronal function by [CONTACT_717196]. The effect on functional 
neuroimaging markers at 24 weeks in subjects with mild AD was found to be predictive of a 
clinical response at 50  weeks (Wischik et al., 2015). The reduced efficacy of the 100 -mg 
capsule dose (228 mg MT/day) relative to the 60 -mg capsule dose (138 mg MT/day) was also 
confirmed by [CONTACT_95425].  
 
Two Phase [ADDRESS_977609] recently been completed  (Gauthier et al., 
2016; Wilcock et al. 2018) ; final study reports are in preparation . These were a 15 -month 
study in subjects with mild to moderate AD comparing doses of 150 mg/day and 250 mg/day 
with a control arm of 8  mg/day  (TRx -237-015), and an 18-month study in subjects with mild 
AD comparing a dose of 200 mg/day and the 8 -mg/day control  (TRx -237-005). AChEIs 
and/or memantine were used concomitantly by [CONTACT_3450] 80 % to 85% of t he subjects 
Protocol: TRx -237-[ADDRESS_977610] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 32 of 145 depending on study. Briefly, there was no statistically significant difference between LMTM 
in the higher doses of 150 to 250  mg/day in either of the two co -primary clinical efficacy 
endpoints or lateral ventricular volume (LVV) when compared with the dose of LMTM 
8 mg/day, i ntended as a control. Based on the results of the Phase 2 study, it was assumed 
that a dose of 8 mg/day of LMTM would be without activity and could thus be used to 
control for urinary discoloration because of concerns about blinding. Further analyses of 
results from both studies suggest that LMTM 8  mg/day given as monotherapy may be 
effective in delaying progression of mild to moderate AD on co -primary clinical efficacy 
endpoints, the 11 -item version of the ADAS -cog ( ADAS -cog 11) or the Alzheimer’s Disease 
Cooperative Study - Activities of Daily Living scale, 23 -item version (ADCS -ADL 23), and 
also on imaging measures of progression of brain atrophy ( MRI and 18F-FDG -PET), and that 
there is no added benefit to using approximately ≥20 -fold hi gher doses than 8  mg/day.   
 
Recent population PK studies suggest  that there are concentration -response relationship s for 
cognitive and neuroimaging outcomes at the 8 -mg/day dose. This is seen whether LMTM is 
taken alone or as add -on to symptomatic treatments  (Schelter et al., 2019 ). In a within -cohort 
meta -analysis of both studies, LMTM at a  dose of 8  mg/day as monotherapy was found to 
produce significant deceleration in the annualized rate of whole brain atrophy after 9 months 
of treatment.  The magnitude of the concentration -dependent treatment effects was reduced by 
[CONTACT_717197]/or memantine . The reduction in treatment effect s of LMTM  by [CONTACT_717198] A ChEI 
or memantine  has been reproduced in a tau transgenic mouse model, and appears to reflect a 
generali zed homeostatic downregulation that is induced in multiple brain systems to 
compensate for the activating effects of symptomatic treatments ( Riedel  et al., 2020). 
 
[IP_ADDRESS]  Safety  
As of [ADDRESS_977611] a single dose of MT (as 
LMTM, MTC, or an earlier reduced salt studied previously ). With respect to LMTM, a total 
of 2283 subjects ( 337 healthy volunteers, 40 hepatically or renally impaired subjects, 1688 
subjects with AD and 218 subjects with bvFTD ) have received at least one dose (ranging 
from 8 to 1000 mg/day) in completed TauRx -sponsored studies. A total of [ADDRESS_977612] common adverse events  (AEs)  associated with MT are anemia and  gastrointestinal 
(GI), genitourinary , and central nervous system (CNS)  effects; these are also the most 
common reasons for discontinuing treatment. These were seen in both the Phase 2 study 
performed with MTC (given in MT doses up to 228 mg/day) as well as in the Phase 3  studies 
with LMTM given in MT doses up to 250  mg/day. When all  treatment -emergent adverse 
events ( TEAEs ) reflective of anemia are grouped, the overall incidence is 13% in subjects 
randomized to LMTM 8 mg/day. The GI and genitourinary TEAEs are less common at 
LMTM 8 mg/day  than at higher doses . Overall, GI events occurred in 21% of subjects 
randomized to LMTM 8  mg/day; diarrhea and nausea were amongst the most common 
individual treatment -related TEAEs, occurring in 7% and 2%  of subjects , respectively. The 
most common urinary TEAEs were frequency, urgency, and incontinence, each treatment 
related in 1 to 2% . Other less likely TEAEs were agitation, dizziness, fatigue, headache (each 
with an incidence of 2%) , and confusional state (with an incidence of 1%).  
 
Protocol: TRx -237-[ADDRESS_977613] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 33 of 145 Additional details regarding clinical findings from studies are described in the Investigator’s 
Brochure.  
8.2 Rationale  
The two recently completed Phase 3 studies conducted in subjects with mild to moderate AD 
(TRx -237-015) and mild AD (TRx -237-005) were designed on the basis of results from the 
earlier Phase 2 study of MTC as monotherapy in mild to moderate AD. In that study, the 
minimum dose required for benefit on clinical and imaging endpoin ts was found to be 
138 mg/day. Both of the Phase 3 studies were therefore designed on the assumption that a 
dose of 8  mg/day of LMTM could be used to control for urinary discoloration  becau se of 
concerns about blinding. As noted earlier, results from both Phase [ADDRESS_977614] that LMTM 8 mg/day given as monotherapy may be effective 
in delaying progression of AD and that there is no added benefit to us ing doses of 150 to 
250 mg/day.  
 
The results of the first of the studies to become available (TRx -237-015) showed that there 
was no statistically significant differen ce between LMTM in doses of 150  mg/day or 
250 mg/day in either of the two co -primary clinical efficacy endpoints or LVV  when 
compared with the dose of LMTM 8  mg/day intended as a control. However, of the pre -
specified terms in the analysis model used in the primary analysis, use of approved AD 
co-medications (AChEI s and/or memantine) at Baseline was a highly significant term. 
Further pre -specified analyses in which monotherapy and add -on subjects  in the higher dose 
treatment arms were compared separately with the control group as randomized suggested 
that LMTM may be effective when given as monotherapy, but not when taken as add -on to 
approved treatments for AD. LMTM 8 mg/day as monotherapy was also found to differ 
significantly from 8 mg/day as add -on to existing AD treatments. In light of these  results 
from TRx -237-015, the Statistical Analysis P lan (SAP)  of TRx -237-005 was modified prior 
to database lock and unblinding to specify as primary two similar parallel analyses, each at a 
statistical threshold of 0.025, to examine 200 mg/day as monotherapy co mpared with the 
8 mg/day control group as randomly assigned, and also 8  mg/day as monotherapy compared 
with 8 mg/day as ad d-on to approved AD treatments.  Both of these sets of comparisons were 
statistically significant at the 0.025 threshold for both of the co -primary clinical efficacy 
endpoints, as well as LVV . No difference in baseline characteristics has been identified in 
either of the two Phase 3 studies that accounts for the discrepant responses between subjects  
taking and not taking approved AD treat ments , nor is a pharmacokinetic basis for an 
interaction evident.  As indicated above, a within -cohort meta -analysis of both studies  showed 
that LMTM at a dose of 8 mg/day as monotherapy was associated with  significant 
deceleration in the annualized rate of whole brain atrophy after 9 months of treatment.  
 
In the continued development of LMTM, the efficacy of LMTM is to be confirmed in a 
placebo -controlled study  at a dose of 16 mg/day . A population PK model was developed 
based on Study TRx-237-036 and applied to plasma concentrations from the Phase 3 studies. 
Using per -patient  peak steady -state plasma concentration  (Cmax,ss) estimates, concentration -
response analyses for ADAS -cog 11 decline over 65 weeks were pe rformed and a C max,ss 
threshold of 0.373 ng/mL was identified. The clearance of parent MT /LMT  is most 
significantly associated with renal function, suggesting that the most important predictor of 
whether or not a subject achieves a parent MT /LMT  Cmax,ss above the threshold is creatinine 
clearance. At a dose of 8 mg/day, approximately 60% of subjects  with normal renal function  
Protocol: TRx -237-[ADDRESS_977615] -[ADDRESS_977616] plasma concentrations above th e threshold , whereas at a dose of 
16 mg/day, all subjects would.  
 
The co -primary endpoints are ADAS -cog 11 and ADCS -ADL 23, consistent with trials in 
subjects with mild to moderate AD. Based on the prior studies, a 12 -month duration is 
deemed sufficient to demonstrate superiority to placebo. To address concerns regarding 
inadvertent unblinding  due to urinary discoloration, subjects randomized to placebo may 
recei ve a 4 -mg MTC tablet as one of the four tablets to be taken daily . As subjects with early 
AD (also referred to as prodromal AD/mild cognitive impairment due to AD [ MCI -AD]) are 
also included in the study, 18F-FDG -PET and clinical composite scale s are included as 
sensitive endpoints for this subset of subjects.  
 
An open -label, “delayed -start” phase is also included to demonstrate a disease -modifying 
drug effect. During the delayed -start phase, placebo subjects are switched to receive the 
active treatment and thus become delayed -start subjects or “late” starters. Active -treatment 
subjects continue to receive active treatment (all at a dose of 16 mg/day) during the delayed -
start phase and are labeled as “early” starters. The rationale of a delayed -start design is that 
under the null hypothesis, when the active drug h as a purely symptomatic effect and has no 
effect on neuropathologic process, a delay in administration should have no lasting effect on 
subjects. A n effect that slows the progression of disease by [CONTACT_717199], rather than only attenuating symptoms , would be evident if late starters 
fail to “catch up” t o early starters . Demonstrating a disease -modifying effect would imply a 
sustained benefit of starting such drugs early. Throughout (that is, both the placebo -controlled 
and d elayed -start p hases ), all subjec ts and study personnel are blinded to each subjec t’s 
randomization to the early -start or late -start treatment group.  
 
9 OBJECTIVES  
The primary objectives of the study pertain to the randomi zed, double -blind treatment period. 
The secondary objectives are presented separately for the double -blind treatment period and 
the open -label, delayed -start phase . Further exp loratory analyses and exploratory analyses 
compared to external data are described in Section 17.5. 
9.1 Primary Objective s 
1. To compare the LMTM dose of 16 mg/day  with the placebo group on  the following 
co-primary endpoints : 
a. ADAS -cog 11  
b. ADCS -ADL 23 
2. To assess the safety and tolerability of LMTM 16 mg/day  given for up to 52 weeks 
9.2 Secondary Objectives  
9.2.1 Doub le-Blind Treatment Period 
3. To compare the LMTM dose of 16 mg/day  with the placebo group in annualized rate 
of whole brain atrophy over 52 weeks as measured by [CONTACT_717200] (MRI) and quantified using the Boundary Shift Integral (BSI)  
Protocol: TRx -237-[ADDRESS_977617] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 35 of 145 4. To compare the LMTM dose of 16 mg/day with the placebo group in temporal lobe 
18F-FDG -PET change in Standardized Uptake Value Ratio (SUVR) (normalized to 
pons) over 52 week s, restricted to subjects with Clinical Dementia Rating (CDR ) 
0.5 at Screening , if a predefined threshold is reached for a sufficient number of 
subjects providing data  
5. To compare the LMTM dose of 8 mg/day with the placebo group in temporal lobe 
18F-FDG -PET change in SUVR (normalized to pons) over [ADDRESS_977618] 0.5  at Screening , if a predefined threshold is reached for a 
sufficient number of subjects providing data  
6. To compare the LMTM dose of 8 mg/day with the placebo group on the co -primary 
endpoints (ADAS -cog 11 and ADCS -ADL 23)  
7. To compare the LMTM dose s of 8 and 16 mg/day with the placebo group in 
annualized rate of temporal and parietal lobe atrophy over 52 weeks as measured 
by [CONTACT_717201]  
8. To assess the safety and tolerability of LMTM 8 mg/day given for up to 52 weeks  
 
9.2.2 Open-Label, Delayed -Start Phase  
9. To determine if there is a difference in disease progression on the co -primary clinical 
endpoints and the MRI imaging endpoint for subjects who started treatment in the 
double -blind treatment phase and those who started treatment in the open -label, 
delayed -start phase (referred to as “early” and “late” LMTM starters, respectively)  
a. Only ADAS -cog 11 will serve as a secondary endpoint ; ADCS -ADL 23 and other 
imaging endpoints are exploratory with the aim to be directionally supportive  
10. To assess the safety and tolerability of LMTM given for up to 104 weeks 
 
Population PK analyses will be performed to estimate  PK exposure in each subjec t for use in 
the evaluation of exposure -response relationships . These will be defined in a separate 
Population PK SAP  or a dedicated section of the SAP . 
 
Additional analyses including exploratory and sensitivity analyses are described in Section 17 
and further detailed in the SAP.  
 
10 STUDY DESIGN  
10.1 General Description  
This is a two -phase outpatient study of LMTM administered as monotherapy in subjects  with 
early to mild -moderate AD: a randomized, double -blind, placebo -controlled, 52 -week 
treatment period followed by a 52 -week open -label, delayed -start phase. In the latter , all 
subjects are to continue with open -label treatment, such that subjects originally randomized 
to placebo are “late” starters of LMTM and subjects originally randomized to LMTM 
8 mg/day or 16 mg/day are “early” starters. The total duration of partici pation for an 
individual subject will be up to [ADDRESS_977619]  pathophysio logical changes as confirmed by [CONTACT_717202] a Mini -Mental State Examination ( MMSE ) score of 16-27 / Global 
Clinical Dementia Rating ( CDR ) score of 0.[ADDRESS_977620] used 
an AChEI and/or memantine within the 60 days prior to the baseline  assessment s (inclu sive 
Protocol: TRx -237-[ADDRESS_977621] -[ADDRESS_977622] of 0.5) . The 
primary treatment group comparisons are of LMTM 16 mg/day  and placebo; secondary 
comparisons will be done for subjects receiving LMTM 8 mg/day versus  placebo. Following 
completion of the 52 -week treatment period, subjects will continue open -label treatment with 
LMTM 16 mg/day  for a further 52 weeks ; prior treatment assignment will not be unblinded . 
(However, upon completion of the initial 52 -week, double -blind, placebo -contro lled 
treatment period, the database  will be locked and unblinded for  analysis ; individual subject 
prior treatment assignment will not be divulged to subjects or individuals involved in the 
operational conduct of the ongoing open -label, treatment phase) . A description of the study is 
provided below; s ee Section 10.2 for a summary of the alternate arrangements that may be 
implemented due to the Coronavirus Disease 2019 Public Health Emergency  (hereafter 
referred to as COVID -19). 
 
Following provision of written informed consent by [CONTACT_423] (and/or LAR, consistent with 
national and/or local law) and study partner (s), eligibility will be assessed initially during the 
Screening period which may require multiple visits  (collectively designated as Visit  1).  
 
A sufficient number of subjects will be recruited from sites in North America  ([LOCATION_002] 
and Canada)  and Europe such that  approximately 500 subjects are enrolled . Beginning with 
Protocol Version  5.0, approximately 450 are to be enrolled and randomized  in a 4:1:4 ratio 
(at the study level) to the LMTM 16 -mg/day (200 subjects) , LMTM  8-mg/day  (50 subjects) , 
and placebo  (200 subjects)  groups . The randomization will be stratified by [CONTACT_926] ( three 
levels: MMSE 16-19, 20-25, or 26 -27, with a target ratio of approximately 2:3:1 for those 
randomized to Protocol Version  5.0 and above ), prior use of AChEIs and/or memantine (two  
levels: prior use of either any AChEI s and/or memantine  or none) , and region ( two levels: 
North America  or Europe) .  
 
Eligibilit y will be confirmed during the Screening  period , with the duration of screening 
depending on whether or not  the subject enters the study using an approved AD medication, 
described  as follows (and illustrated in  Table 10-1): 
• The Screening period will be up to 9 weeks for subjects who  are not receiving an 
AChEI and/or memantine at the time of signing the Informed Consent  (Initial 
Screening Visit, Visit 1) . 
• The Screening period will be extended for up to a further 6 weeks , 15 weeks in total  
(+7 days at Sponsor discretion ), for subjects who are receiving an AChEI and/or 
memantine at the time of signing the Informed Consent  to allow for the performance 
of necessary screening tests to confirm eligibility prior to the discontinuation of 
AChEI and/or memantine and to permit a washout of at least [ADDRESS_977623] 
dose prior to the baseline assessments  (inclu sive of  the baseline 18F-FDG-PET scan in 
subjects who have a screening CDR of 0.5) . 
• The Screening visit window may be further extended at the discretion of the Sponsor 
when justification is provided.  
 
For eligible subjects, one Baseline/Randomization (Visit 2: imaging , efficacy, and safety) , 
and five post -Baseline  double -blind visits (Visit 3: safety , and Visits 4, 5, 6, and 7: efficacy,  
imaging , and safety) , and three open -label treatment visits (Visits 8 [telephone contact [INVESTIGATOR_13701]], 
9, and 10)  are scheduled . Unscheduled visits may occur as needed for assessment, or upon 
early termination . In addition, subjects are to be followed as needed to monitor for the 
resolution or acceptable stabilization of AEs (including after the last dose), consistent with 
the investigator’s medical judgement . For women of childbearing potential this includes a 
Protocol: TRx -237-[ADDRESS_977624] -[ADDRESS_977625] exposure to study drug 
in the event of delayed menstruation.    
 
Visit 2 (Base line/Randomization) must be scheduled to occur in the morning  when the first 
dose of study drug will be administered in the clinic.  Visit 3  (after 4 weeks of study drug) , 
Visit 7 (after 52 weeks of study drug) , and Visit 10 (after 104 weeks of study drug) should 
also be scheduled to occur in the morning; subjects are to be instructed not to take the 
morning dose of study drug as it  will be administered in the clinic . Subjects will be required 
to remain at the clinic for at least [ADDRESS_977626] scales, ADAS -cog 13 and ACDS -
ADL 23, will be performed at Baseline , approximately every 3 months  during the double -blind 
treatment period  (Visits 4, 5, 6 , and 7 ), and after the additional 26 and 52 weeks of open -label 
treatment  (Visits 9 and 10) , or upon early termination . These will be captured electronically 
on tablets and subject to independent review . The MMSE and CDR will be repeated after 52 
weeks  of double -blind treatment  (Visit 7) and at the final open -label visit (Visit 10 ) or upon 
early termination . To the greatest extent practicable, a consistent  rater(s) for a given subject is 
to be maintained throughout the study.  
 
The MRI obtained during Screening will also be the basis for the baseline volumetric MRI; 
volumetric MRI will be repeated approximately every 13  weeks (Visits 4, 5, 6, and 7). The 
imaging endpoints will be quantified by [CONTACT_717203]. MRI will also be done 
after the additional 26 and 52 weeks of open -label treatment (Visits 9 and 10).18F-FDG -PET 
imaging will be performed at Baseline and Visit 7 (after 52 weeks), or upon early 
termination, only in subjects with CDR 0.5.  
 
Safety assessments (AE and concomitant medication review , vital sign review , targeted 
physical and neurological examination s, and review of clinical laboratory results) will be 
performed by  [CONTACT_717204] ; where 
specified , the assessments must be made by a medical assessor (physician, doctor of medicine  
[MD], or doctor of osteopathic medicine  [DO]) . These will be performed at each clinic visit 
during the double -blind treatment period (Visits 2  to 7) and after 26 and 52 weeks of open -
label treatment  (Visits 9  and 10), and when needed to follow up on an AE . Selected safety 
assessments will also be performed during a telephone contact [CONTACT_3435] 4 weeks in the open -
label, delayed -start phase (Visit 8) . An o phthalmological examination (only to be conducted 
in subjects with lens implants) will be performed prior to the first dose of study drug  (during 
the screening  procedures  or as part of the baseline  assessments ) and at the final visits in each 
of the study phases ( Visit s 7 and 10 ), or upon early termination , to assess for potential 
discolo ration  of the lens.  See Table 10-2, Table 10-3 and Section 15.4 for more details on 
these assessments and the  qualifications required to perform them .  
 
Other assessments include collection of blood for plasma and whole blood MT concentration 
determination and (optionally) collection of a blood sample for Apolipoprotein  E (ApoE ) 
genotypi[INVESTIGATOR_007].  
10.[ADDRESS_977627] and 
Protocol: TRx -237-[ADDRESS_977628] -[ADDRESS_977629] subjects due to COVID -19 
as described in Sections 10.2.1  and 10.2.2 , respectively . For subjects already enrolled under 
earlier versions of the protocol (prior to Protoc ol Version 6.0), subjects will be re -consented 
at their next in -clinic visit;  in the interim, verbal consent will be obtained as needed for 
changes to study procedures. Changes to the statistical analyses, includ ing sensitivity 
analyses to address any impact of COVID -[ADDRESS_977630] ceased  and abstention from treatment with an AChEI 
and/or memantine should be retained . Screening MMSE/CDR/DV, brain scans, and G6PD 
blood sample collection do not require repetition if already confirmed. The approach for 
individual assessments is described further below . Re-screening is addressed in Section  11.3. 
 
Both t he Screening  visit (including informed consent and all screening assessments)  and the 
Baseline/Randomization visit must continue to occur in the clinic at the study site. The first 
dose of study drug (Visit 2) will be administered in the clinic. This visit should be scheduled 
to occur in the morning and subjects will be required to remain a t the site for at least [ADDRESS_977631] -Baseline visits , i.e., Visits 3, 4, 5, 6 and 7 (after 4, 13, 26, 29, and 
52 weeks of double -blind study drug) , for clinical safety assessments (adverse event and 
concomitant medication recording/review),  safety and PK blood sample collection  (inclusive 
of the optional genotypi[INVESTIGATOR_717132]  7), as well as efficacy assessments , may be completed in -clinic at the site, in the 
subject’s home  by [CONTACT_717205] , or at other safe, suitable alternative  location,  if 
deemed necessary to protect a subject due to COVID -19. Similarly, Visits 9 and 10 (after 26 
and 52 weeks of open -label treatment) may also be completed in  the clinic at the site, in the 
subject’s home  by [CONTACT_717205] , or at other safe, suitable alternative  location . 
Efficacy scales may also be performed remotely , if approved by [CONTACT_717206] a 
case-by-case basis,  as further described below. The principa l investigators ( PIs) retain 
unilateral decision -making  and discretion regarding  ongoing subject participation dependent 
on local circumstance and authority recommendations. Travel to the investigational site is the 
subject ’s decision . The following procedures are also to be implemented as necessary:  
• Consideration may be given on an individual site basis to expand the allowable time 
windows for study visits if a site closure is anticipated to be short -term. 
• Alternative arrangements for dispensing study drug supplies ( e.g., home delivery that 
would not raise new safety risks) may be permitted if deemed necessary to protect 
subjects due to COVID -19. If a trial site is not able to deliver  study drug to subjects, 
the study drug may , as an exception , be shipped directly to the subjects by a 
distributor independent from and acting  on behalf of the Sponsor , in line with national 
law or temporary emergency measures. R equirements for obtaining subject consent  
consisten t with local and nationa l requirements , maintaining the specified  study drug  
storage conditions  and handling , accountability , and compliance monitoring will be 
addressed and documented.  In the event that  a given  subject cannot attend a visit at 
the study site, the study personnel  will make reaso nable attempt s to assess study drug 
Protocol: TRx -237-[ADDRESS_977632] -[ADDRESS_977633] or study partner(s)  and document the assessment in the 
source until it can be verified . 
• The ADAS -cog [ADDRESS_977634]’s home or at other safe, suitable 
alternatives , in person  or remotely via videoconference. For remote administrations  to 
avoid loss of data , MedAvante ProPhase  will provide clinical sites with electronic 
tablets  provisioned with  Zoom  (or equivalent)  videoconferencing software only6. The 
electronic t ablets will be shipped by [CONTACT_717207] , and 
guidance will be provided to subjects and study partners regarding the use of the 
electronic tablets for remote scale administration as well as instructions for returning 
the electronic tablets to the sites. When assessments are performed remotely , the rater 
will confirm the identity of the subject  and study partner before proceeding . The 
approved site raters will administer the scales through the videoconferencing software 
and will docu ment the assessment as they would if performing the assessment in 
person ; source data and audio recording s will still be captured via the Virgil system.  
o In the remote administration of the ADAS -cog 13 (if applicable at that visit) , the 
standard  (i.e., validated) mode of administration has been adapted to enable data 
to be captured by [CONTACT_717208] e, with the exception of Commands (only 
partially supported , and thus a total score cannot be calculated for this subset), 
Ideational Praxis, and Number Cancellation. Due to these missing data (not all 
subtests can be administered remotely ), total scores will not be calculated  directly 
for the remote administration of the ADAS -cog 13 but a derived upscaled score will 
be used for analysis as defined in the SAP . 
• The MMSE, CDR, and ADCS -ADL [ADDRESS_977635]’s home or 
at other safe, suitable alternatives in person or remotely  by [CONTACT_717209] . If 
assessments are performed remotely , the rater will confirm the identity of the subject  
and study partner before proceeding . The approved site raters will document the 
assessment as they would if performing the assessment in person; source data and 
audio recording s will still be captured via the Virgil system .  
o In the remote administration of the MMSE  (if applicable at that visit) , the 
approved site rater will administer as much of the MMSE as possible. For those 
elements that cannot be administered remotely, the rater will confirm that these 
were omitted before submitting the data to MedAvante -ProPhase per usual 
practice. Due to m issing data, total MMSE scores for remote assessments will not 
be directly calculated but upscaled as per the SAP . 
o In the remote administration of an ADCS -ADL [ADDRESS_977636]  (if applicable at that 
visit) , all items will be scored . 
• All MRI  scans  are to be performed at approved MRI centers using approved scanners; 
no alternative scanners will be accepted  and there is to be no change in scanner for a 
given subject over the course of the study .  
o Guidance will be provided for scheduled MRI visits at approved imaging 
centers that may be closed due to COVID -19, including acceptable windows 
outside the scheduled visit window during which MRI scans can still be 
performed at approved imaging centers and would be accepted for analysis . 
 
[ADDRESS_977637] on the data collected , and to minimize loss of data.  
Protocol: TRx -237-[ADDRESS_977638] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 40 of 145 • In subjects with CDR  0.5 at Screening, 18F-FDG -PET imaging will be performed at 
Baseline (unless the Sponsor approves subject randomization without a brain 
18F-FDG -PET scan,  if the scan cannot be performed  due to COVID -19). All 
18F-FDG -PET scans are to be performed at approved PET centers using approved  
scanners ; no alternative scanners will be accepted and there is to  be no change in 
scanner for a given subject over the course of the study.  
o If a Baseline  18F-FDG -PET scan cannot be done due to lack of imaging 
facility , a follow -up 18F-FDG -PET scan will not be required  
• Blood samples for safety laboratory assessments  and PK as well as optional 
genotypi[INVESTIGATOR_717133] , in the subject’s 
home, or at other safe, suitable alternative  location,  using the central laboratory 
(Labcorp ) kits for sample collection; samples are to be shipped to Labcorp  for 
analysis using a designated courier service , and the shipment parameters as per  the 
laboratory manual  must be adhered to during transfer ( e.g., between the subject’s 
home, primary care pro vider, or clinical site) .  
o If blood samples for safety laboratory assessments cannot be shipped to Labcorp , 
sample analysis for hematology testing will be performed at a local laboratory. As 
the first post -Baseline (Visit 3) hematology sample analysis is key in monitoring 
the adverse event of special interest (AESI) of hemolytic anemia, clinical sites 
will not be permitted to randomize a subject if the  Visit [ADDRESS_977639]. Blood chemistry and genotypi[INVESTIGATOR_717134] a 
local laboratory or m ay be stored at -20 °C at the clinical site until shipment to the 
central laboratory.  
o If blood samples for PK laboratory assessments cannot be shipped to Labcorp , 
plasma PK samples should be stored at -20 °C at the clinical site; whole blood PK 
data may be compromised as the samples are stable for a limited period. The 
University of Aberdeen GLP Test Facility  must analyze  the PK whole blood 
sample within [ADDRESS_977640] serum pregnancy 
testing (to be performed at the subject’s home or a t other suitable, safe 
alternative s) in the event of a delayed menstrual period to rule out possible 
pregnancy , during study conduct and for up to [ADDRESS_977641]’s home  (although timing of previous dose should be 
ascertained as accurately as possible) . 
• Multiple study partners participating only as caregivers will be permitted for a given 
subject, either simultaneously or as replacements for previous study partners, with no 
specified maximum. For study partners participating as informants providing data 
from assessments of the subject, a maximum total of two study partners ( i.e., one 
replacement) would normally be permitted for a given subject; however, up to a total 
of four study partners ( i.e., three replacements) are permitted if circumstances change 
due to COVID -[ADDRESS_977642] has more than one study partner providing data for analysis.  
Protocol: TRx -237-[ADDRESS_977643] -[ADDRESS_977644] -baseline data for th is study. All study 
subjects should continue to attend clinic visits as defined in the protocol as long as it is safe 
and feasible to do so. However, in the event that subjects and/or study partners are unable to 
attend post -Baseline visits at the clinic in person, guidance  for continued data collection to be 
completed  in the subject’s home or at o ther safe, suitable alternatives is described in  
Section  10.2.[ADDRESS_977645] participation in the study will be 
recorded in the eCRFs.  
 
Due to the unpredictable nature of COVID -19, remote monitoring may be conducted in lieu  
of onsite monitoring , including the targeting of critical data and source (for example to 
include consent, eligibility , subject  safety and drug accountability) for periods where a source 
data verification backlog exists due to inaccessibility  of the site to the clinical monitor . Any 
change to monitoring of the study as a direct result of COVID -19, such as remote monitoring 
policies and procedures,  will be captured through an addendum/amendment to  the Clinical 
Monitoring Plan (CMP) . Every effort will be made to complete the same monitoring tasks 
remotely as would be conducted onsite while accommodating site -specific policies and 
limitations. Every effort will also be made to ensure the continued protection of subject 
safety, subje ct rights, and data integrity. Any deviations from the CMP  will be clearly 
documented.  
 
There is the possibility of increased amounts of missing data and protocol deviations due to 
limitations on protocol implementation imposed by [CONTACT_4113] -19. Clinical sites are expected to 
maintain documentation of missing data and protocol deviations in source documents with 
data entered accordingly in the eCRFs.  
 
As the study continues, there will be a need to address other new and challenging scenarios in 
real time as they arise at different clinical sites during COVID -19. The Sponsor will continue 
to assess any limitations imposed on protocol implementation that may pose safety risks to 
study subjects,  and whether it is feasible to mitigate these risks by [CONTACT_717210]/or procedures  such that subject  safety, trial integrity, and compliance with regulations are 
assured.  
 
10.2.[ADDRESS_977646] o f analyses will be 
provided in the SAP including the conditions that need to be met in order to trigger these 
analyses. At a minimum, the number of missing or likely impacted assessments and data 
points will be provided.  
 
Sites projected to recruit more than 10% of the subjects will be closely monitored to ensure 
that the MMSE balance is met as closely as possible. It is acknowledged that COVID -[ADDRESS_977647] on certain MMSE groups as they are more likely to be asked to take social 
distancing precautions ; corresponding sensitivity analyses will be implemented to assess the 
impact  as briefly described below and summarized further in the SAP .  
Protocol: TRx -237-[ADDRESS_977648] -[ADDRESS_977649] on primary endpoints. If 
more than 5% of all the assessments (over all subjects and visits) of a given primary endpoint 
are impacted by [CONTACT_4113] -19 (based on the eCRF Covid -[ADDRESS_977650] Assessment), the 
assessments impacted by [CONTACT_4113] -19 will be excluded and upscaled when the respectiv e 
primary endpoint is analyzed.  
 
Other sensitivi ty analyse s include : 
• Subgroup analysis by [CONTACT_717211] (in -clinic, remote). A subject 
is assigned to the subgroup with the most visits done with respect to in -clinic or  
remote ly (excluding Baseline and Week 52, which must be performed in -clinic).  
• ADAS -cog11: Include only the subset of items (for all visits), which can be 
administered remote ly by [CONTACT_165164] . 
• ADCS -ADL 23: Exclude items which are affected by [CONTACT_4113] -19 restrictions.  
• A composite scale designed as a COVID -[ADDRESS_977651] free joint score (“COVID -19 
Composite Scale”) will be analyzed. It will include items , selected from ADAS -Cog 11 
and ADCS -ADL 23, that are not expected to be impacted by [CONTACT_4113] -19. 
 
Details and further analysis will be specified in the SAP.  
 
If a significant number of  assessments is impacted by [CONTACT_4113] -19, a sample size increase may 
be applied. The conditions for this to happen will be outlined and specified before any 
analyses/assessments are conducted.  
 
As indicated  above,  a more exhaustive list will be provided accounting for regulatory 
guidelines in the SAP.  
10.[ADDRESS_977652] AD based on a diagnosis of probable 
AD or MCI -AD according to the criteria of the 2011 National Institute on Aging [NIA] / 
Alzheimer’s Association [AA] with documented pathological chan ges as confirmed by 
[CONTACT_717212]  (McKhann et al., 2011 ; Albert et al., 2011) . The allowable severity 
will be a MMSE score of 16 to 27 (inclusive) and Global CDR score of 0.5  to 2 (if 0.5, 
including a score of >0 in one of the functional domains ). Inclusion and exclusion criteria are 
given in Section 11.  
 
The study will be conducted in approximately  [ADDRESS_977653]  approximately 500 subjects who will 
be enrolled , of whom approximately 450 are to be enrolled and randomized under Protocol 
Version  5.0 and above . Randomization will be such that  subjects will be assigned to the 
MMSE severity groups at study level based on screening MMSE score with a target  ratio of 
approximately 2:3:1 (MMSE 16 -19, MMSE 20 -25, MMSE of 26 -27, respectively)  for those 
Protocol: TRx -237-[ADDRESS_977654] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 43 of 145 randomized to Protocol Version  5.0 and above . To achieve this target, enrollment will be 
monitored and controlled at the site level for high recruiting sites (i.e., sites projected to 
recruit more than 10% of the subjects ) as per Section 10.2.3  and capped as needed at the 
study level  via the Randomization and Trial  Supply  Management (RTSM ) system. Subjects 
who drop out after randomization  will not be replaced; subjects will be encouraged to 
continue with study visits until the scheduled completion  of the double -blind treatment period 
(Visit 7) . Only subjects who continue in the study and receiv e LMTM until and including the 
last open -label visit (Visit 10) may  be eligible for a separate  EAP .  
10.[ADDRESS_977655] will be up to 120 weeks, including 
a Screening period of up to 16 weeks (112 days , with further exten sion permitted at the 
discretion of the Sponsor when justification is provided ), a double -blind treatment period of 
[ADDRESS_977656] a likely diagnosis of probable AD or MCI -AD prior to being offered 
the consent forms  on the basis of  investigator interview and examination . Subjects for whom 
legally acceptable informed consent has been obtained will be screened at trial sites for 
determination of eligibility to enter the study on the basis of further diagnostic evaluations, 
cognitive assessments, and safety assessments (clinical laboratory testing, vital signs, 
complete physical and neurological examinations, and a local 12-lead electrocardiogram 
[ECG ]). An overview of the screening assessments is provided in Table 10-1 below ; 
assessments must be performed in the sequence presented . Where required and indicated, 
eligibility should be  confirmed prior to progressing to the next screening assessment . 
18F-FDG -PET, to be evaluated only in subjects with CDR 0.5  at Screening , is not an 
eligibility assessment ; however , a valid baseline scan is required prior to randomization , 
hence it is included on this table . See Section 10.2 for a summary of alternate arrangements 
that may be implemented due to COVID -19. 
 
Protocol: TRx -237-[ADDRESS_977657] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 44 of 145 Table 10-1: Schedule of Screening Assessments   
(Over Multiple Visits, Collectively Designated Visit 1)  
Required Sequence of Assessments  Time Frame  
On AChMem  
at Start of Screening  Not on AChMem  
at Start of Screening  
1. Likely diagnosis of  probable AD or MCI -AD (M)  
9 to 16 weeks before 
Baseline ,  
Days -112 to -63  
(+7 days at Sponsor 
discretion )d ≤[ADDRESS_977658] (and/or LAR) and Study 
Partner (s) (Ma) 
3. Demographics  
4. Medical history and concomitant medication review (M)  
5. NIA/AA probable AD or MCI -AD clinical diagnosis 
confirmed (M)  
6. MMSE  
7. CDR  
8. Diagnostic Verification  Form (M)  
9. Medical assessments (M):  
Vital sign measurementb 
Physical/neurological examinationsc 
12-lead electrocardiogram  
Laboratory testing:  
Serum chemistry  
Hematology  
Haptoglobin  
Folate / vitamin B [ADDRESS_977659] (women of childbearing 
potential only)  
10. Wait for Confirmation of Eligibility email received from 
MedAvante -ProPhase and laboratory testing 
confirmation of compliance by [CONTACT_717213] 11 
11. Amyloid PET scan  
• Document ation of prior positive scan  
OR 
• If no negative scan within prior 3  years, perform 
using approved amyloid ligand  
12. Wait for Amyloid PET scan confirmation of compliance 
by [CONTACT_5737] / central imaging center (if scan required)  
13. MRI  scan 
14. Wait for MRI confirmation of compliance by [CONTACT_717214]  
15. Withdraw ACh EI/m emantine  ≥ [ADDRESS_977660]  (M) Repeat within [ADDRESS_977661] 0.5   
(Not a n eligibility assessment , but i ndependent 
confirmation of a valid baseline 18F-FDG -PET) Within [ADDRESS_977662] dose of A ChEI 
and/or memantine  Within [ADDRESS_977663] 0.5  Before randomization  
Abbreviations: AChEI = anticholinesterase inhibitor; ACh/Mem = AChEI and/or memantine; AD = Alzheimer’s disease; 
CDR = Clinical Dementia Rating; 18F-FDG = 18F-fluorodeoxyglucose positron emission tomography; LAR = Legally 
Acceptable Representative ; MCI -AD = mild cognitive impairment due to Alzheimer’s disease; MMSE = Mini -Mental State 
Examination; MRI = magnetic resonance imaging; PET = positron emission tomography  
Note: (M) requires medical assessor ( physician  / MD / DO) ; study partner = caregiver or informant  
Protocol: TRx -237-[ADDRESS_977664] -[ADDRESS_977665] be a p hysician  (such as a neurologist , psychiatrist ) or 
other medically qualified assess or (physician/ MD/DO ); in the case of subjects with reduced decision -making capacity, 
LARs , consisten t with national and/or local law, may provide written informed consent  
b Vital signs include seated blood pressure and pulse, height, and body weight  
c Based on medical history, subjects with a history of lens implantation  should be scheduled for an ophthalmological 
examination  by a licensed  ophthalmologist, optometrist, or other suitably qualified medical assess or (physician/MD/DO) 
to occur prior to the first dose of study drug (once eligibility has been confirmed) , during the screening procedures or as 
part of the baseline assessments  
d The Screening visit window may be further extended at the discretion of the Sponsor when justification is provided.  
 
 
[IP_ADDRESS]  Diagnostic and Cognitive Eligibility Assessments  
After consent is obta ined, the principal investigator ( PI) (or sub-investigator [SI] ) is required 
to review medical records and confirm the accuracy of the diagnosis during the examination 
of each subject.  The NIA/AA diagnostic interview must be conducted with the subject , and 
the designated study partner ( i.e., a caregiver  or informant ) providing data from assessments 
of the subject, by [CONTACT_978] (or SI). In brief : 
• Subject s with probable AD dementia must have insidious onset, worsening 
impairment in at least two cognitive areas (learning and recall, language, executive 
function, visuospatial skills), sufficient to significantly interfere with work or usual 
activities, that is not explained by [CONTACT_477883], drugs, major psychiatric disorder, medical 
illness, cerebrovas cular disease, other forms of dementia, or neurological disorder.  
• In subjects with MCI -AD, there should be evidence of concern about a change in 
cognition in comparison with the person’s previous level verified by a knowledgeable 
informant or clinician. There should also be evidence of lower performance in 
epi[INVESTIGATOR_297120] y than would be expected for the subject’s age and educational 
background (typi[INVESTIGATOR_897] [ADDRESS_977666] deviations below the mean). Other mild 
cognitive deficits may also be present, but there must be preservation of independence 
in functional abilities. Su bjects should not meet the criteria for dementia. The 
cognitive changes must be mild and there must be no evidence of a significant 
impairment in social or occupational functioning. Impairments must not be explained 
by [CONTACT_477883], drugs, major psychiatric di sorder, medical illness, cerebrovascular 
disease, other forms of dementia, or neurological disorder.  
 
The diagnostic interview should be completed and documented in the subject’s medical 
records prior to administering the MMSE and CDR . The MMSE will be the first evaluation at 
Screening (Visit 1), followed by [CONTACT_717215] , to obtain Severity Ratings . These will be assessed 
on a Virgil tablet. Note that the CDR assessment should only be performed if the subject 
meets the MMSE inclusion criteri on. If the subject does not qualify with either of these 
scales, no further assessments should be made and the subject should be considered a screen 
failure. If eligible, a  Diagnostic Verification F orm will be completed by [CONTACT_978]/SI  and 
submitted to i ndependent reviewers  at MedAvante -ProPhase  Inc., who  will confirm the 
accuracy of the diagnosis and Severity Rating s and will provide confirmation (by e -mail) that 
the subject is eligible to proceed to the remaining screening assessments . The PI [INVESTIGATOR_717135] t o subject randomization . In the 
event that MedAvante -ProPhase central reviewers  identify  issues that cannot be resolved, the 
subject will be deemed not eligible . The subject may be re -screened  (after a wait of [ADDRESS_977667] MMSE), inclusive of repeat of MMSE and CDR  which will again be subject to the 
independent review to confirm eligibility.  
 
Protocol: TRx -237-[ADDRESS_977668] -[ADDRESS_977669]  has a negative amyloid  PET scan 
that is dated  >[ADDRESS_977670]  be conducted as part of 
screening . A negative amyloid  PET scan  within 3 years prior to Screening  is exclusionary 
and no amyloid PET scan should be performed . If a new amyloid PET scan is performed as 
part of screening, local determination (or central for those sites not able to read locally) of 
positivity using criteria routinely applied at the local imaging facility and using an amyloid 
PET ligand that is approved in the country of participation will be accepted. With subject  
(and/or LAR)  consent, these and previous amyloid PET scans will be sent to a core imaging 
laboratory for storage  and later exploratory analysis .  
 
The screening assessments should be performed so that MRI is the last of the key eligibility 
assessment s to be scheduled . The screening MRI scan (s) results (of sufficient quality) must 
be available for the purpose of inclusion/exclusion review and confirmation of compliance 
with inclusion and exclusion criteria by [CONTACT_717216]. If the initial 
screening MRI is not of sufficient quality , then a repeat screening scan may be performed. If 
the repeat scan cannot be accomplished within the pertinent  window  (see Table 10-1), then 
the subject must be re -consented and re -screened. For subjects who are re -screened for other 
reasons and an acceptable MRI scan was already completed during the original Screening 
window, the scan does not require repetition . See Section 10.2 for a summary of alternate 
arrangements that may be implemented due to COVID -19.  
 
In subjects receiving an AChEI and/or memantine at Screening, documentation of amyloid 
positive PET imaging (either by [CONTACT_717217]) and 
confirmation of compliance with inclusion and exclusion criteria by [CONTACT_717218] (inclusive of screening MRI) , must be available  prior to the discontinuation 
of such medication.  
 
At any step, s hould any of the assessments indicate th e subject’s ineligibility, the screening 
process should  be stopped immediately (no further assessments performed) and the subject 
considered a screen failure.  The reason (s) for screen failure is  (are)  to be documented.  
 
[IP_ADDRESS]  Other Medical Screening Assessments  
Medical screening assessments will include a review of medical history and concomitant 
medications. Physical and neurological examinations will be conducted by a qualified 
medical ass essor (physician/ MD/DO)  at Screening. The complete physical examination is to 
consist of an evaluation of the skin, head, eyes, ears, nose, throat, neck, thyroid, lungs, heart, 
lymph nodes, abdomen, and extremities. The complete neurological examination is to consist 
of an evaluation of appearance and behavior (including observ ation for tremor and abnormal 
movements) and an evaluation of the following: speech, cranial nerves (2 -12), motor (muscle 
strength), muscle tone, sensory abnormalities, coordination, gait, and tendon reflexes. At 
Screening, the primary aim of this assessment is to exclude neurological disorders other th an 
the condition of interest. Any abnormalities  noted on either the physical or neurological 
examination  should be described.   
 
An ophthalmological examination will be performed by a licensed  optometrist, 
ophthalmologist, or other suitably qualified medical ass essor (physician/ MD/DO) prior to the 
first dose of study drug  (during the  screening procedures or as part of the  baseline  
assessments ) in subjects with a history of lens implantation.   
Protocol: TRx -237-[ADDRESS_977671] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 47 of 145  
At Screening , vital signs will be measured  (seated blood pressure and pulse, body weight,  and 
height) , blood obtained for clinical laboratory testing, and a 12 -lead ECG performed. Clinical 
laboratory testing at Screening will include  hematology, serum chemistry panels, glucose -6-
phosphate -dehydrogenase ( G6PD ) activity, haptoglobin, vitamin B 12, and folate . A serum 
pregnancy test will be performed in women of childbearing potential only. Thyroid 
stimulating hormone ( TSH ) will be measured during screening , with a thyroid hormone panel 
obtained only in the event of an elevated TSH , if clinically warranted , to determine further 
treatment before re -screening . Clinical laboratory testing (serum chemistry, hematology , and 
serum pregnancy test) and medical history and concomitant medication review should be 
repeated within 42 days of Baseline if the initial screening assessments were performed 
earlier.  Review of the clinical laboratory and ECG results should be performed by a medical 
assessor (physician/ MD/DO).  
 
Should a subject be found to have met one or more of the exclusion criteria, he/she will be 
considered a screen  failure; the reason(s) will be documented. For eligible subjects, f indings 
will be documented in the subject's medical record and in the electronic Case Report Form 
(eCRF ). 
 
10.5.[ADDRESS_977672] -randomization assessm ents during the double -blind treatment period  
are presented below in  Table 10-2. The procedures are further described, briefly, in the 
subsections that follow (with reference to more detailed discussions).  See Section 10.2 for a 
summary of alternate arrangements that may be implemented related to COVID -19. 
 
Protocol: TRx -237-[ADDRESS_977673] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 48 of 145 Table 10-2: Schedule of Post -Screening Assessments  (Double -Blind Treatment Period)  
Visit Name [CONTACT_717330] -Blind Treatment Period  
Visit Number 2 3 4 5 6 7 (or ET)  
Also 
Baseline/  
Day [ADDRESS_977674]-
Dose  (±3) (±14)  (±14)  (±14)  (±14)  
18F-FDG-PET (see Table 10-1) b       X 
Randomization  X       
MRI c    X X X X 
ADAS-cog13 and ADCS -ADL23 d, o X   X X X X 
AE/Concomitant Medication  
Recording/ Review e (M) X X X X X X X 
Targeted P hysical/Neurological 
Examinations f (M) X X X X X X X 
Ophthalmological Examination g (M/O) X      X 
Clinical Laboratory Testing h (M) X  X X X X X 
Pregnancy Testing i X  X X X X X 
Blood Pressure, Pulse, Body Weight  j X X X X X X X 
Study Drug Dis pensing X   X X X Xp 
Study Drug C ompliance Assessment k   X X X X X 
Blood Sample for MT Concentration l X X X    X 
Blood Sample for Genotypi[INVESTIGATOR_007] (optional) m X       
MMSE  n, o       X 
CDR  n, o       X 
Abbreviations: ADAS -cog 13 = Alzheimer’s Disease Assessment Scale – cognitive subscale (13 -item); ADCS -ADL 23 = 
Alzheimer’s Disease Cooperative Study – Activities of Daily Living (23 -item); AE = adverse event; CDR = Clinical 
Dementia Rating; EOT/ET = end of treatment/early termination; 18F-FDG -PET = 18F-fluorodeoxyglucose positron emission 
tomography; MMSE = Mini -Mental State Examination; MRI = magnetic resonance imaging; MT  = methylthioninium.  
Note: Screening assessments , which include a PET scan for amyloid and a 12 -lead ECG, are described in Table 10 -1 
Note : (M) = assessment of the result requires medical assessor ( physician / doctor of medicine [MD] / doctor of osteopath ic 
medicine  [DO]); M/O = licensed optometrist/ophthalmologist or other suitably qualified medical assessor  
(physician/MD/DO)   
a The Baseline visit (Visit 2) may span over 2 -3 days if necessary; Day [ADDRESS_977675] 0.5. The Baseline 18F-FDG -PET should be performed within a 42 -day window prior to Baseline 
(Visit  2), at least [ADDRESS_977676] dose of AChEI and/or memantine, and as described in Table [ADDRESS_977677]’s last 18F-FDG -PET scan was performed ≥[ADDRESS_977678] be repeated as part of the ET visit assessments within the time window of the EOT/ET vis it (i.e., ± 14 days of 
the EOT/ET visit ).  
Note : Use of sedatives is not permitted within [ADDRESS_977679]’s fasting (for at 
least 4 to 6 hours) blood glucose should be <180 mg/dL (<9.9 mmol) for the injection to take place.  
c Volumetric MRI scans will be obtained at Screening (which also will be the baseline scan) and approximately every 
13 weeks after randomization; the screening MRI will also be used for purposes of confirmation of compliance with 
inclusion and exclusion criteria by [CONTACT_717216]. Subjects may or may not be receiving concomitant 
treatment with AChEI and/or memantine at the time of the screening MRI; the screening MRI will be used as the 
baseline. For subjects who terminate early, if the sub ject’s last MRI scan was performed <[ADDRESS_977680] to central review by 
[CONTACT_717219] -ProPhase clinicians in the native language.  
e AEs and concomitant medication use will be evaluated by a medical assessor (M) and recorded on an ongoing basis 
starting after signing of informed consent, including at each scheduled visit; unscheduled visits should occur as needed 
to follow up an AE (including after the last dose of study drug), consistent with the physician/ MD/DO judgment.  
Protocol: TRx -237-[ADDRESS_977681] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 49 of 145 f Targeted examinations will be performed by a medical assessor (M) pre-dose and approximately [ADDRESS_977682] dose of study drug (Visit 2). Thereafter, targeted examinations are to be performed at each 
subsequent clinic visit (or upon ET). At a minimum, targeted examinations should include heart and lung auscultation 
and brief neurological assessment guided by [CONTACT_717186]/symptoms/AEs ( e.g., evaluating subjects for potential 
serotonin toxicity ).  
g Ophthalmological examination (slit lamp) is to be performed only in those subjects with history of lens implant to 
evaluate discoloration of lens. The initial examination will be performed prior to the first dose of study drug (during the 
screening procedures or as part of the baseline assessments); performance of this examination is not restricted to the 
[ADDRESS_977683] dose of study drug.  The final evaluation (EOT/ET) should be done after completion of the 
efficacy assessments.  
h At each identified time point, blood samples will be obtained for chemistry and hematology panels; results are to be 
reviewed by a  medical assessor  (M). Testing is also to be performed as needed to follow -up on an AE.  
i Serum pregnancy testing is to be performed at each identified time point in women of childbearing potential only.  
j Within 1 hour prior to dosing on Day 1, blood pressure and pulse will be measured with subjects in a seated position 
(for at least 5  minutes). The post -dose measurement on Day [ADDRESS_977684] -dose (after the 
1-2 hour PK sample i s taken). Body weight will be measured at each visit (pre -dose at Visit 2).  
k Compliance with study drug will be assessed by [CONTACT_21442] (see Section 12.6). 
l At Visits 2, 3, and 7, blood will be collected on the same day on three occasions , pre-dose and again approximately [ADDRESS_977685] -dose (these should be morning appointments); and a third sample with time of dose and sample at 
approximately 4 hours after the dose. Note : The time of the dose from the previous day  must be collected and recorded 
at Visit s [ADDRESS_977686] has discontinued study 
drug but wants to continue to attend study visits off -treatment (the off  treatment  on study [TOTOS ] group ), then MT 
concentration blood samples will not continue to be collected . 
m A single blood sample for ApoE  can be collected any time after eligibility for randomization and continued participation 
in the study has been confirmed (but prior to Visit 7, the end of the double -blind treatment period) for subjects who 
provide legally acceptable consent.  
n These are to be rated by [CONTACT_116207], where possible,  as at Screening, after all other efficacy assessments have been 
completed. MMSE and CDR assessments will be subject to central review by [CONTACT_717219] -ProPhase clinicians in the 
native language.  
o The clinical efficacy scale assessments should be performed at approximately the same time of day throughout the 
study for a given subject, to the greatest extent possible.  
p In-clinic dose  at Visit 7  to be taken after pre -dose assessments , from newly dispensed  Visit 7 open-label  study drug kit  
(see Table 10-[ADDRESS_977687] -dose assessments to be performed at Visit 7) . 
 
[IP_ADDRESS]  Imaging Efficacy Assessment s in Double -Blind 
Treatment Period  
Only in subjects with CDR 0.5 at Screening, 18F-FDG -PET will be performed within the 
42 days before Baseline (but no t earlier ) and after [ADDRESS_977688]’s last 18F-FDG -PET scan was performed ≥[ADDRESS_977689] be repeated as part of the early 
termination visit assessments within the time window of the early t ermination visit ( i.e., 
± [ADDRESS_977690] dose of study drug).  18F-FDG -PET data will be evaluated by [CONTACT_64693], nuclear medicine staff physician experienced in neuro 18F-FDG -PET, not 
involved in the clinical conduct of the study, and trained on the study endpoints.  Note : The 
use of sedatives is not permitted  within  [ADDRESS_977691] a fasting (at least 4 to 6 hours) blood glucose level <180 mg/dL (<9.9 mmol/L) 
in order for  the injection to take place . 
 
Brain MRI (obtained at Screening and approximately every 13 weeks  during the double -blind 
treatment period after randomization  or upon early termination ) will be evaluated for change 
in various parameters  to determine whether there is reduction of temporal, parietal, whole 
brain , lateral ventricular, hippocampal, putamen, nucleus accumbens , and nucleus basalis 
Protocol: TRx -237-[ADDRESS_977692] -[ADDRESS_977693]’s last MRI scan was performed <90 days 
prior to the early termination date, no additional MRI scan is required.  
 
The obtainment and assessment of imaging data are further described in Section  15.3. 
 
[IP_ADDRESS]  Clinical Efficacy Assessments  in Double -Blind 
Treatment Period  
The ADAS -cog 13 and ADCS -ADL 23 will be performed at Baseline  and every 13 weeks after 
randomization ( or upon early t ermination ) during the double -blind treatment period by [CONTACT_717220] R ater using electronic tablets . Assessments will be re corded and reviewed 
independently as  further described in Section  15.2.  
 
As exploratory clinical efficacy assessments, the MMSE and CDR sum of boxes will be 
performed after 52 weeks of double -blind treatment (or upon early termination). For a given 
subject, t hese are to be performed by [CONTACT_116207] , where possible,  who made the screening 
assessments and recorded on electronic tablets , as further described in Section  15.2. These are 
to be the last assessments performed, i.e., after all other efficacy assessments have been 
completed.  
 
All clinical efficacy assessments will be subject to independent review (all subjects, all 
applicable time  points).  
 
[IP_ADDRESS]  Safety Assessments  in Double -Blind Treatment Period  
Safety assessments (described in Section  15.4) will be performed throughout study 
participation, including at Baseline (prior to dosing and during the [ADDRESS_977694] -dose 
evaluation  at Visit 2 ) and during the balance of the double -blind t reatment period  (Visit s 3, 4, 
5, 6, and 7 , or upon early t ermination ). Safety assessments will be performed by [CONTACT_717221] ; where specified, the 
assessments must be made by a medical assessor ( physician/ MD/DO). Study visits during the 
double -blind t reatment period will occur at time points approximately  4, 13, 26, 39, and 
[ADDRESS_977695] be reviewed by a medical assessor ( physician/ MD/DO). 
 
Other post-screening  assessments include  measuring  vital signs,  performing  targeted physical 
and neurological examinations, clinical laboratory testing ( e.g., hematology, serum chemistry 
panels), and serum pregnancy test ing (women of childbearing potential only) . The targeted 
physical and neurological examinations  and review of the clinical laboratory results should be 
performed by a medical ass essor (physician/ MD/DO). 
 
Subjects with a history of lens implant will undergo an ophthalmologic examination by a 
licensed  optometrist, ophthalmologist, or other suitably qualified medical ass essor 
(physician/ MD/DO) prior to the first dose of study drug ( during the screening  procedures or 
as part of the baseline assessments)  and at Visit 7  of the double -blind treatment period  or 
Protocol: TRx -237-[ADDRESS_977696] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 51 of 145 upon early termination  (after completion of the efficacy assessments) , to evaluate whether the 
lens has become discolored .  Sites that do not have access to a licensed  optometrist, 
ophthalmologist, or other suitably qualified medical ass essor (physician/ MD/DO) are not 
permitted to screen subjec ts with a history of lens implant . 
 
[IP_ADDRESS]  Other Assessments  in Double -Blind Treatment Period  
At Visit s 2, 3, and 7, blood will be collected for determination of MT  concentrations.  
Samples will be collected  pre-dose, approximately [ADDRESS_977697]-dose. To achieve this sample collection  schedule , these should be morning 
appointments  (and for Visits 3 and 7, subjects instructed not to take their morning dose at 
home) . See Section 15.5.1  for further details.  
 
For any early termination visit during the double -blind  treatment period , also refer to  
Section  15.5.1  for blood sampling requirements for determination of MT concentrations.  
 
ApoE  genotype will be determined for subjects who provide  legally acceptable consent. A 
single blood sample may be collected any time after eligibility for randomization  and 
continued participation in the study has been c onfirmed at Baseline (Visit  2), but prior to 
Visit 7 (end of the double -blind treatment period) . Sample collection is further described in 
Section 15.5.2 . 
 
10.5.3  Asse ssments in the Open-Label, De layed -Start Phase 
The assessments during the  open -label, delayed -start phase are presented below in  Table 
10-3. The procedures are further described, briefly, in the subsections that follow (with 
reference to more detailed discussions in Section 15). See Section 10.2 for a summary of 
alternate arrangements that may be implemented due to COVID -19. 
 
Protocol: TRx -237-[ADDRESS_977698] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 52 of 145 Table 10-3: Schedule of  Assessments ( Open -Label, Delayed -Start  Phase)  
Visit NameBaseline/Day 1 for 
Open -Label Phase  Continued Open -Label Treatment  
Visit Number 7 8 (TC)  9 10 
(OL-EOT or 
OL-ET) 
Weeks Relative to Visit 2 Baseline 52 weeks  56 weeks  78 weeks  104 weeks  
Allowable Time Window in Days(±14 days ) (±3 days ) (±14 days ) (±14 days ) Pre-Dose  Post-Dose  
18F-FDG-PET (see Table 10-1 and Table 10-2) X     
MRI a X   X X 
ADAS-cog13 and ADCS -ADL23 b, l X   X X 
AE/Concomitant Medication Recording/ Review c (M) X X X X X 
Targeted P hysical/Neurological E xaminations d (M) X   X X 
Ophthalmological Examinatione (M/O) X    X 
Clinical Laboratory testing f (M) X   X X 
Pregnancy Testing g X   X X 
Blood Pressure, Pulse, Body Weight  h X   X X 
Study Drug Dis pensing Xm    X  
Study Drug C ompliance Assessment i X  X X X 
Blood Sample for MT Concentration j X X   X 
MMSE k, l X    X 
CDR k, l X    X 
 
Abbreviations: ADAS -cog 13 = Alzheimer’s Disease Assessment Scale – cognitive subscale (13 -item); ADCS -ADL 23 = 
Alzheimer’s Disease Cooperative Study – Activities of Daily Living (23 -item); AE = adverse event; CDR = Clinical 
Dementia Rating; MMSE = Mini -Mental State Examination; MRI = magnetic resonance imaging; OL-EOT  = open -label end 
of treatment ; OL-ET = open -label early termination;  TC = telephone contact . 
Note :  Visit 7 results from Table 10-2 provide baseline values for the open -label, delayed -start phase.  
Note :  (M) = requires medical assessor  (physician/ doctor of medicine [MD]/doctor of osteopathy [DO]) ; M/O = licensed 
optometrist/ophthalmologist or other suitably qualified medical assessor  (physician/MD/DO)  is also acceptable  
a For subjects who terminate early, if the subject’s last MRI scan was performed <[ADDRESS_977699] to central review by 
[CONTACT_717219] -ProPhase clinicians in the native language.  
c AEs and concomitant medication use will be evaluated by a medical assessor and recorded on an ongoing basis starting 
after signing of informed consent, including at each scheduled visit ; unscheduled visits should occur as needed to 
follow up an AE (including after the last dose of study drug), consistent with the physician/ MD/DO judgment . 
d Targeted examinations are to be performed by a medical assessor at each clinic visit (or upon ET). At a minimum, 
targeted examinations should include heart and lung auscultation and brief neurological assessment guided by [CONTACT_717222]/symptoms/AEs ( e.g., evaluating subjects for potential serotonin toxicity ).  
e Ophthalmological examination (slit lamp) is to be performed only in those subjects with history of lens implant to 
evaluate discoloration of lens . The final evaluation (OL -EOT  or OL-ET) should be done after completion of the 
efficacy assessments.  
f At each identified time point, blood samples will be obtained for chemistry and hematology panels; results are to be 
medically reviewed by a medical assessor . Testing is also to be performed as needed to follow -up on an AE.  
g Serum pregnancy testing is to be performed at each identified time point in women of childbearing potential only.  
h Blood pressure and pulse will be measured with subjects in a seated position (for at least 5  minutes).  
i Compliance with study drug will be assessed by [CONTACT_21442] (see Section 12.6); compliance will also be 
queried in the TC . 
j At Visits [ADDRESS_977700] -dose (these should be morning appointments); and a third sample with time of dose and sample at 
approximately 4  hours after the dose. Note: The time of the dose from the previous day must be collected and recorded 
at Visits [ADDRESS_977701] has discontinued study 
drug but wants to continue to attend study visits off-treatment (TOTOS group ), then MT concentration blood samples 
will not continue to  be collected . 
Protocol: TRx -237-[ADDRESS_977702] -[ADDRESS_977703] extent possible.  
m In-clinic dose at Visit 7 to be taken after pre -dose assessments, from new ly dispensed  Visit 7 open -label study drug kit . 
 
 
[IP_ADDRESS]  Imaging Efficacy Assessments  in the Open -Label, 
Delayed -Start  Phase  
Brain MRI will be obtained  after the additional 26 and 52 weeks of open -label treatment 
(Visit 9/Week 78 and Visit 10/Week 104) and  will be evaluated and quantified as briefly 
described in Section [IP_ADDRESS]  for the double -blind treatment period . The obtainment and 
assessment of imaging data are further described in Section  15.3. 
 
For subjects who terminate early, if the subject’s last MRI scan was performed <90 days 
prior to the early termination date, no additional MRI scan is required.  
 
[IP_ADDRESS]  Clinical Efficacy Assessments  in the Open -Label , 
Delayed -Start  Phase  
The ADAS -cog 13 and ADCS -ADL 23 will be performed  after the additional 26 and 52 weeks 
of open -label treatment (Visit 9/Week 78 and Visit 10/Week 104) by [CONTACT_717223]. Assessments will be recorded and reviewed independently as 
further described in Section  15.2. 
 
As exploratory clinical efficacy assessments, the MMSE and CDR sum of boxes will be 
performed after the additional 52  weeks of open -label treatment (Visit 10/Week 104 or upon 
early termination). These are to be performed by [CONTACT_116207], where possible, who made 
the screening assessments and recorded on electronic tablets, as further described in 
Section  15.2. These are to be the last assessments performed, i.e., after all other efficacy 
assessments have been completed.  
 
All clinical efficacy assessments will be subject to independent review (all subjects, all 
applicable time points).  
 
[IP_ADDRESS]  Safety Assessments  in the Open -Label , Delayed -Start  
Phase  
Safety assessments (described in Section  15.3) will be performed  after 26 and 52 weeks 
(Visit 9/Week 78 and Visit 10/Week 104) of open -label treatment and will include AE 
review, concomitant medication recording and review, targeted physical and neurological 
examinations, clinical laboratory testing ( e.g., hematology and serum chemistry panels), 
serum pregnancy testing (women of childbearing potential only), and vital sign  
measurement s. In addition, AEs and changes in concomitant medications will be recorded 
during a telephone contact [CONTACT_3435] 4 weeks of open -label treatment (Visit 8/Week 5 6). The 
targeted physical and neurological ex aminations  along with review of any AEs, changes in 
concomitant medications, and clinical laboratory results should be performed by a medical 
assessor (physician/ MD/DO).  
 
Protocol: TRx -237-[ADDRESS_977704] -[ADDRESS_977705], or other suitably qualified medical ass essor 
(physician/ MD/DO) at the final visit of the open -label treatment period (Visit 10/Week 104) , 
or upon early termination  (after completion of the efficacy assessments) , to evaluate whether 
the lens has become discolored . 
 
[IP_ADDRESS]  Other Assessments  in Open -Label , Delayed -Start  Phase  
At Visit 10/Week [ADDRESS_977706]  (DSMB ) throughout the 
duration of study conduct. At any time, the DSMB may recommend that dosing be modified 
or enrol lment stopped due to safety concerns . The DSMB may also request to receive 
additional data unblinded to the subject level in response to identified safety concerns.  
 
Routine meetings are to be scheduled as determined by [CONTACT_4318]. Ad hoc  meetings will be 
convened if needed in response to safety concerns. The DSMB Charter will describe the 
composition of the DSMB and safety monitoring details, as well as the frequency of meetings 
needed as the study progresses.  
10.[ADDRESS_977707]  has completed the final study visit in the 
open -label , delayed -start phase (whether or not the visit occurs as scheduled).  As noted in 
Section 17.9, an analysis will be performed after the last subject completes the last visit in the 
double -blind treatment period.  
 
Subjects who complete the study  and receive treatment with LMTM  up to and including the 
last open -label visit  may be offered an opportunity to subsequently receive treatment with 
LMTM in a separate EAP . 
 
[ADDRESS_977708] meet all of the following inclusion 
criteria:  
 
1. AD, encompassing probable AD and MCI -AD based on 2011 N IA/AA criteria: 
• All cause dementia and probable AD (probable AD)  
In brief, subjects with probable AD dementia must have insidious onset, 
Protocol: TRx -237-[ADDRESS_977709] -[ADDRESS_977710] two cognitive areas (learning and recall, 
language, executive function, visuospatial skills), sufficient to significantly 
interfere with work or usual activities, that is not explained by [CONTACT_477883], drugs, 
major psychiatric disorder, medical illness, cerebrovascular disease, other 
forms of dementia, or neurological disorder. The accuracy of the diagnosis 
will be confirmed independently  by [CONTACT_717224] . 
OR 
• MCI-AD 
In subjects with MCI -AD, there should be evidence of concern about a  change 
in cognition, in comparison with the person’s previous level verified by a 
knowledgeable informant or clinician. Other mild cognitive deficits may also 
be present, but there must be preservation of independence in functional 
abilities. Subjects shou ld not meet the criteria for dementia. The cognitive 
changes must be mild and there must be no evidence of a significant 
impairment in social or occupational functioning. Impairmen ts must not be 
explained by [CONTACT_477883], drugs, major psychiatric disorder, medical illness, 
cerebrovascular disease, other forms of dementia, or neurological disorder.  
2. Documented PET scan that is positive for amyloid; if most recent PET scan was 
performed >3 years prior to Screening and was negative, it may be repeated ( a 
negative amyloid PET scan within the 3 years prior to Screening is exclusionary ) 
3. MMSE  score of 16-27 (inclusive) at Screening , subject to stratification requirements  
4. Global CDR  score  of 0.5 to 2 at Screening  (if 0.5, including a score of >0 in one of the 
functional domains : Community Affairs, Home and Hobbies, or Personal Care)  
5. Age <[ADDRESS_977711] meet one of the following: 
• Surgically sterile (hysterectomy, bilateral salpi[INVESTIGATOR_1656] / oophorectomy) for 
at least 6 months minimum 
• Have undergone  bilateral tubal occlusion / ligation at least 6 months prior 
• Post-menopausal  for at least 1 year 
• Using adequate contraception (a barrier method [such as condo m, diaphragm 
or cervical/vault cap] with spermicidal foam, gel, film, cream, or suppository; 
intrauterine device [IUD] or system, or oral or long -acting  injected or 
implanted hormonal contraceptives for at least 90 days prior to Baseline; or 
vasect omized partner [with the appropr iate post-vasect omy documentation of 
the absence of spermatozoa in the ejaculate]) or true abstinence (when this is 
in line with the preferred and usual lifestyle of the subject); subjects must be 
competent to use adequate contraception and to agree to continue to maintain 
adequate contraception throughout participation in the study (including up to 
[ADDRESS_977712] dose of study drug)  
7. Subject and/or , in the case of reduced decision -making capacity, legally acceptable 
representative(s)  (LAR(s)) , consistent with local and national law, is able to read, 
understand, and provide written informed consent in the designated  language of the 
study site  
8. Has one (or more) identified  adult study partner ( i.e., a caregiver or informant)  who 
meets the following criteria: 
• Either lives with the subject, or in the investigator’s opi[INVESTIGATOR_1649], the extent of 
contact [CONTACT_717225]: TRx -237-[ADDRESS_977713] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 56 of 145 behavior and function over time and provide information on safety and 
tolerability  (e.g., sees the subject on average for ≥1  hour/day ≥3  days/week)  
• Is willing to provide written informed consent for his/her own participation  
• Is able to read, understand, and speak the designated language (s) at the study 
site 
• Agrees to accompany the subject to each study visit  
• Is able to verify compliance with study drug  
9. The subject must not have been taking either an AChEI, i.e., donepezil, galantamine, 
or rivastigmine, and/or memantine, for at least 60 days  at the time of the baseline 
assessments  
• Subjects never previously treated with an AChEI and/ or memantine may be 
enrolled if initiation of treatment with these medications is not planned for the 
time period during which the subject will be participating in this study 
10. Able to comply with the study procedures in the view of the investigator 
11.2 Exclusion Criteria  
The exclusion criteria are:  
 
1. Significant central nervous system (CNS) disorder other than probabl e AD or MCI -
AD, e.g., Lewy body dementia, Parkinson’s disease, multiple sclerosis, progressive 
supranuclear palsy, hydrocephalus, Huntington’s disease, any condition directly or 
indirectly caused by [CONTACT_717226] (TSE), Creutzfeldt -
Jakob Disease (CJD), variant Creutzfeldt -Jakob Disease (vCJD), or new variant 
Creutzfeldt -Jakob Disease (nvCJD)  
2. Significant intracranial focal or vascular pathology seen on brain MRI scan that would, 
based on the independent reviewer imaging evaluation, lead to a diagnosis other than 
probable AD or MCI -AD, including but not limited to:  
• Large confluent white matter hyperintense lesions ( i.e., Fazekas score of 3)  
• Other focal brain lesions judged clinically relevant by [CONTACT_093]  
• Evidence of a prior or current macrohemorrhage  
3. Clinical evidence or history of any of the following (within specified period prior to 
Baseline): 
• Cerebrovascular accident (2 years)  
• Transient ischemic attack (6 months)  
• Significant head injury , for example,  associated loss of consciousness, skull 
fracture or persisting cognitive impairment (2 years)  
• Other unexplained or recurrent loss of consciousness ≥15 minutes (2 years)  
4. Diagnosed with epi[INVESTIGATOR_002] (a single prior seizure  >6 months prior to Screening  is 
considered acceptable)  
5. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria met (for 
any of the following within specified period):  
• Major depressive disorder (current)  
• Schizophrenia (lifetime)  
• Other psychotic disorders, bipolar disorder (within the past 5 years)  
• Substance (including alcohol) related disorders ( within the past 2 years ) 
Protocol: TRx -237-[ADDRESS_977714] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 57 of 145 6. Metal implants in the head (except dental), pacemaker, cochlear implants, or any 
other non -removable items that are contraindications to MRI. MRI compatible 
prosthetics, clips, stents, or any other device proven to be compatible are allowed  
7. Resides in hospi[INVESTIGATOR_717125] 
(residence in low grade assisted living facility where there is sufficient autonomy to 
permit valid evaluation of activities of daily living is allowed so long as it is not 
mandate d by [CONTACT_717227])  
8. Any physical disability that would prevent completion of study procedures or 
assessments ( e.g., blindness or significant uncorrected visual impairment, deafness or 
significant hearing loss not corrected by [CONTACT_148289], non -AD-related speech 
impairment)  
9. History of swallowing difficulties (note: study drug should be swallowed whole and 
MUST NOT be broken, crushed, chewed, or dissolved in fluids prior to ingestion)  
10. Pregnant or breastfeeding  
11. G6PD deficiency based on World Health Organization (WHO ) classification (<60% 
of normal, i.e., <6.1 U/g hemoglobin [ Hgb]) 
12. History of significant hematological abnormality or current acute or chronic clinically 
significant abnormality, including:  
• History of hemoglobinopathy, myelodysplastic syndrome, hemolytic anemia, 
or splenectomy  
• Screening Hgb value (confirmed upon repeat) below age/sex appropriate 
lower limit of the central laboratory normal range  
Subjects in whom folate is <4.0 ng/mL may be entered into the study provided folate 
supplementation (approximately 1 mg/day) is initiated and maintained for the duration 
of the study ; subjects in whom vitamin B 12 is <150 pg/mL can be allowed if the 
investigator confirms that it does not affect the cognitive state of the subject and that 
the subject is supplemented as appropriate prior to the initiation of study drug  
13. Abnormal serum chemistry laboratory value at Screening deemed to be clinically 
significant  by [CONTACT_093]. In addition, subjects with either of the following 
abnormalities must be excluded:  
• Creatinine clearance <30 mL/min, estimated by [CONTACT_717228]  
• TSH above laboratory normal range (subject may be treated [if clinically 
indicated based on further laboratory testing] and re -screened after 90 days)  
14. Clinically significant cardiovascular disease or abnormal assessments (based on the 
investigator’s interpretation of the locally obtained ECG) such as:  
• Hospi[INVESTIGATOR_252671] (acute myocardial infarction or 
unstable angina) or symptoms consistent with angina pectoris, within the 
12 months preceding Baseline  
• Signs or symptoms of clinical heart failure within the 12 months preceding 
Baseline  
• Atrial fibrillation on screening ECG or history of atrial fibrillation that is not 
currently controlled (heart rate ≥85 bpm and/or inappropriate anticoagulation)  
• QTcF (QT corrected for heart rate using Fridericia’s formula) at Screening 
>460 msec in males or >470 msec in females, or low or flat T  waves making 
measurement of QT interval unreliable  
Protocol: TRx -237-[ADDRESS_977715] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 58 of 145 • Recent history of poorly controlled hypertension, systolic blood pressure 
>180  mmHg, or diastolic blood pressure >100 mmHg, after 5 minutes in a 
seated position at Screening  
• Hypotension: systolic blood pressure <100 mmHg after 5 minutes in a seated 
position at Screening  
• Heart rate <48 bpm or >96 bpm by [CONTACT_717176] (after 5  minutes 
in a seated position) or by [CONTACT_717177]  
15. Pre-existing or current signs or symptoms of respi[INVESTIGATOR_1399], e.g., caused by 
[CONTACT_717229], bronchial asthma, lung fibrosis, or other 
disease  
• Subjects with currently  diagnosed moderate to severe sleep apnea should be 
excluded ; the definition of moderate to severe includes oxygen 
supplementation, e.g., nasal prongs or Continuous Positive Airway Pressure 
(CPAP)  
16. Concurrent acute or chronic clinically significant (in the opi[INVESTIGATOR_871]) 
immunologic, hepatobiliary (such as presence of encephalopathy or ascites), or 
endocrine disease (not adequately treated) , and/or other unstable or major disease 
other than probable AD or MCI -AD; the following are specifically excluded : 
• Active hepatitis or primary biliary cirrhosis  
• Active Human T -Cell Lymphocytic Virus Type III (HTLV -III), 
Lymphadenopathy Associated Virus (LAV), any mutants or derivatives of 
HLTV -III or LAV, any condition associated with active Acquired 
Immunodeficiency Syndrome or similar condition however named  
17. Diagnosis of cancer ( excluding  basal cell carcinoma, squamous cell carcinoma, or 
prostate carcinoma in situ [Stage 1] ) meeting either of the following criteria:  
• Newly diagnosed within past 2 years  
• Previous (>2 years) diagnosis of cancer that has required any form of 
intervention or treatment within the past 2 years, e.g., chemotherapy, 
radiotherapy, hormonal therapy, or surgery  
18. Prior intolerance or hypersensitivity to MT -containing drug or methemoglobinemia 
induced by [CONTACT_134206] -containing drug, similar organic dyes, or any of the excipi[INVESTIGATOR_840]  
19. Treatment currently or within 90 days before Baseline with any of the following:  
• Souvenaid® 
• Antipsychotics  
o Clozapi[INVESTIGATOR_050] (and there is no intent to initiate therapy during the course of the 
study)  
o Other antipsychotics are allowable provided they have not been initiated 
within 90 days before Baseline and preferably at a stable dose and regimen  
• Carbamazepi[INVESTIGATOR_050], primidone, valproate  
• Drugs for which there is a warning or precaution in the labeling about 
methemoglobinemia at approved doses ( e.g., dapsone, local anesthetics such 
as benzocaine used chronically, primaquine , and related antimalarials)  
20. Current or prior participation in a clinical trial as follows:  
• Any clinical trial of LMTM  
• Clinical trial of a product for cognition prior to Baseline  in which the last dose 
was received within [ADDRESS_977716] been 
randomized to placebo  
Protocol: TRx -237-[ADDRESS_977717] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 59 of 145 • A clinical trial of a ny other investigational  drug, biologic, device, or medical 
food in which the last dose was received within [ADDRESS_977718] is allowed in selected instances, as listed below  (to a maximum of 
two re-screening occasions ). Upon re -consent and re -screening, the subject must continue to 
meet all of the inclusion and exclusion criteria described in Section 11.1 and Section 11.2, 
respectively. Prior to re -consent, the PI (or SI) should confirm that the subject continues to 
meet the diagnosis of AD, encompassing probable AD and MCI -AD, of the acceptable 
severity (MMSE 16-[ADDRESS_977719] score of 0.5 to 2 [if 0.5, including a score of >0 in one of 
the functional domains ]), and has not used an A ChEI and/or memantine for at least 60  days 
prior to the baseline assessments (inclu sive of  the baseline 18F-FDG-PET scan in subjects 
who have a screening CDR of 0.5) . Screening may also be paused  at a given site due to 
COVID -19 as described in Section 10.2.1 ; such subjects do not require re -consent but 
otherwise, the principles listed below with respect to repeat testing apply.  
 
1. At the initial Screening, MMSE score will be obtained  first to determine eligibility. 
CDR score s will also be obtained for eligibility. A Diagnostic Verification Form will 
be completed to confirm diagnosis of probable AD  or MCI -AD. These assessments 
will be subject to independent review. If scoring discrepancies  are found that cannot 
be resolved, the subject will be deemed not eligible . The subject may be re -screened  
(after a wait of [ADDRESS_977720] MMSE ), inclusive of repeat of MMSE and CDR  
which will again be subject to the independent review to confirm eligibility.  For the 
avoidance of doubt, re -screening is not allowed if a valid MMSE or CDR score falls 
outside the acceptable criteria.  
2. If the initial screening MRI scan is not of sufficient quality  as determined by [CONTACT_717230] , a repeat scan may be performed . If the repeat scan cannot be 
accomplished within the time window  specified in  Table 10-1, the subject must be re -
consented and re-screen ed. For subjects who are re-screen ed for other reasons and an 
acceptable MRI scan was already completed during the original Screening window, 
the scan does not require repetition . 
3. Evidence of atrial fibrillation on initial screening ECG or history of atrial fibrillation 
that is not currently controlled (heart rate ≥85 bpm and/or inappropriate 
anticoagulation)  is not allowed . If better control of the heart rate and/or of 
anticoagulation can be achieved after adequate treatment, the subject may be entered 
into the study if still within the 42 -day wind ow; otherwise  the subject must be re -
consented and re -screened. A cardiology consult should be sought for further ECG 
evaluation if deeme d necessary by [CONTACT_093].  
4. Subjects with vitamin B 12 levels <150 pg/mL at initial screening  which cannot be 
corrected during the Screening period may be reconsented  and re -screened after the 
deficit has been corrected (see Section 13.8 for further details) . 
5. Subjects with a TSH above laboratory normal range  at the initial screening may be 
treated (if clinically indicated ) and re-consented and re -screen ed after 90 days . 
 
Any other criteri on not listed above would require justification and approval by [CONTACT_717231].  
 
No other minimum time is required for re -screening unless specifically stated above or 
elsewhere in the protocol.  
Protocol: TRx -237-[ADDRESS_977721] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 60 of 145 11.4 Discontinuations / Withdrawals  
11.4.[ADDRESS_977722] ug 
For a discussion of reasons for permanent discontinuation of study medication on the basis of 
safety, see Section  16.11 . These include, but are not limited to , clinically evident hemolytic 
anemia (Section 16.11.1 ) and decrease in renal function  when it raises  renal concerns  
(Section 16.11.3 ). 
 
Subjects may discontinue study drug at any time for any reason. Furthermore, the investigator 
also has the right to discontinue study medication if he or she judges that treatment is no 
longer appropriate, if the subject ’s clinical condition is worsening, or for an  AE. 
 
If study drug is discontinued, the reason and the last date of study drug should be recorded on 
the eCRF.  
 
For subjects who cease taking study drug but who wish to continue in the study, the planned 
schedule of assessments should be followed , except for the collection of blood samples  for 
MT concentration s. These subjects will be class ified as “the off -treatment -on-study ” 
(TOTOS)  group . Subjects w ho continue in the study off -treatmen t will not be eligible for a 
separate EAP.  The handling of data for these subjects is discussed in Section [IP_ADDRESS] . 
 
As discussed in Section 13.1, study drug must be discontinued in subjects who initiate 
treatment with an A ChEI and/or memantine . The handling of data for these subjects is 
discussed in Section  [IP_ADDRESS] . 
 
11.4.2  Handling of Stud y Disc ontinuation  / Withdrawal 
Subjects may withdraw (drop out) from the study at any time for any reason. A study partner  
(who is functioning as an informant) may also withdraw his or her consent from study 
participation at any time for any reason. If a study partner  withdraws his or her consent, the 
subject must then also be withdrawn if alternative arrangements are not available ( e.g., an 
alternate study partner ). (See Section 11.4.3  for replacement of study partners.)  
 
If the subject withdraws from study participation, the reason should be recorded on the eCRF 
as one of the  following:  
• Adverse event  
• Death  
• Lack of efficacy (including progressive disease or worsening of cognitive capacity)  
• Lost to follow -up 
• Withdrawal by [CONTACT_717232] (or study partner ), 
including specific reason (s), wherever possible  
• Protocol deviation  
• Non-compliance with study drug  
• Pregnancy  
• Study terminated by [CONTACT_2728]  
• Physician decision, including specific reason(s), wherever possible  
• COVID -19 
• Other (specify)  
 
Protocol: TRx -237-[ADDRESS_977723] -[ADDRESS_977724] be made 
to clearly document the outcome. If the reason for premature discontinuati on is a  serious 
adverse event ( SAE ), this must be documented and an SAE form completed.  
 
For subjects who withdraw from the study for reasons other than death or subject /LAR  or 
study partner  consent withdrawn, a visit should be scheduled as soon as possible after the last 
dose of study drug and the End-of-Treatment safety evaluations for the current treatment 
period performed. For subjects  or legally acceptable representatives  who withdraw consent or 
when a study partner  withdraws consent without available alternate study partner , the 
investigator should request that the reason be specified and  the subject have any clinically 
indicated safety assessments performed.  
 
11.4.[ADDRESS_977725], either simultaneously or as replacements for previous study partners, with no 
specified maximum . 
 
12 STUDY DRUG  
12.1 Treatments Administered : Form, Dosage and Administration  
Study drug is available as blue, round , film -coated, immediate -release tablets (5 -mm 
diameter, approximately 55 -mg core weight) manufactured and packed for TauRx in 
accordance with Good Manufacturing Practice (GMP), as detailed in the European Union 
(EU) Guide to GMP. These and visually matching placebo tablets are debossed on one side 
with the Greek “Tau” symbol.  
 
12.1.1  Active Ingredient 
The active ingredient  (drug substance)  is LMTM ([LOCATION_003]N hydromethylthionine  mesylate , also 
known as leuco -methylthioninium bis(hydromethanesulfonate) or the code name , TRx0237). 
It is included in the tablets as 4 mg LMT (expressed as MT base equivalent).  
 
12.1.2  Inactive Ingredients  
Tablets also contain the following inactive compendial excipi[INVESTIGATOR_840]: mannitol, crospovidone, 
microcrystalline cellulose, and magnesium stearate.  
 
The film coat of study drug tablets contains polyvinyl alcohol -part hydrolyzed, talc, titanium 
dioxide, Macrogol PEG 3350, lecithin (soya), as well as non -compendial FD&C blue #2 
(indigo carmine aluminum lake).  
Protocol: TRx -237-[ADDRESS_977726] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 62 of 145 12.2 Study Regimens  
All subjects will receive four tablets orally per day ( two in the morning and two in the 
evening ) in a double -blind fashion for 52 weeks  in one of the following t hree study regimens , 
in a 4:1:4 ratio for Protocol Version 5.0 and above :  
• LMTM 16 -mg/day group: Two 4 -mg tablets in the morning, and two 4 -mg tablets 
in the evening  
• LMTM 8-mg/day  group: One placebo tablet and one 4-mg tablet in  the morning, 
and on e placebo tablet and one 4-mg tablet in the evening 
• Placebo group: Two “dumm y” tablets in the mornin g, and two “dummy ” tablet s in 
the evening ; one of which may be replaced by a 4 -mg MTC tablet to maintain the 
treatment blind  (the remainder being placebo tablets)  
 
After the completion of the 52 -week double -blind treatment period, beginning with supplies 
dispensed at Visit 7, all subjects will receive open -label LMTM 16 mg/day (two 4 -mg tablets 
in the morning and two 4 -mg tablets in the evening) for an additional [ADDRESS_977727] dose of study drug (Visit 2)  and the morning dose at  Visit 3  (after 4 weeks of study 
drug) , Visit 7 (after 52 weeks of study drug) , and Visit 10 (after 104 weeks of study drug) 
will be administered in the clinic. These visits should be scheduled to occur in the morning, 
with subjects instructed no t to take their morning dose at home; subjects will be required to 
remain in the c linic for at least [ADDRESS_977728] -dose on each occasion . The time of the dose (and 
at Visit s 3, 7 and 10, also the time of t he prior dose  taken on the preceding day ) will be 
recorded.  Note: the Visit [ADDRESS_977729] been completed  (see Table 10-[ADDRESS_977730] -dose assessments to be performed at Visit 7) . 
 
All other doses will be taken on an outpatient basis.  The subject/study partner will be asked 
to establish the times of day that the subject will take the study medication (twice daily), with 
further inquiry as to whether this will be before or after a meal. They will be asked to adhere, 
to the best of their capability, to the same administration schedule throughout the study.  
 
Alternative arrangements for dosing and dispensing study drug supplies due to COVID -[ADDRESS_977731] consent  consistent with local and nationa l requirements , maintaining the specified  
study drug  storage conditions , accountability, and compliance monitoring will be addressed 
and documented . 
 
12.2.1  Maxim um Anticip ated Dosage  
The maximum dosage of study drug will be LMTM 16 mg/day. 
 
Note : Dose reduction is not permitted.  
 
Protocol: TRx -237-[ADDRESS_977732] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 63 of 145 12.2.2  Dose  Interruption 
Interruption of dosing for up to a maximum of 14 consecutive days may be allowed if the 
investigator determines this is  indicated  (e.g., due to an AE or any other reported change in 
the subject’s physical condition in the judgment of the investigator)  on a maximum of two 
occasions. The reason for dose interruption should be recorded  in the source  documentation . 
If this is exceeded, study drug would need to be discontinued; however, the subject will be 
encouraged to continue study participation off -treatment . Subjects who continue in the study 
off-treatment will not be eligible for a separate EAP . 
12.3 Randomization  
Subjects will be randomized to one of t hree study regimens described in Section 12.2: 
LMTM 16 mg/day, LMTM 8 mg/day, or placebo (4:1:4, at the study level) . Randomization 
will be stratified according to severity ( three  levels: MMSE 16-19, 20-25, or 26 -27) at study 
level for those randomized to Protocol Version  5.[ADDRESS_977733] AD  
treatment (two  levels: A ChEI/memantine or n one), and region (two levels: North America  or 
Europe ).  
 
Enrollment will be such that subjects are assigned to the MMSE severity groups base d on 
screening MMSE score with a target of approximately 2:3:1 (MMSE 16 -19, MMSE 20 -25, 
and MMSE 26 -27, respectively)  for those randomized to Protocol Version  5.0 and above ; to 
achieve this target, enrollment will be monitored and controlled at the site level for high 
recruiting sites and capped as needed at the study level . 
 
Randomization, stratification, and enrollment cap requirements will be controlled by a web -
based RTSM system.  
12.[ADDRESS_977734] 
cartons with sufficient supplies until the next scheduled study visit at which dispensing is 
planned ( see Section 12.5, Dispensing ). Additional 28-tablet  blister wallet s will be included 
in cartons as needed to allow for delays in visit scheduling (or if original medication is lost or 
damaged).  
 
Study drug package labels will be compl iant with applicable regulatory requirements and will 
include the statement “Keep out of reach of children ,” the cautionary statement “Caution: 
New Drug – Limited by [CONTACT_4496] ([LOCATION_002]) law to investigational use” and/or “For 
clinical trial use only” as appropriate, as well as any other locally mandated statements. 
Labels will also be translated into the local language  as required . 
 
At a minimum, labels will also include the following information: the name [CONTACT_717331], the study code, a unique identifier, and appropriate contact [CONTACT_3031]. In those 
jurisdictions where required, a n expi[INVESTIGATOR_717136].  
 
At the study site, study drug must be stored securely ( e.g., locked area, pharmacy) and at a 
temperature not more than 25C. The temperature at which study  drug is stored at the study 
Protocol: TRx -237-[ADDRESS_977735] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 64 of 145 site will be recorded daily using a centralized temperature monitoring system if this is 
available. If not, study drug storage temperature will be recorded each working day using a 
maximum -minimum thermometer. The packaging protects the study drug from lig ht and 
moisture.  
 
Subjects and study partners  should also be provided with information about required storage 
conditions. Study drug should be ingested immediately after removal from the blister wallet . 
12.5 Dispensing  
At the Baseline /Randomization visit (Visit 2), all subjects /study partners  will receive a supply 
of study drug according to their randomization  to take home for use until Visit 4 (13 weeks 
after Baseline). At subsequent drug -dispensing visits , Visit s 4, 5, 6, and 7  (13, 26, 39, and 52  
weeks after Baseline , respectively ) of the double -blind treatment period, as well as Visit 9 
(78 weeks after Baseline) of the open -label delayed -start phase, all subjects /study partners  
will be required to return the complete study drug kit, including all unused study drug and 
empty packaging, dispensed at the preceding drug -dispensing visit (Visits 2 , 4, 5, 6, and 7 ) 
before receiving a re -supply of either randomized  study drug  or open -label treatment,  to take 
home for use until the next scheduled visit . Visit 7 is Baseline/Day 1 of the open -label 
treatment phase, at which study drug from a new ly dispensed  Visit 7 open -label study drug 
kit should be administered after pre -dose assessments  (see Table 10-[ADDRESS_977736]-dose assessments to be performed at Visit 7) . 
 
Subjects and study partners  will be provided with information about storage conditions and 
taking study drug, including instructions indicating that study drug must be used only as 
described in this protocol. They will also be informed that tablets should be swallowed whole 
and MUST NOT be  broken, crushed, chewed, or dissolved in fluids prior to ingestion. If 
there are swallowing difficulties which prevent taking the medication as instructed, subjects 
should not be entered into the study. Subjects and study  partners  should be warned that if the 
product is not swallowed immediately and is allowed to dissolve in the mouth, it may cause 
discolo ration  of teeth and oral mucosa.  
 
In the event of a dose interruption, the subjects and study partners  will be provided with 
updated dosing instructions.  
 
See Section 10.[ADDRESS_977737]/ study partner  
will be recorded.  
 
At the Week 4 visit (Visit 3) and at each clinic visit thereafter (Visits 4  to 7 during the 
double -blind t reatment period , and Visits 9 and 10 during the open -label, delayed -start 
phase), the subject/ study partner  will bring the complete study drug kit, including unused 
study drug and empty packaging , to the study site. The number of tablets (all tablets 
remaining in unopened blister wallet s plus any tablets that have been removed from the 
blister wallets ) will be counted and recorded by [CONTACT_108575]. Following the compliance 
check , the complete study drug kit , including unused study drug and empty packaging , should 
Protocol: TRx -237-[ADDRESS_977738] -[ADDRESS_977739]/ study partner . 
 
Subject compliance with prescribed study drug will also be assessed at each clinic visit 
(Visits 4 to 7 during the double -blind t reatment period , and Visits 9 and 10 during the open -
label, delayed -start phase) as well as during the telephone contact (Visit 8) by [CONTACT_717233] . Any apparent discrepancies between the number of tablets taken 
and the number of tablets which should have been taken since the last visit will be discussed 
with the subject and study partner . 
 
Any dose interruptions will also be recorded  in the source documentation and will be 
captured in the eCRF.  
 
If during participation in the study , a subject’s compliance is determined to be <80% or 
>120% (taking into consideration any dose interruptions), the subject and study partner  
should be re -educated about taking study drug properly and the clinical research associate 
should be informed promptly. If compliance problems are recurrent, the investigator should 
inform the clinical research associate and contact [CONTACT_717234].  
12.[ADDRESS_977740] management/system build personnel at the RTSM system vendor .  
 
The blind for an individual subject should not be broken during conduct of the study except 
in the case of a medical situation for which it is deemed essential to know which treatment 
the subject has received during the double -blind treatment period to provide appropriate care. 
If possible, discussion with the Sponsor should be sought before the blind is broken. In an 
emergency, the investigator may unblind a specific subject and determine the identity of 
treatment using the RTSM System. Instructions regard ing treatment identification using the 
RTSM System will be available in separate guidance documents. In such circumstances, the 
Medical Monitor must  be contact[CONTACT_717235]. The 
date, time, and reason for unblinding must be documented.  In case of after -hours emergency 
Protocol: TRx -237-[ADDRESS_977741] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 66 of 145 unblinding or in circumstances when the investigator is not available, a 24/7 emergency 
number (provided on patient cards) will be available to determine the identity of the 
treatment.  This will be achieved via a “peek blind” function within the RTSM system, 
whereby [CONTACT_717236]. Completion of the peek blind transaction will reinstate the blinded status of the 
subject.  
 
If a subject is unblinded, study drug will be discontinued and the subject will be followed 
until resolution or stabilization of the event. He/she will then be discontinued from the study.  
 
Information about any subject for whom an unblinding occurs will be provided to the DSMB 
by [CONTACT_10557] 15 days (within 7 days in the event of a fatal event ). For 
requirements and unblinding procedures for suspected unexpected serious adverse 
event  (S[LOCATION_003]R ) reporting , refer to Section 16.8. 
 
After the last subject completes the [ADDRESS_977742] populations determined  by [CONTACT_717237]. The 
database will then be un blinded  for purposes of performing primary and secondary efficacy 
analyses , and a report will be prepared  (see Section 17.9); individual subject treatment 
assignment will not be revealed either to the subjects or personnel involved in the ongoing 
management and assessment of subjects in the open -label treatment phase . 
 
[ADDRESS_977743] 90 days  from 
Screening , as well as a lifetime history (as far as possible) of AChEI and/or memantine use 
will be recorded at the Screening visit (Visit 1). While in the clinic at Baseline (Visit 2; 
before and after the first dose of study drug is administered), any medications administered 
will be recorded. “Medication” is used to enc ompass prescription and over -the-counter drugs 
or biologics, vitamins used in supra -pharmacologic doses , alternative pharmacotherapi[INVESTIGATOR_717137], medical foods, and for women, forms of contraception. At each subsequent 
scheduled visit  (i.e., Visits 3  to 7 during the double -blind treatment period, and Visits 8  to 10  
during the open -label, delayed -start phase) or upon early termination , any changes to existing 
concomitant medication and any new concomitant medication will be reviewed and recorded.  
These must be reviewed by a medical assessor  (physician/ MD/DO). 
 
Concomitant medications identified at Screening generally should be maintained at a constant 
dose for the duration of the stud y if clinically indicated. The i nvestigator should evaluate any 
changes in the dose s of existing concomitant medications and/or initiation of new 
concomitant medications, and the Medical Monitor should be contact[CONTACT_717238]. The date of commencement, dose, and date of any change of dose of 
concomitant medications are to be recorded in the eCRF.  
 
Disallowed treatments and the time windows are listed in Section 28.1. 
13.1 AChEI and/or Memantine  
Subjects are not to be treated with an A ChEI and/or memantine within the 60 days prior to 
the baseline assessments  (inclu sive of  the baseline 18F-FDG-PET scan in subjects who have a 
screening CDR of 0.5) . If a subject decides to discontinue AD medication in order to enter 
Protocol: TRx -237-[ADDRESS_977744] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 67 of 145 the study, a letter will be sent to his/her primary care physician informing him/her of the 
subject’s decision.  The withdrawal / discontinuation of AD medication for study inclusion 
should not occur until the subject has been confirmed eligible for the study.  
 
If a subject begins an A ChEI and/or memantine during the study, LMTM will be 
discontinued  and LMTM will not be made available via the EAP. Subjects will be 
encouraged to continue with scheduled assessments if willing to do so without LMTM. 
Handling of data for such subjects is described in Section  [IP_ADDRESS] .  
13.2 Drugs with Serotonergic Potential  
Methylene blue (MTC) has been shown to be an inhibitor of monoamine oxidase ( MAO ) and 
to be associated with serotonin toxicity in conjunction with other serotonergic drugs 
(discussed in the Investigator’s Brochure). Most cases have followed intravenous 
administration. Two cases have also been reported , one each  following enteral and oral 
administration; however, neither case provides compelling evidence of MT -induced serotonin 
toxicity via these routes. There is a theoretical potential for serotonin toxicit y following 
administration of oral LMTM alone, as well as a theoretical possibility of clinically 
significant drug interaction following co -administration of LMTM with a serotonergic 
medication. There have been four potential cases in the Phase 3 studies of LMTM; it is 
difficult to determine from the available information whether any represents a true case of 
serotonin toxicity.  
 
There is no proscription against the use of serotonergic drugs ; however, investigators should 
evaluate subjects for potential serotonin toxicity. For a dditional details regarding clinical 
findings from studies , refer to the Investigator’s Brochure.  A list of drug s with serotonergic 
potential will be provided separately.  
13.3 CYP and P -gp Substrates  
Results of a completed drug -drug interaction study using LMTM 450 mg/day indicate that 
LMTM is generally a weak inhibitor of CYP3A4, CYP2C8, and CYP2C19 enzymes (see the 
Investigator’s Brochure for examples of drugs metabolized by [CONTACT_36918]). The extent to 
which this occurs within an individual or with a given drug is not known, especially for those 
drugs  with multiple metabolic pathways. Therefore, subjects on drugs known to be 
metabolized by [CONTACT_717239] (especially those that have a narrow 
therapeutic index) should be closely monitored for AEs that could suggest an increase in 
systemic e xposure. Dose adjustment of the concomitant medication may be warranted.  
 
LMTM is also a weak inducer of CYP2B6 and P -gp transporter at concentrations relevant to 
higher doses (see the Investigator’s Brochure for examples of substrates) ; the extent to which 
this might occur at LMTM dose s of up to 16 mg/day is not known . Co-administration of 
LMTM with digoxin, a P -gp substrate, was shown to result in decreased concentrations of 
digoxin. Therefor e, it is advisable to obtain a baseline digoxin level in subjects on this drug 
and to monitor digoxin levels while on study. Any such resu lts obtained from the local 
laboratory should be entered into the eCRF.  
13.4 Drugs Used to Manage Behavioral Disturbance  
Subjects may be treated with antipsychotics (other than clozapi[INVESTIGATOR_050]) provided they have been 
used in a stable dose and regimen for at least 90 days  prior to Baseline. There should be no 
Protocol: TRx -237-[ADDRESS_977745] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 68 of 145 intent to initiate such therapy during the course of the study. Should treatment be initiated, 
the reason(s) should be clearly documented by [CONTACT_717240]: delusions, hallucinations, agitation/aggression, depression, anxie ty, elation/euphoria, 
apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, nighttime 
behavior, or appetite/eating change.  
 
“As-needed” use of antipsychotics is to be avoided if possible, but such use does not preclude 
further participation. Similarly, regular or occasional use of benzodiazepi[INVESTIGATOR_717138], agitation, etc. does not preclude further participation, with the exception of prior to 
18F-FDG-PET scans  to be obtained in subjects with CDR 0.5 at Screening only (the u se of 
sedatives is not permitted within 24 hours prior to 18F-FDG -PET scans ). These must  not be 
used within the 12 hours prior to cognitive testing.  
13.5 Other Medications  
The medical food and o ther medications listed in Exclusion Criterion No.  19 (see Section 
11.2) are specifically prohibited during participation in this study.  
 
Anxiolytics and/or sedatives/hypnotics may be used as sedation for claustrophobia or 
agitation or to manage excessive movement during MRI scans; however, use of sedatives is 
not permitted within  [ADDRESS_977746] 0.5 . Regular 
or occasional benzodiazepi[INVESTIGATOR_1651], chloral hydrate, low dose trazodone (50 mg), or zolpi[INVESTIGATOR_717139].  
 
Unless otherwise prohibited, concomitant medications (preferably at stable doses) considered 
appropriate by [CONTACT_423]’s physician are allowable but should be kept to the minimum 
possible as clinically indicated. If there are questions about whether or no t a medication is 
permitted in the study, the Medical Monitor should be consulted.  
13.[ADDRESS_977747] been reported to be associated with hypertensive 
crises caused by [CONTACT_717241] (known as a 
tyramine or “cheese ” reaction). While there is a theoretical potential for a tyramine reaction 
with MT, there have been no reports to date in subjects taking part in TauRx -sponsored 
studies, even though there have been no dietary restrictions in these studies. There have also 
been no effects on blood pressure. Nonetheless, as a prec aution, subjects and their study 
partners  (caregivers /informants ) should be advised about this potential while taking LMTM 
(see the Investigator´s Brochure for examples of tyramine -rich foods and beverages, such as 
air-dried, aged or fermented meats , sausages and salamis; aged  cheeses ; fava bean pods ; non-
pasteurized beers ; sauerkraut ; and most soybean products). They should also be advised to 
seek medical care immediately in the event of signs or symptoms of hypertensive crisis 
(sudden onset of severe headache, nausea, stiff neck, tachycardia or palpi[INVESTIGATOR_814], profuse 
sweating, and/or c onfusion) or other sudden or unusual symptoms following ingestion of 
tyramine -rich foods or beverages.  
13.7 Contraceptive Measures  
As a precautionary measure, women of childbearing potential ( i.e., not documented to be 
post-menopausal for at least 1 year or not having undergone hysterectomy or bilateral 
salpi[INVESTIGATOR_1656] /oophorectomy for at least 6 months minimum) , either must have undergone 
Protocol: TRx -237-[ADDRESS_977748] -[ADDRESS_977749] dose of study drug.  Examples of adequate contraception 
include : 
• Use of a barrier method (condom, diaphragm or cervical/vault cap) with spermicidal 
foam, gel, film, cream, or suppository  
• IUD or system  
• Oral or long -acting injected or implanted hormonal contraceptives for at least 90 days 
prior to Baseline  
• Sexual activity restricted to a vasectomized partner (with the appropriate post -
vasectomy documentation of the absence of spermatozoa in the ejaculate).  
• Abstinence is only acceptable as true abstinence when this is in line with the subject ’s 
preferred and usual lifestyle; periodic abstinence ( e.g., calendar, ovulation, 
symptothermal, and post -ovulation methods) and withdrawal are not acceptable 
methods of birth control.  
 
Serum pregnancy testing will be performed at each scheduled study visit in w omen of 
childbearing  potential . Such women  should be encouraged to  return to the clinic in the event 
of a delayed menstrual period to rule out possible pregnancy , during study conduct and for up 
to [ADDRESS_977750] dose of study drug . Alternative arrangements related to COVID -19 
for pregnancy monitoring may be permitted and are described in Section  10.2.   
 
The risk of drug secretion through the ejaculate is not fully studied. To ensure that the fetus is 
not exposed to MT through vaginal absorption, male subjects (including men who have had 
vasectomies) whose partners are pregnant should use condoms for the d uration of the study 
and for an additional [ADDRESS_977751] kits used by [CONTACT_717242]  B12 has established the following normal ranges (healthy U.S. males  and females 
aged 18 years and older): 5.9 -24.8 ng/mL for folate and 180 -914 pg/mL for vitamin B 12. 
However, these values are not applicable for all geographi cal areas  as food in the United 
States is supplemented with these vitamins. Prior to initiating study drug, subjects with folate 
levels <4.0  ng/mL or vitamin B 12 levels <150 pg/mL ( i.e., deficient according to WHO 
Technical Consultation, 2008, 2012), should be supplemented  for the duration of the study . 
Subjects with folate levels <4.0  ng/mL may be entered into the study provided they are 
supplemented (approximately 1  mg/day folate). Subjects with vitamin B 12 levels <150 pg/mL 
should be referred to their primary care physician for evaluation and treatment or the Medical 
Monitor consulted. There must be a treatment plan in place for any applicable chronic 
condition. If a condition is diagnosed  that the primary care physician believes cannot be 
reliably or continuously corrected, the subject should be excluded from the study.  If review 
and correcti on can be achieved within the Screening  window, the subject may be entered into 
the study; otherwise the subject must be re -consented and re -screened after the deficit has 
been corrected.  
 
Protocol: TRx -237-[ADDRESS_977752] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 70 of 145 14 TERMINATION OF  THE STUDY  
The Sponsor reserves the right to terminate the study for duly justified reasons in accordance 
with the national laws. These reasons include in particular:  
• Administrative reasons: e.g., financial reasons  
• Interest of subject welfare: e.g., new information or events that result in an 
unfavorable risk -benefit profile  
 
Continued access to investigational study drug may be available as detailed in separate 
EAP  Protocols or by [CONTACT_717243].  
 
15 STUDY ASSESSMENTS  
15.1 Demographic Data/Medical History  
The PI (or SI) must complete the NIA/AA diagnostic interview with the subject and study 
partner . The NIA/AA criteria should be used as a guide and the information recorded in the 
subject’s medical records. The accuracy of the diagnosis will be confirmed independently by 
[CONTACT_717219] -ProPhase (Section [IP_ADDRESS] ). 
 
The investigator should collect the following demographic data:  age of the subject at 
informed consent, gender, ethnicity, race, and geographic region.  
 
General baseline characteristics that should be collected are  height, weight, creatinine 
clearance, smoking history, and age at leaving full -time education. Further information 
indicating years spent in full -time education and its type b efore the age of 26 years is to be 
collected ( see Section 28.3); also, main occupation during working life is to be provided as 
indicated.  
 
Disease -specific baseline characteristics that should be collected are  time from diagnosis of 
AD to informed consent (years); amyloid biomarker confirmation;  MMSE;  CDR;  use of an 
AChEI and/or memantine (previous use or never used  and if previous use, drug[s], how long 
used, when stopped, and reason for stoppi[INVESTIGATOR_007] ); and use of other anti -dementia treatments or 
medical foods other than A ChEIs or memantine.  Medical history (including history of lens 
implantation) will be recorded.  
 
Recently used medications (lifetime use of antidementia medications and within 90 days prior 
to Screening for other medications) will be recorded at Screening. Concomitantly used 
medications will be recorded throughout study participation.  
15.2 Assessment of Efficacy  
15.2.1  Raters 
Efficacy instruments (ADAS -cog13, ADCS -ADL 23, MMSE , and  CDR ) will be completed by 
[CONTACT_26065]/raters who are not involved in the assessment of safety parameters that could result 
in unblinding . These will be admin istered  using Virgil tablets in the local language. Efficacy 
assessments should be performed at approximately the same time of day throughout the study 
for a given subject, to the greatest extent  possible. For a given subject, raters should remain 
constant throughout the study. Investigators and other raters will be trained and approved by 
[CONTACT_1738]: TRx -237-[ADDRESS_977753] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 71 of 145 MedAvante -ProPhase; only individuals approved to complete each assessment will receive 
access via the Virgil System. Rater performance and consistency will be subject to 
surveillance throughout the study. One to two efficacy raters are required at each site  (with 
back -ups as need ed).  
 
Information  obtained from study partners providing data from assessments of the subject ( i.e., 
informants) will be appropriately identified to distinguish each informant  in the event that a 
given subject has more than one study partner  providing data for analysis (see Section 10.2 
for a summary of alternate arrangements that may be implement ed due to COVID -19). 
 
A summary of the efficacy rater allocation and the order of efficacy assessments  by [CONTACT_717244] 15-1. 
 
Protocol: TRx -237-[ADDRESS_977754] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 72 of 145 Table 15-1: Efficacy Rater Allocation and Order of Assessments by [CONTACT_717245] 1. Rater Allocation  
Assessments are made by [CONTACT_717246].  
It is expected that the SAME rater completes the efficacy assessments for a given subject throughout the study.  
Raters should carry out assessments according to a specific allocation:  
Rater Allocation 1 (Preferred)  Rater Allocation [ADDRESS_977755]  
Rater 2  ADAS -cog 13 ADAS -cog 13 ADAS -cog 13 
ADCS -ADL 23 ADCS -ADL 23 ADCS -ADL 23 
Section 2. Order of Assessments  
Assessments are to be carried out in the order specified. The order of assessment depends on the visit type.  
Visit  Order  Assessment  
Visit 1 Screening  1. MMSE (Eligibility)  
2. CDR (Eligibility)  
 
Visit 2 Baseline  1. ADAS -cog 13 
2. ADCS -ADL 23 
 
Visit 4, 5, 6  1. ADAS -cog 13 
2. ADCS -ADL 23 
 
Visit 7 or Double -Blind ET  
(Also Baseline/Day 1 for 
Open -Label Phase)  1. ADAS -cog [ADDRESS_977756]  
4. MMSE  
Abbreviations: ADAS -cog 13 = Alzheimer’s Disease Assessment Scale – cognitive subscale (13 -item); ADCS -ADL 23 = 
Alzheimer’s Disease Cooperative Study – Activities of Daily Living (23 -item); CDR = Clinical Dementia Rating; ET = early 
termination; MMSE = Mini -Mental State Examination; OL-EOT  = open label end of treatment ; OL-ET = open -label early 
termination  
 
 
15.2.2  Instruments 
The main efficacy instruments include the following: ADAS -cog 13 (cognition)  and 
ADCS -ADL 23 (activities of daily living) .  From these , Composite Score s will be derived as 
an exploratory endpoint : at least one that is designed to be sensitive to early stages of the 
disease as well as on e that is less/not impacted by [CONTACT_4113] -19 (all Composite Scores will be 
defined in the SAP prior to sign off and database lock /unbl inding). The MMSE and CDR 
(total and sums of boxes) are rated a s secondary instruments. All are described briefly below.  
 
For a given subject, the ADAS -cog [ADDRESS_977757], or enter data 
Protocol: TRx -237-[ADDRESS_977758] -[ADDRESS_977759] questionnaires and the ADAS -cog 13 and ADCS -ADL 23 will be 
assessed in the native language  by [CONTACT_717247] -ProPhase  
by [CONTACT_717248]. The objective of these independent 
reviews is to ensure raters adhere to the administration and scoring conventions detailed in 
rater training. Where necessary , raters will be requested to review their performance and 
confirm the scor ing. For eligibility assessments ( screening MMSE and CDR), adjudication  
will occur for any subject where assessments fall outside of the inclusion criteria . Once 
efficacy assessments are completed and uploaded, raters should review and discuss with 
MedAvante -ProPhase  and receive approval prior to making any proposed change in scoring . 
A Diagnostic Verification F orm (on the Virgil Tablet) completed by [CONTACT_978] (or SI) at 
Screening  will be reviewed by [CONTACT_717247] -ProPhase  
prior to subject s proceeding to imaging assessments  to ensure that subjects meet those 
elements of the inclusion criteria that relate to clinical diagnosis of probable AD or MCI -AD.  
 
Efficacy assessments should be performed at approximately the same time of day throughout 
the study for a given subject, to the greatest extent possible. The clinical efficacy assessments 
should be administered before vital signs measurement and blood sample collection. All 
attempts should be made to have the same rater collect efficacy outcome data at all visits. The 
key efficacy scales are described below.  
 
[IP_ADDRESS]  ADAS -cog 
The ADAS was designed to evaluate the severity of cognitive and non -cognitive or 
behavioral symptoms of AD ( Rosen et al., 1984 ). The ADAS -cog is the cognitive subscale of 
the ADAS, originally proposed with [ADDRESS_977760] been 
added in  the ADAS -cog 13 to provide additional sensitivity to change in cognition at earlier 
stages of the disease  (Mohs et al., 1997) ; these are Delayed Word Recall and Number 
Cancellation.  
 
As the original ADAS -cog 11 was used in the earlier Phase 3 studies , that score will be derived 
from the assessment of the ADAS -cog 13 for the primary analyses . The Composite Scale 
described in Section [IP_ADDRESS]  will be based on items selected from the ADAS -cog 13. 
 
Protocol: TRx -237-[ADDRESS_977761] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 74 of 145 [IP_ADDRESS]  ADCS -ADL 23 
The ADCS -ADL 23 includes 23 items that were derived from a larger set of items describing 
performance of activities of daily living (ADL) by [CONTACT_717249] (Galasko et al., 1997 ). Of [ADDRESS_977762] reliability over 1  to 2 months (Galasko et al., 2005 ). Scores of these items 
(ADCS -ADL 23) were also shown to correlate with MMSE scores of AD patients and to 
decline over [ADDRESS_977763] 20% of AD patients.  The Composite Scale described in 
Section [IP_ADDRESS]  will also be based on selected items from the ADCS -ADL 23. 
 
[IP_ADDRESS]  Composite Scale (s) 
The new Composite Scale  based on selected item s of the ADAS -cog 13 and the ADCS -ADL 23 
will be analy zed at 9 months and 12 months  during the double -blind treatment period  to 
evaluate its usefulness for future studies . It consists of cognitive subdomains (orientation [ 8], 
constructional praxis [5], word recall, third trial [10], assessor rating of subject speech [5], 
and assessor rating of subject comprehension [5]) from the standard ADAS -cog 11, and 
functional items (use of telephone [5], keepi[INVESTIGATOR_55228] [3], cooking and preparation of 
meals [4], and cleaning dishes [3]) from the standard ADCS -ADL 23. The selected cognitive 
items are based on a non -interventional study (Study TRx -GTD -025) examining performance 
of a range of psychometric tools which decline over 12 months in discriminating subjects 
with mild AD from age -matched healthy controls, supple mented with functional items 
identified as declining over 9 months in add -on treatment arms in  Study TRx -237-005, 
independently confirmed by [CONTACT_717250] -237-015, and supported by [CONTACT_717251] . 
The items listed provide a maximum possible score of 48 ( higher score indicates less 
impairment ).  
 
Additional Composite Endpoints (if any) such as one that is less/not impacted by [CONTACT_4113] -19 
will be defined in the SAP and signed off prior to database lock  and unblinding.  
 
[IP_ADDRESS]  Mini -Mental State Examination  (MMSE)  
The MMSE (Folstein et al., 1975) was originally developed to differentiate between 
psychiatric patients with functional and organic conditions, to quantify the level of cognitive 
impairment, and to monitor changes over time. The MMSE subsequently has become a 
widely used and exte nsively validated cognitive test demonstrating satisfactory reliability, 
validity, and change sensitivity under a wide variety of conditions (Tombaugh and McIntyre, 
1992).  A modified version of the form, supplied by [CONTACT_717252], is 
used in this study.  
 
The utility of the MMSE as a means of assessing treatment response in AD has been 
questioned (Bowie et al., 1999), but its status as a clinical outcome measure has been 
supported by [CONTACT_717253] (NICE, 2001). 
Furthermore, the MMSE has demonstrated an ability to detect change in clinical studies with 
AChEIs (Birks and Harvey, 200 4). Further, i n an epi[INVESTIGATOR_119262] (Mukaetova -
Ladinska et al., 2000), pre -mortem MMSE scores have been correlated with post -mortem  
Braak stage (based on the spread of tau pathology through the brain).  
 
Protocol: TRx -237-[ADDRESS_977764] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 75 of 145 [IP_ADDRESS]  Clinical Dementia Rating  (CDR)  
The CDR  rates overall severity of dementia (Hughes et al., 1982). The CDR has been shown 
to have good reliability (Morris et al., 1997) and validity (Fillenbaum et al., 1996) and to 
correlate with neuropathological status (Morris et al., 1988). The scale is sensitive to change 
over longer time periods (Berg et al., 1988).  
 
The CDR is administered using a worksheet and semi -structured interview of a reliable 
informant ( e.g., caregiver)  followed by  [CONTACT_717254]: memory, orientation, judgment and problem solving, community affairs, home and 
hobbies, and personal care. Each domain is scored on a 5 -point scale, where 0  = normal, 
0.5 = questionable impairment, 1  = mild impairment, 2  = moderate impairment, an d 
3 = severe impairment.  The CDR  total score (also sometimes referred to as  the CDR global 
score) is derived from individual (“box”) scores for each of the six domains, in accordance 
with published scoring rules.  
 
15.3 Imaging Assessments and Procedures  
15.3.1  Gener al Con sideration s 
PET imaging using an amyloid ligand and b rain MRI play  a role in this protocol for 
eligibility determination  of the subjects ; brain MRI is also used as a secondary efficacy 
endpoint as well as to confirm a lack of treatment unblinding . 18F-FDG -PET will be 
performed in subjects with CDR 0.[ADDRESS_977765]’s 
(and/or LAR’s) consent, collection of amyloid PET scan performed either in the course of the 
study or previously.  The total radiation exposure to subjects  from the amyloid PET scan 
procedure (if not performed previously)  is estimated to be  9 mSv for a single scan ; the limits 
for radiation exposure from the 18F-FDG -PET scans are discussed in Section [IP_ADDRESS] . 
 
With respect to 18F-FDG -PET and MRI , the core laborator ies will be responsible for checking 
the quality of imaging data, verifying  that site anonymization of the images is maintained, 
pre-processing of images, presenting  data to the reader(s) (for MRI eligibility and volumetric 
evaluations and 18F-FDG -PET), and analyzing  the data. Each  core laboratory will provide 
SAS datasets to the data management and statistics facilit ies for analysis. All systems and 
processes used for independent and central reads of t his trial will be 21 CFR Part 11 
compliant.  
 
Before commencement of central evaluations, vendor study -specific documents such as 
charters and manuals  will be developed that will describe in detail the imaging acquisition 
protocols, image collection procedures, quality check  procedures, site training procedures, 
reader training, image evaluation procedures (central determination of subjects’ eligibility, 
efficacy, and safety), and communication plans.  
 
All sites will be prospectively trained about imaging requirements including scanner 
requirements, image acquisition, image  transfer to the core laboratories , and timelines that are 
critical for this trial . 
 
Protocol: TRx -237-[ADDRESS_977766] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 76 of 145 See Section  10.2 for a summary of alternate arrangements that may be implemented due to 
COVID -19. 
 
15.3.2  Site Selection and Qualification   
A site imaging technical evaluation questionnaire will be distributed to potential clinical sites 
to evaluate their technical and personnel capabilities that will include machine description, 
availability of phantoms (if applicable), onsite availability of modality -specific technologist 
or physicist ( depending on 18F-FDG -PET or MRI facility ), site experience in evaluating brain 
18F-FDG-PET and/or MRI, experience in AD and other dementia trials, etc. The site’s 
capability of producing quality data that are n ecessary for this trial will also be evaluated by 
[CONTACT_717255]/or review of imaging data of the site’s first subject. 
Continuous monitoring of the quality of imaging data will be performed throughout the trial. 
Technical details of imaging and quality check  procedures will be describe d in a separate 
imaging manual.  
 
15.3.3  Imaging Method s for  Efficacy 
A separate imaging manual will be developed that will outline imaging methods for both 
18F-FDG -PET and brain MRI to harmonize image acquisition across the sites. 18F-FDG -PET 
should be obtained with computerized tomography (CT); brain -dedicated high -resolution 
PET devices, such as the Siemens High Resolution Research Tomograph system, that use a 
transmission source for attenuation correction will also be considered from  expert sites.  
 
[IP_ADDRESS]  18F-FDG -PET 
An 18F-FDG-PET scan will be performed in subjects with CDR 0.5 at Screening using 
PET/ CT or a brain -dedicated high -resolution PET device .   
 
Use of sedatives is not permitted for a period of [ADDRESS_977767]’s  fasting (at least 4 to 6 hours) blood glucose level, carried out by [CONTACT_717256]’s standard operating procedures, should be < 180 mg/dL (<9.9 mmol/L)  in order for the 
injection to take place. If a screening amyloid scan is acquired under the study, there must be 
a minimum of 16  hours between the amyloid scan and the 18F-FDG-PET scan due to the half -
life of fluorine.  
 
The baseline 18F-FDG-PET scan is to be performed within 4 2 days before Baseline (Visit  2) 
only in subjects confirmed to meet all inclusion and exclusion criteria and who have a 
screening CDR of 0.5 . Subjects who were previously treated with an AChEI and/or 
memantine must have received the last dose at least 60 days prior to this scan. If the initial 
screening/ baseline 18F-FDG -PET is not of sufficient q uality to serve as an adequate baseline 
as determined by [CONTACT_717257], then the scan must be repea ted within [ADDRESS_977768] that 
exceeds the limits for the clinical trial (approximately 4.7 mSv for a single scan and 14.1 mSv 
in total, if a repeat scan is deemed necessary ). If the repeat  scan cann ot be accomplished 
within the [ADDRESS_977769] be re -consented and re -screened. 
For subjects who are re -screened for other reasons and an acceptable 18F-FDG-PET scan was 
already  completed during the original S creening window, the scan does not require repetition . 
 
Protocol: TRx -237-[ADDRESS_977770] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 77 of 145 The Week 52 (end of double -blind treatment)  18F-FDG -PET scan should be performed within 
± [ADDRESS_977771]’s last 
18F-FDG -PET scan was performed ≥[ADDRESS_977772] 
be done  as part of the early termination visit assessments within the time window of the early 
termination visit ( i.e., ± [ADDRESS_977773] dose of study drug).  The allowable time window 
for the early termination  18F-FDG-PET scan can be extended to up to [ADDRESS_977774] 
dose of study drug in the double -blind treatment period only with the permission of the 
Sponsor/ Medical Monitor . 
 
Imaging assessments will be made by [CONTACT_717183]:  
• Brain 18F-FDG -PET will be evaluated for temporal, parietal , and frontal lobe SUVR 
(normalized with respect to pons and cerebellum ) at Baseline and after 52 weeks  of 
double -blind treatment , or upon early termination. Other SUVR  ROIs will also be 
examined including, but not restricted to, inferior temporal gyrus, angular gyrus, 
anterior and posterior cingulate gyrus, and cerebellum. Change in SUVR parameters 
will be quantified by [CONTACT_3539].  
• SPM preprocessing may be performed, which involves realignment of the dynamic 
18F-FDG-PET images, the summation of those images, registration to the MR images 
in native space, normalization to atlas space, count normalization to a reference 
region, and smoothing for statistical purposes. After  database lock, the voxelwise 
change in the SUVR maps may be quantified using an SPM approach (models to be 
characteri zed in the SAP ). Details of analysis conducted will be reported in a separate 
report .  
[IP_ADDRESS]  MRI 
The screening MRI (to be obtained within the 9 -week Screening period [Days  -63 to -1] in 
subjects not receiving an AChEI and/or memantine, or Days -112 to -63 in subjects who 
begin Screening on an AChEI and/or memantine) will also be used as the baseline for 
volumetric measurements. The volumetric MRI will be repeated approximately every 
13 weeks in the double -blind treatment period after randomization ( i.e., after 13, 26, 39, and 
52 weeks) as well as after the additional 26 and 52 weeks of open -label treatment.  For 
subjects who terminate early  (in either the double -blind treatment or open -label treatment 
periods) , if the subject’s last MRI scan was performed <90 days prior to the early termination 
date, no additional MRI scan is required.  
 
Imaging assessments will be made by [CONTACT_717183]:  
• Brain MRI will be evaluated for temporal and parietal, whole brain, lateral 
ventricular, hippocampal, putamen, nucleus accumbens, and nucleus basalis ROI 
volumes. Change in MRI volumetri c parameters will be quantified by [CONTACT_3125].  
• T2*-weighted gradient -recalled echo is to be included to enable the detection and 
quantification of the image hyperintensities . 
• SPM preprocessing may be performed, which involves registration of the MR images 
to atlas space, segmentation into tissue types (grey, white, cerebral spi[INVESTIGATOR_872]). After 
database lock, the voxelwise change may be quantified in the segmented MR maps 
using an SPM approach (models to be characterized in the SAP).  Details of analysis 
conducted will be reported in a separate report . 
Protocol: TRx -237-[ADDRESS_977775] -[ADDRESS_977776] eligibility for 
enrol lment . All safety assessments will be performed by [CONTACT_717258]; where specified below, the assessments must be made 
by a medical assessor ( physician/ MD/DO). For enrolled subjects, safety assessments will be 
made at Baseline and at each clinic visit ( i.e., after 4, 13, 26, 39, and 52 weeks during the 
double -blind treatment period as well as after 26 and 52 we eks in the open -label, delayed -
start phase); during a telephone contact  [CONTACT_3435] 4 weeks in the open -label, delayed -start phase; 
when needed to follow up on an AE ; and upon early termination. See Section  10.2 for a 
summary of a lternate arrangements that may be implemented due to COVID -19. All AEs, 
vital signs, ECG, clinical laboratory findings,  physical and neurological examinations , and 
ophthalmological examinations  (as applicable) will be assessed according to the following:  
• AEs will be recorded from the time informed consent is signed and recording will 
continue throughout the study. The recording and assessment of AEs will be 
performed by a medical assessor  (physician/MD/DO ) separate from those 
administering the efficacy outcome scales (ADAS -cog [ADDRESS_977777] and MMSE ). AEs with an onset after the first dose of study drug or that 
worsen in intensity or treatment relationship after the first dose will be considered 
treatment -emergent  (and must be reviewed by a medical assessor  
[physician/MD/DO ]). Assessment should continue as needed to follow up an AE to its 
resolution or acceptable stabilization (including after the last dose  of study drug ), 
consistent with the medical judgment of the investigator.  
• Blood pressure and pulse will be obtained at Screening, on Day 1 (within [ADDRESS_977778] -dose), and at each clinic visit thereafter or upon 
early termination. Blood pressure and pulse will be measured after the subject has 
been in a seated position for at least 5 minutes.   
• Height will be measured at Screening only. Body weight will be measured at 
Screening and at each clinic visit thereafter or upon early termination.  
• A 12 -lead ECG will be obtained at Screening , with the site judging eligibility based 
on the local interpretation  by a medical assessor  (physician/MD/DO ). 
• TSH, vitamin B12, folate, haptoglobin , and G6PD will be measured at Screening ; a 
thyroid panel may be obtained in response to an elevated TSH. Standard clinical 
laboratory testing, including hematology  and blood chemistry , will be performed at 
Screening and each  subsequent clinic  visit (or upon early termination) . Testing may 
also be performed at unscheduled visits as necessary to follow -up an AE  (see 
Section  16.11.1  for testing in response to possible hemolytic anemia ). All laboratory 
results are to be reviewed by a medical assessor  (physician/MD/DO ). Any abnormal 
laboratory test  result from Screening assessments (pr ior to treatment) is to be added to 
the subject’s medical history , unless deemed clinically significant by [CONTACT_717259] (MD/DO) in which case it will be  recorded  as an AE . 
• A blood sample for a serum pregnancy test will be collected f rom all women  of 
childbearing potential at Screening and at each subsequent clinic visit (or upon early 
termination ). 
• Complete physical and neurological assessments will be performed at Screening  (see 
Section [IP_ADDRESS] ). Targeted examinations will be performed pre -dose and 
approximately [ADDRESS_977779] dose of study drug (Visit 2) . 
Thereafter, targeted examinations are to be performed at each subsequent  clinic  visit 
(upon early termination ). At a minimum, targeted examinations should include heart 
and lung auscultation and brief neurological assessment guided by [CONTACT_717260]: TRx -237-[ADDRESS_977780] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 79 of 145 signs/symptoms/AEs ( e.g., evaluating subjects for potential serotonin toxicity ). These 
examinations are to be performed by a medical assessor  (physician/MD/DO) . 
• Slit lamp ophthalmological examination of subjects with history of lens implants will 
be performed by a licensed  optometrist, ophthalmologist, or other suitably qualified 
medical assessor (physician/MD/DO) prior to the first dose of study drug (during the  
screening procedures or as part of the baseline assessments) , at Visit 7, and at Visit 10 
/ early termination  (after completion of efficacy assessments) , to assess whether the 
lens has been discolored during the trial. The slit lamp examination should also be 
performed if a subjec t has  cataract  surgery / lens i mplantation at any point during  his 
or her  study participation  (as soon as possible after the surgery), as well as in response 
to visual complaints if suggestive of lens discoloration . 
• At Screening , medications admin istered within the last 90 days  will be recorded, with 
the exception of  anti-dementia  medications , where lifetime use (as far as possible) is 
to be recorded . Changes in concomitant medications and any new concomitant 
medications  will be recorde d at all visits, including the telephone contact [CONTACT_717261] -label, delayed -start phase, and reviewed by a medical assessor  
(physician/MD/DO) . For antipsychotics, the reason for use should be document ed 
(see Section 13.4). 
 
Further details regarding  alternate arrangements for sample collection  and shipment that may 
be implemented due to COVID -19 are described in Section  10.2.   
 
15.5 Other Assessments  
15.5.1  MT Conce ntration  
At Visit s 2, 3, 7, and 10,  blood will be collected on the same day on three occasions  for 
determination of plasma and whole blood MT concentrations ( to the extent possible, parent 
MT/LMT  and N-desmethyl MT , and after the sample has had acid and heat treatment, total 
MT); these visits should be scheduled to occur in the morning . Samples will be collected 
prior to dosing (in the clinic), approximately [ADDRESS_977781] be collected and recorded .   
 
For subjects who continue in the study  off-treatment (TOTOS group), blood samples will not 
continue to be collected for the determination of MT concentrations.  
 
Concentration results will not be made available to the study sites during the conduct of the 
study. However, results for a given subject (if available) may be provided to the DSMB if 
requested to aid in interpretation of a significant subject safety issue .  
 
Protocol: TRx -237-[ADDRESS_977782] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 80 of 145 The collection, handling, and shippi[INVESTIGATOR_717140]. These are to be 
analyzed using validated analytical methods.  
 
See Section  10.2 for a summary of alternate arrangements that may be implemented due to 
COVID -19. 
 
[IP_ADDRESS]  Procedure for Blood S ample Collection  
Blood samples ( 9 mL) will be collected into a suitable vacutainer (9.0 mL ), as d efined in the  
laboratory manual. A portion of t he w hole blood will be centrifuged  under refrigeration ; the 
separated plasma will be transferred as defined in the laboratory manual . Both the whole 
blood aliquot and separated plasma will be stored at ca -20°C until shipment to the central 
laboratory for storage. The complete sample collection and handling procedures to be 
followed can be found in the laboratory manual.  
 
[IP_ADDRESS]  Packaging, Labeling, and Shippi[INVESTIGATOR_717141] ; other labeling information 
will be detailed in the laboratory manual. Labels must remain intact and indelible throughout 
processing and frozen storage. Samples will be clearly distinguished from the other 
bioanalytical samples.  Samples are to be transported in insulated containers filled with dry 
ice. They will be shipped to the central laboratory where they will be stored frozen and 
shipped in batches to the analytical laboratory.  
 
15.5.2  Genotyp ing 
A single blood sample will be obtained only from subjects who provide legally acceptable 
informed consent for genotypi[INVESTIGATOR_717142] . The blood sample may be collected any 
time after eligibility for randomization and continued participation in the study has been 
confirmed  but prior to Visit 7 (end of double -blind treatment period) . A volume of 
approximately 2 mL is to be collected and  shipped ambient to the central laboratory 
(Labcorp) on the day of collection.  See Section  10.2 for a summary of alternate arrangements 
that may be implemented due to COVID -19. 
 
Genotypi[INVESTIGATOR_717143].  
 
16 ADVERSE EVENTS AND SAFETY  
16.1 Definition of AEs, Period of Observation, and Recording of AE s 
An AE is any unfavorable or unintended sign, symptom, or disease, whether or not 
considered related to the study treatment. This also includes events resulting from medication 
error or inappropriate use. AE recording will begin at the time the  informed consent form  
(ICF) is signed. Thereafter, AEs will be ascertained by [CONTACT_63397] (and study partner ) 
how the subject has been since the last visit. A clinical abnormality, laboratory test value 
abnormality, or imaging abnormality that the investigator deems to be clinically significant 
should be recorded as an AE.   Any abnormal laboratory test result from Screening 
assessments (prior to treatment) is to be added to the subject’s medical history, unless 
deemed clinically significant by [CONTACT_717262] (MD/DO) in which case it will be 
reported as an AE . 
Protocol: TRx -237-[ADDRESS_977783] -[ADDRESS_977784]. Follow -up should be continued beyond the scheduled final visit  if needed, 
until the AE or its sequelae resolve or stabilize at a level acceptable to the investigator  in his / 
her medical judgement . 
 
For each AE, information recorded will include the following: the date when the AE started, 
the date when the AE stopped (or whether it remained ongoing), the intensity of the AE, the 
relationship of the AE to study drug, action taken with regard to study drug (none, 
interrupted, or discontinued), other drug therapy (no change, new medication, altered 
medication, or both of the latter), outcome, and whether or not the AE was considered an 
SAE.  
16.3 Categori zing Intensity  
The intensity (severity) of each AE will be assessed by [CONTACT_378899], 
moderate, or severe, as follows:  
• Mild: An AE that is easily tolerated by [CONTACT_423], causes minimal discomfort and 
does not interfere with everyday activities  
• Moderate: An AE that is sufficiently discomforting to interfere with normal everyday 
activities  
• Severe: An AE that prevents normal everyday activities  
An AE that is assessed as severe should not be confused with an SAE. Severity is a 
category utilized  for rating the intensity of an event; and both AEs and SAEs can be 
assessed as severe.  
Protocol: TRx -237-[ADDRESS_977785] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 82 of 145 16.4 Investigator ’s Brochure  
The Investigator ’s Brochure will be used as a guide to assess causality . 
16.5 Assessing Causality  
The investigator will make a judg ement considering whether or not , in his or her opi[INVESTIGATOR_1649], 
each AE is related to the study drug according to classifications described here. However, 
even if the investigator feels that there is no relationship to the study drug, the AE should be 
reported nevertheless. For each AE, the rel ationship or association (causality) of the AE to 
study drug will be assessed by [CONTACT_717263], unlikely 
related, possibly related, or related as follows:  
• Not related: If there is a confirmed cause of the AE (other medical condition, other 
therapy) which does not involve the study drug  
• Unlikely related: If the temporal association between the AE and the study drug is 
such that the AE is not likely to be related to the study drug  
• Possibly related: If the AE shows a reasonable temporal association to study drug 
administration but could be due to the subject’s clinical state or other therapi[INVESTIGATOR_124888]  
• Related: If the AE shows a reasonable temporal association to study drug 
administration  and cannot be explained by [CONTACT_20612]’s 
clinical state  
16.[ADDRESS_977786]  outcome of each AE.  
 
Note : While negligible to slight coloration of urine or feces may occur  as a result of study 
drug, these manifestations  should not be recorded as AE s. 
 
Definitions for possible results of an AE outcome  are: 
• Recovered/resolved: the event has improved or the subject  recuperated  
• Recovering/resolving: the event is improving  
• Not recovered/not resolved: the event has not improved or the subject  has not 
recuperated  
• Recovered/resolved with sequelae: the subject  recuperated but retained pathological 
conditions directly resulting from the disease or injury  
• Fatal: termination of life as a result of an AE  
• Unknown: not known, not observed, not recorded, or refused  
16.7 Serious Adverse Event Reporting  
An SAE is defined as any event that:  
• Results in death (including suicide)  
• Is life-threatening  
• Results in hospi[INVESTIGATOR_148244]  
o Planned admissions for respi[INVESTIGATOR_717144] (the 
Medical Monitor should be contact[CONTACT_717264][INVESTIGATOR_717145]). 
Protocol: TRx -237-[ADDRESS_977787] -[ADDRESS_977788]'s condition.  
o An admission or prolongation of existing hospi[INVESTIGATOR_717146], or because the study partner  is unable or 
unwilling to care for the subject, is not to be considered an SAE.  
o Admissions to a hospi[INVESTIGATOR_717147] -existing  medical condition are not to be 
considered an SAE.  
• Results in persistent or significant disability or incapacity  
• Is a congenital anomaly or birth defect  
• Important medical events tha t might not be immediately life -threatening or result in 
death or hospi[INVESTIGATOR_483708] e the subject  or might require intervention 
to prevent one of the other outcomes listed above. Examples of such events are 
intensive treatment in an emergency room or at home for allergic bronchospasm, 
blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_1838] , or development 
of dependency or abuse  
 
Medical and scientific judgment should be exercised in deciding whether an event is serious 
and whether expedited reporting is appropriate in other situations, such as important medical 
events that may not be immediately life -threatening or result in death  or hospi[INVESTIGATOR_717148].  
 
All SAEs must be reported on the eCRF. An assessment should be made by [CONTACT_717265] -related, i.e., is ‘causally’ related to the study drug.  
 
All SAEs (including a ny SAEs associated with COVID -19 that occur during study 
participation)  should  be reported to the Sponsor designee, Syneos Health , immediately (and 
not exceeding 24  hours following knowledge of the event) . These should be  followed by 
[CONTACT_6492] -up reports as soon as possible, whether or not the events are deemed study drug -
related.  
 
SAEs  must  be reported by [CONTACT_717266]/SAE Section of the eCRF  
system. The information provided in the eCRF  system should be as complete as possible, but 
must contain the following minimum fields:  
• Subject number  
• Brief description of the SAE (diagnosis or signs/symptoms)  
• Serious criteria  
• Causality assessment  
• Assessment of the intensity of the event  
Syneos Health  Drug Safety will receive notification of the initial SAE via an e-mail alert 
generated from the eCRF  system. In the event of any temporary disruption of the electronic  
system, an alternative SAE reporting mechanism will be available to site personnel; in this 
instance, a paper SAE report form will be available. Site personnel will complete the paper 
SAE report form, scan , and e -mail it within 24 hours to the following e -mail address:  
[EMAIL_1604]  
Fax: +[PHONE_3639]  
Address:  
Protocol: TRx -237-[ADDRESS_977789] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 84 of 145 Syneos Health  
Safety/Pharmacovigilance Department  
Farnborough Business Park – [ADDRESS_977790]’s identity beyond the agreed study 
identifier. The investigator should ensure that information reported is accurate and consistent.  
 
Information not available at the time of the initial report ( e.g., an end date for the AE, 
laboratory values received after the report, or hospi[INVESTIGATOR_44458]) must be 
documented on a follow -up form. All follow -up information must be reported in the same 
timelines as initial information.  
 
Any SAEs considered related to the study drug and discovered by [CONTACT_717267] [ADDRESS_977791] and are both unexpected ( i.e., the nature or severity is not 
expected from the information provided in the Investigator's Brochure) and serious. As stated 
in the EU ‘CT -3’ Communication from the Commission (2011/C 172/01) and the US Code of 
Federal Regulations (21 CFR 312.32), for the re to be a reasonable possibility of a causal 
relationship between the event and study drug there must be facts (evidence) or arguments to 
suggest a causa l relationship. Final assessment of expectedness for purposes of regulatory 
reporting is the responsibility of the Sponsor.  
 
It is the responsibility of the Sponsor to determine whether a reported SAE fits the 
classification of a S[LOCATION_003]R and to notify the investigator of the decision as soon as possible.  
 
All S[LOCATION_003]R reporting, whether determined following unblinding during study conduct or 
apparent only after the study has ended, will adhere to European Directives 2001/20/EC, 
21 CFR 312.32 of the U.S. Code of Federal Regulations, Health Canada Food and Drug 
Regulation C.05.014, and other regions as applicable.  
Protocol: TRx -237-[ADDRESS_977792] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 85 of 145 16.9 Malignancies  
All cases of malignancies, other than non -melanoma skin cancers, are to be reported to the 
Sponsor designee, Syneos Health , as outlined above in Section  16.7. Adverse events of 
malignancies other than non -melanoma skin cancers are to be reported regardless of causality  
or whether they meet the criteria for serious . These will be reported to Health Canada as 
Adverse Drug Reactions (ADRs). Expedited reporting in other countries will be consistent 
with the handling of S[LOCATION_003]Rs.    
16.[ADDRESS_977793]. An event of a pregnancy will be 
reported to the Sponsor designee, Syneos Health , immediately (and not exceeding 24  hours 
following knowledge of the event) , and followed by [CONTACT_6492] -up reports as soon as possible . 
 
Subjects who become pregnant during the clinical study should discontinue study drug 
immediately and contact [CONTACT_093]. Subjects should be instructed to notify the 
investigator of  a pregnancy either during the T reatment period of the study or within [ADDRESS_977794] dose of study drug. Whenever possible, a pregnancy should be followed to term, 
any premature terminations reported, and the status of the mother and child reported to the 
Sponsor after delivery.  
 
Although the pregnancy is not considered to be an AE or SAE, any pregnancy complications 
should be recorded as AEs or SAEs (if applicable). Any pregnancy should be followed 
through delivery for observation of any SAE , if possible . Therefore, regardless of whether or 
not a pregnancy is actually considered an SAE, a pregnancy form should be completed for all 
pregnancies.  
 
The information provided in the eCRF  should be as complete as possible, but must contain 
the following minimum fields:  
• Subject number  
• Confirmation that the s ubject ’s contact [CONTACT_717268]  
• Date of report of pregnancy  
• Expected delivery date  
 
All data related to pregnancy, pregnancy outcome, and SAE s associated with pregnancy 
should be recorded in a safety database maintained by [CONTACT_717269] . Pregnancies should initially be reported in the 
Pregnancy Notification Form, Part I and sent by e -mail to the e -mail address provided below. 
When the outcome of the pregnancy is known, site personnel will complete the Pregnancy 
Notification Form, Part II and e -mail it to the same e -mail address noted below.  
 
Syneos Health  Drug Safety will receive notification of the pregnancy  via an e-mail alert 
generated from the eCRF  system. In the event of any temporary disruption of the electronic  
system, site personnel will scan and e -mail a written report  within 24 hours to the following 
e-mail address :  
[EMAIL_1604]  
Fax: +[PHONE_3639]  
Address:  
Protocol: TRx -237-[ADDRESS_977795] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 86 of 145 Syneos Health  
Safety/Pharmacovigilance Department  
Farnborough Business Park – [ADDRESS_977796] 
and/or potential interruption or discontinuation of study drug are presented . 
 
16.11.1  Hem olytic  Anem ia 
When there are signs and/or symptoms of clinically evident hemolytic anemia, dosing should 
be interrupted . A hemolysis panel should be considered ( including complete blood count with 
differential, reticulocyte count [including absolute reticulocyte number], lactate 
dehydrogenase (LDH), direct and indirect bilirubin, and haptoglobin). See Section 13.8 for 
guidance on vitamin B 12. If confirmed as related to study drug, dosing should be 
discontinued.  
 
Signs of possible treatment -emergent hemolytic anemia include:  
• Decrease by 20% from screening in red blood cell (RBC) count and/or hemoglobin  
• Abnormal RBCs in peripheral blood smear  
• Elevation of reticulocyte count to above laboratory normal range  
• Increase in LDH or indirect bilirubin, or low er haptoglobin  than screening  
 
16.11.2  Lens Discolor ation  
For subjects with a history of lens implants, o phthalmological examinations (slit lamp 
examinations) will be  performed  prior to the first dose of study drug (during Screening or as 
part of Baseline assessments), at Visit 7, and at Visit 10 / early termination  as scheduled 
procedures. Subjects and investigators are informed of t he potential for lens discoloration in 
the Informed Consent Form and Investigator’s Brochure, respectively . If a lens discoloration 
is identified by [CONTACT_283705], this is to be recorded as an AESI  in the AE eCRF; 
however , no specific  action is required for the study drug . Slit lamp examination should  also 
be performed if a subject has cataract surgery  / lens implantation  at any point during his or 
her study participation  (as soon as possible after the surgery ), as well as in response to visual 
complaints if suggestive of lens discoloration . 
 
16.11.3  Other Safety Reason s Requiring Disc ontinuation  of Stud y 
Drug 
If the calculated creatinine clearance is <30 mL/min  and renal concerns arise , study drug 
should be discontinued.  
 
Protocol: TRx -237-[ADDRESS_977797] -[ADDRESS_977798]  number  (see Section 4) should be contact[CONTACT_717270] . 
16.[ADDRESS_977799] to their health or safety.  
 
The Sponsor and the Medical Monitor or designated deputy will be notified of any urgent 
safety measures taken by [CONTACT_717271]. The investigator or qualified des ignee will 
notify the Independent Ethics Committee/Institutional Review Board ( IEC/IRB ). 
 
If these measures are taken, the Sponsor or investigator shall immediately give written notice 
to the pertinent regulatory authorities consistent with the regional/national requirements , 
IEC/IRB , and DSMB  of the measures taken and the circumstances giving rise to those 
measures. In any event, the written notice shall be no later than 7 days from t he date the 
measures are taken.  
 
17 STATISTICAL  ANALYSIS  
A SAP will be finalized and signed off prior to database lock and unblinding. The SAP will 
provide details about the planned analysis. A brief overview of the plans for the primary 
analysis and selected secondary and exploratory analys es is given in the following sections . 
Specific ROI and SPM  techniqu es and comparisons to previous P hase 3 data or external 
databases as well as Population PK analyses will be described in the SAP or a corresponding 
additional SAP where necessary ; the SAP will provide details .  
 
Changes to the planned analysis will be documented in the SAP prior t o database lock and 
unblinding.  Deviations from the SAP (if any) will be noted in the clinical study report . 
 
The primary target of estimation is the difference in ADAS -cog 11 and ADCS -ADL 23 over 
52 weeks  in subjects receiving the LMTM dose of 16 mg/day as compared to placebo.  
 
The primary efficacy analyses for FDA will be performed on the Efficacy  Modified Intent -to-
Treat ( E-MITT) which will include all randomized subjects who took at least one dose of 
study drug and have a baseline and a valid post -baseline efficacy assessment, and for EMA 
on the Intent -to-Treat (ITT) population with conservative assumptions about disease 
progression made for subjects who have missing post -baseline assessments. Subjects will be 
analyzed in the treatment group and according to the stratification variables to which they 
were randomized.  
 
Changes from baseline to Week 52 on the co -primary efficacy endpoints and other modalities 
with repeated measures such as MRI will be analyzed using a linear mixed model for 
repeated measures with unstructured covariance matrix  (this assumption about the covariance 
matrix might be relaxed if the model does not converge ; the SAP will provide details) . The 
linear mixed model will contain fixed effects for time, treatment, and a treatment -by-time 
interaction; additionally, the baseline value of the correspondi ng endpoint will be included as 
a covariate and the randomization stratification variables of prior usage of AChEIs and/or 
Protocol: TRx -237-[ADDRESS_977800] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 88 of 145 memantine, MMSE split (16 -19, 20 -25 or 26 -27) as determined at Screening, and region will 
be included as fixed effects  in the model . 18F-FDG -PET and other modalities with only one 
planned post -baseline assessment will be analyzed using an ANCOVA ; the covariates for this 
model will be adjusted accordingly by [CONTACT_717187].  
 
Sever al of the analyses described below will be performed  separately for the comparisons of 
LMTM 16 mg/day  with placebo  and 8  mg/day with placebo . As only the LMTM 16 mg/day 
and placebo comparison is a primary endpoint , the models will use two treatment levels 
dependent on the comparison of interest . Several analyses provided for the comparisons of 
LMTM 16 mg/day and placebo  will be repeated for the LMTM 8 mg/day versus  placebo 
group as secondary or exploratory/sensitivity endpoints.  The SAP will detail which analyses 
are performed for which treatment groups, and in which case s the LMTM 8 mg/day with 
placebo comparisons will be provided for which sensitivity, subgroup, and exploratory 
analyses.   
 
Further analysis on selected primary and secondary endpoints will be provided for pooled 
LMTM 16 mg/day and 8 mg/day arms compared to placebo. The analysis models will be 
identical to the 16 mg/day versus  placebo  with the exception of pooled treatment arms . The 
SAP will detail which analys es are repeated for the pooled 16 mg/day and 8 mg/day arms.  
 
More details about the exact contrast statements used for these tests as well as further 
sensitivity analyses, additional analyses of the primary variables (such as responder analyses 
and subgroup analyses), and the analyses of the secondary and explorator y endpoints are 
described in the subsections below as well as in the SAP.  
 
“Late” starters, i.e., subjects originally randomized to placebo, will be compared to “early ” 
starters, i.e., those originally randomized to LMTM 16 mg/day or 8  mg/day (pooled, and 
individually for both groups as a sensitivity  analysis ). The last assessment prior to start of 
open -label treatment ( pre-dose at Visit 7) will serve as the baseline assessment for these 
comparisons. The analyses will be based on a similar linear mixed model for repeated 
measures with the aim to investigate whether there is a diff erence in change in primary and 
MRI imaging endpoints dependent on LMTM treatment history. The comparison will be 
implemented through a non -inferiority test.  
 
The non-inferiority margin for the primary endpoint of ADAS -cog [ADDRESS_977801] 
of > 5 units (~40% of this effect size). Margins for other endpoints which are exploratory to 
support a disease modifying argument will be defin ed in the SAP. The results will also be 
presented with the Visit 2 Baseline as baseline and treat ment  visits Week 26 and Week 52 in 
the open -label, delayed -start phase as Week 78 and Week 104 . 
17.1 Efficacy Endpoints  
17.1.1  Primary Efficacy Endpoints for Doub le-Blind Treatment 
Period 
• ADAS -cog 11 (LMTM 16 mg/day versus  placebo)  
• ADCS -ADL 23 (LMTM 16 mg/day versus  placebo)  
 
Protocol: TRx -237-[ADDRESS_977802] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 89 of 145 17.1.2  Secondary Efficacy Endpoints for Doub le-Blind Treatment 
Period 
• Annualized rate of whole brain  atrophy on brain MRI using BSI  (LMTM 16 mg/day 
versus  placebo)  
• Difference in temporal lobe 18F-FDG -PET change in SUVR  normalized to pons  in 
subjects with CDR 0.5 at Screening (LMTM 16 mg/day versus  placebo, and LMTM 
8 mg/day versus placebo ), if a sufficient  number of  subjects have provided data as 
specified in the SAP  
• ADAS -cog 11 and ADCS -ADL 23 (LMTM 8 mg/day versus  placebo)  
• Annualized rate of temporal and parietal lobe  atrophy on brain MRI using BSI 
(LMTM 16 mg/day versus  placebo, and LMTM 8  mg/day versus placebo)  
 
17.1.3  Secondary Endpoint for Open-Label, Delayed -Start Phase  
• Difference in disease progression on the co -primary clinical endpoints and the MRI 
imaging endpoint for subjects  who started treatment in the double -blind treatment 
phase and those who started treatment in the open -label, delayed -start phase (referred 
to as “early ” and “late” LMTM starters , respectively ) 
o Only ADAS -cog 11 will serve as a secondary endpoint ; ADCS -ADL 23 and 
other imaging endpoints are exploratory with the aim to be directionally 
supportive  
 
17.2 Number of Subjects and Sample Size Calculation  
The target number of subjects is approximately 450 subjects enrolled in Protocol Version  5.0 
and above, random ized in a ratio of  4:1:4 (at the study level) to the LMTM 16 mg/day (200 
subjects), LMTM 8  mg/day  (50 subjects)  and placebo (200 subjects) groups ; total enrollment 
is approximately 500  subjects . Subjects will be assigned to the MMSE severity groups based 
on screening MMSE score with a target of approximately 2:3:1 (MMSE 16 -19, 
MMSE  20-25, MMSE 26 -27 respectively)  for those randomized to Protocol Version  5.0 and 
above . Subjects who drop out after randomization will not be replaced.  
 
Sample size estimations to achieve 90% power (two -sided alpha = 0.05) to detect a difference 
between LMTM 16 mg/day and placebo  (containing intermittent MTC as a urinary 
discolorant) , the primary treatment group comparison in the double -blind treatment period, 
have been performed for the two co -primary clinical endpoints. These assume a withdrawal 
rate of 20% to 25% over 52 weeks. The study sample size of approximately 450  subjects 
(approximately 200 subjects in each treatment group, with a further 50 subje cts for secondary 
analyses of an LMTM 8 -mg/day group) is based on the ADCS -ADL [ADDRESS_977803] >90% power (two -sided alpha=0.05) to 
detect a reduction in decline of 3.[ADDRESS_977804] of 5.0 ± 1.6 (mean ± standard error) units in the pooled studies TRx -237-005/ 
TRx-237-015.  
 
Protocol: TRx -237-[ADDRESS_977805] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 90 of 145 Based on an estimated decline in ADAS -cog 11 over 52 weeks based on pooled information 
from Studies TRx -237-005 / TRx -237-015 in the control arm of 6.5 units with an estimated 
SD of 5.9 units, 200 subjects per treatment arm provide >90% power (two -sided alpha=0.05) 
to detect a reduction in decline of 2. [ADDRESS_977806] based on pooled Studies TRx -237-005 / TRx -237-015 
is 5.2 ± 1.3 (mean ± standard error) units.  
 
With 200 subjects randomized to the primary comparison in the double -blind treatment 
period  under Protocol Version 5.0 and above , 160 to 170 subjects per arm will enter the open -
label, delayed -start phase assuming the drop -out rates mentioned above. Assuming a further 
10% drop out in the delayed -start phase , the key secondary analysis to demonstrate disease 
modification by [CONTACT_717272] a noninferiority margin of -2 ADAS -
cog 11 units has approximately 80% power.  
 
Subjects who withdraw from treatment will be encouraged to stay in the study and continue 
their assessments off -treatment. Subjects’ withdrawal rates will be closely monitored in a 
blinded fashion, to monitor if sample size calculations remain correct.  
17.[ADDRESS_977807] populations will be used for the statistical analyses ; all definitions 
reply on the treatment period in the double -blind phase excluding open -label assessments 
(population definitions will be used for the delayed -start analyses without any modification s): 
• Intent -to-Treat (ITT) population will include all randomized subjects. Three subsets 
are defined as follows:  
o The Efficacy Modified Intent -to-Treat ( E-MITT) population will include all 
randomized subjects who take at least one dose of the study drug and have a 
baseline  and at least one valid post-baseline efficacy assessment in the 
treatment period (prior to any potential follow -up assessment) .  
o An MRI Imaging Modified Intent -to-Treat (MI -MITT) population will include 
all randomized subjects who took at least one dose of study drug and have at 
least one valid baseline and at least one valid post -baseline volumetric MRI.  
o The I maging Modified Intent -to-Treat population ( PI-MITT) for 18F-FDG -
PET will include all randomized subjects  with screening CDR 0.[ADDRESS_977808] -baseline 
SUVR  assessment.  
• The Per Protocol (PP) population will include all subjects who are in the E-MITT  and 
MI-MITT population s and who do not have any PP exclusionary protocol deviations  
or intercurrent medical events that could confound the interpretations . PP 
exclusionary deviations , irrespective of their classification as minor/major , and 
intercurrent medical events  will be determined prior to treatment unblinding . 
• The Safety population will include all randomized subjects who take at least one dose 
of study drug.  
 
Due to the introduction of MTC spi[INVESTIGATOR_717149] 5.0, the 
respective MITT populations will be restricted to subjects randomized to Protocol Versions 
5.[ADDRESS_977809] step in the EMA 
analysis  (see Section 17.4.3 ). 
Protocol: TRx -237-[ADDRESS_977810] -[ADDRESS_977811] treatment transiently, he/she  will be assigned to the predominant treatment group 
(i.e., the treatment group for which he/she  received the greatest number of doses).  
 
For E-MITT,  MI-MITT, and PI-MITT analyses, only valid data will be included in the 
primary and secondary analyses . In subjects who have initiated treatment with an AChE I 
and/or memantine , assessments made after initiation of such treatment are not considered 
valid as they could confound the interpretation of the results and will be excluded . Such 
subjects and affected assessments will be identified prior to unblinding . Sensitivity analyses 
will be provided for the primary and selected secondary analyses inc luding all data.  
 
The primary and key secondary analyses will be further restricted by [CONTACT_717273] V ersion 5.0; this is due to the spi[INVESTIGATOR_717150]. Sensitivity analyses not applying this restriction will be provided.  
 
Various  imaging and clinical efficacy analyses will be handled differently for the FDA and 
European Medicines Agency ( EMA ). Summary statistics will be tabulated by [CONTACT_717274]. ITT, E-MITT , MI-MITT, and PI-MITT 
population -weighted least squares means (LSM), unless otherwise stated, treatment 
differences , and 95% confidence intervals will also be included; the population will be 
determined by [CONTACT_717275] , dependent on whether the endpoint is an imaging 
endpoint or an efficacy endpoint.  Where requested , annualized rates will be estimated based 
on the population -weighted LSM . 
 
All models will include the randomization stratification variables as covariates unless  
otherwise stated. If the models do not converge because of too few observations for a given 
randomization stratification variable , the corresponding variable/variables will be removed 
from the model.  
 
Various 8 mg/day analyses might be omitted if not promising based on the secondary or other 
analyses. These and corresponding thresholds will be defined in the SAP. In the specification 
of various analys es below , they are included for sake of completeness and as they might be 
performed.  
 
Data listings will include all observed data for the primary and secondary endpoints.  
 
17.4.1  Hypothesis  
There are two co -primary efficacy endpoints for this trial: Baseline adjusted decline in 
ADAS -cog 11 and Baseline adjusted decline in ADCS -ADL 23 from Baseline at Week 52 . Both 
Protocol: TRx -237-[ADDRESS_977812] -[ADDRESS_977813] at the 
alpha =0.05 level of significance  for LMTM to be designated as superior to placebo.  
 
The primary analysis will be performed using the E-MITT /ITT population s as defined in 
Section 17.3, with the additional exclusions mentioned in  Sections  17.3 and 17.4.  
 
The global  null hypotheses are as follows:  
H01:   There is no difference between the LMTM 16 mg/day  and placebo groups 
change  in ADAS -cog 11 from baseline to Week 52  
 
and 
 
H02:   There is no difference between the LMTM 16 mg/day  and placebo groups 
change  in ADCS -ADL [ADDRESS_977814] 
which requires both co -primary endpoints to meet statistical significance at the 5% two -sided 
level of significance for the global null hypothesis to be rejected.   Additional details will be 
provided in the SAP.  
 
All secondary analyses have the same underlying null hypothesis that there is no difference in 
change from baseline in the quantity of interest between the LMTM 16-mg/day  group , or the 
LMTM 8-mg/day  group,  and the placebo group. For association analyses, the null hypothesis 
is that there is no association between the variables of interest . 
 
17.4.2  MITT (FDA) Anal ysis 
The FDA analyses will be based on the E-MITT , MI-MITT, or PI-MITT population , with the 
additional restriction as per Sections 17.[ADDRESS_977815] . No data will be imputed  (unless specified in selected 
sensitivity/exploratory analyses) . Sensitivity analyses for selected endpoints will be provided 
where all assessments are included.  
 
Change from baseline  in the respective efficacy /imaging  parameter will be analyzed using a 
restricted maximum likelihood -based repeated measures linear mixed model. The model will 
include fixed effects for treatment group  (two levels  dependent on the comparison, three 
levels for sensitivity ); nominal time ; the treatment group -by-time interaction ; and covariates 
for categorical severity, region , and prior use of AChEIs and/o r memantine. The 
corresponding baseline parameter will be included as a covariate  (continuous)  as well (certain 
covariates in the model migh t be dropped if the model does not converge ; see SAP for 
details). An unstructured covariance model will be used. The Kenward and Roger method of 
calculating the denominator degrees of freedom will be used for the tests of fixed effects. 
Treatment comparisons will be based on the modeled change from baseline at Week 52. 
 
If there is only one scheduled post -baseline imaging or efficacy assessment, the model will be 
replaced by a simple linear model  with fixed effects for treatment group and the 
randomization stratif ication variables and with the baseline value of the corresponding 
endpoint as a covariate.  
 
For annualized rate of atrophy or decline, time will be used as a continuous variable 
supported by [CONTACT_717276] a nominal variable.  
Protocol: TRx -237-[ADDRESS_977816] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 93 of 145  
17.4.3  ITT (EMA) Anal ysis 
The EMA analyses will be based on the ITT population , regardless of endpoint .  
 
Change from baseline  in the respective efficacy /imaging  parameter will be analyzed using a 
restricted maximum likelihood -based repeated measures linear mixed model  or, in the case of 
only one scheduled post -baseline imaging or efficacy assessment,  using  a simple linear model 
(the models used are described above in Section 17.4.2 ). This analysis  will be restricted to 
scheduled, on -treatment visits  for subjects randomized under Protocol Version 5 .0 and above  
(a sensitivity will be provided including data from subjects of all protocol versions) . An on-
treatment  visit is a visit where a subject was on investigational product and not on any A ChEI 
and/or memantine.  
 
This provides the on -treatment effect, E, at the final time point. For each subject who 
withdrew from the study , the decision will be made as part of the blinded data review 
meeting as to whether the withd rawal was potentially treatment -related. For potentially 
treatment -related  drop-outs, the fraction of subjects randomized to active treatment who 
withdrew at a given time point will be  calculated. If a subject is determined to have 
withdraw n for non -treatment -related reasons, no further adjustment will be  made as the 
mixed effects model correctly accounts for subjects who are missing at random.  
 
In this intervention effect analysis, subjects  who withdraw for potential treatment -related 
reasons are assumed to retain 100% of the treatment effect they had attained up to the point 
of withdrawal but do not continue to benefit from treatment afterwards. This corresponds to 
the estimate I = (E0*w0 + E13*w13  + E26*w26  + E39*w39 ) + E 52*(1-w0-w13-w26-w39), 
where E13 is the treatment effect at week 13. W13 is defined as the fraction of subjects who 
withdrew for potentially treatment -related reasons, have a no n-missing  imaging/efficacy 
parameter at W eek [ADDRESS_977817].  
 
Annualized rate of atrophy or decline will also be analyzed in a similar fashion .  
 
17.4.4  Estimands 
In general, definition of estimands in the analysis of clinical trials become increasingly 
important. The SAP will specify estimands to provide a more comprehensive assessment of 
the performance and efficacy of the drug accounting for various factors  (importantly , 
drop-outs). 
 
In line with the ITT analysis of  Section  17.4.[ADDRESS_977818] of  the LMTM dose of 16 mg/day as monotherapy 
versus  placebo ( occasional 4 mg/day MTC) in the targeted population of subjects with 
probable AD and MCI -AD at Week 52, regardless of study drug  discontinuation, based on 
the two co -primary endpoints.  
This estimand is constructed in line with ICH E9 (R1) addendum. The five components 
defining the estimand of interest are  listed below : 
Protocol: TRx -237-[ADDRESS_977819] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 94 of 145 A. Treatment:  52 weeks of LMTM 16 mg/day or matching placebo (4 mg/day MTC) as 
monotherapy, regardless of adherence.  
B. Population:  Subjects with probable AD or MCI -AD as described by [CONTACT_717277], randomized under Protocol Version 5.0 or higher.  
C. Patient -level 
outcomes / variables:  Change from Baseline of the ADAS -cog 11 and ADCS -ADL 23 at Week 52  as 
co-primary outcomes . 
D. Population -level 
summary:  Population -weighted least square s mean difference.  
E. Intercurrent 
Events  (ICE) : The following ICE have been identified which could prevent measurement of the 
primary outcome or change the interpretation of the measured primary outcome:  
1. Withdraw al from study before completion of 52 -week treatment period for non -treatment 
related reason   
2. Withdraw al from study before completion of 52 -week treatment period for treatment -
related reason   
3. Initiation of AChEI and/or memantine  
4. Study treatment discontinuation for any reason other than initiation of AChEI and/or 
memantine (including discontinuation by [CONTACT_087]/she judges that treatment is 
no longer appropriate, if the subject’s clinical condition is worsening or for an AE, or due 
to study drug dose interruption that is longer / more frequent than specified in ICE #5 
below) (see  Section [IP_ADDRESS]  regarding analysis of the TOTOS group )  
5. A dose interruption for more than 14 consecutive days or more than two occasions of dose 
interruptions up to a maximum of 14 consecutive days  
6. Intercurrent illnesses, or initiation of medical food or medications not allowed by [CONTACT_990] 
(which will be identified during the blinded data review meeting)  
7. Study treatment non -compliance, defined as <80% or >120% taking into consideration any 
dose interruptions (if this cannot be estimated, it does not result automatically in a non -
compliance)  
8. Death before completion of 52 -week treatment period  
9. COVID -19 infection  
10. Death due to COVID -19 
 
The handling of ICEs is described as follows:  
• Events [ADDRESS_977820] stayed on treatment ; in 
a sensitivity analysis , all these subject withdrawals are assumed to be potentially treatment -related, 
which are then handled using the treatment policy approach from ICE #2.  
• Events 2  will be handled using a treatment policy  approach reflecting Copy Incremental from 
Reference strategy (using data after occurrence of the ICE). Subjects who withdraw for treatment -
related reasons are assumed to retain 100% of the treatment effect they had attained up to the point of 
withdrawal b ut do not continue to benefit from treatment afterwards, i.e., assuming that the clinical 
course post ICE for either treatment group follows the placebo group. This corresponds to the estimate 
I = (E0*w0 + E13*w13 + E26*w26 + E39*w39) + E52*(1 -w0-w13-w26-w39), where, for instance, 
E13 is the treatment effect at Week [ADDRESS_977821] a non -missing  efficacy parameter at Week 13, and do not 
Protocol: TRx -237-[ADDRESS_977822] -[ADDRESS_977823] on the LSM (see Section 17.4.3 ). 
o Two sensitivity analyses will be run using hypothetical strategies (not using data after 
occurrence of the ICE), one by [CONTACT_717278], and one by [CONTACT_717279].  
o In another sensitivity analysis, the alternative assumption will be investigated, that the 
subjects withdrawing from treatment for treatment -related reasons do not retain any treatment 
effect after Baseline; the intervention effect I in this case is I=E*(1 -w), where E is the 
treatment effect at Week 52 and w is the fraction of subjects within the active treatment group 
who withdraw for a potential treatment -related reason up to Week 52.  
• Events 3  will be handled according to the original randomized treatment group assuming they stopped 
treatment and did not start AChEI and/or memantine (analyzed same as ICE #2), not using data after 
occurrence of the ICE.  
• Events 4  will be handled according to a treatment policy strategy , using data after occurrence of the 
ICE. In addition, for EMA, the analysis will be carried out using the strategy as described for ICE #2 
(not using data after occurrence of the ICE).  
• Events 5, 6, and 7  will be handled according to a treatment policy approach , using all data (also after 
occurrence of respective ICE).  
• Events [ADDRESS_977824]  dies prior to Week 52, the population 
average in decline within the placebo arm will be imputed.  
• Events [ADDRESS_977825] happened, not using data after occurrence of the ICE . 
 
17.4.5  Handling of M issing and Incomplete Data  
Missing imaging data will not be imputed; it will be assumed that the data are close to 
missing at random after accounting for the terms in the model  for all analyses other than 
those described for the EMA ITT -based analyses . The EMA ITT -based analyses treat 
subjects for whom assessments are missing from a certain point onwards as having no 
treatment benefit thereafter; while the primary analysis assumes that they retained the 
treatment effect that they had at the point of drop -out, a sensitivity analysis t reats them as 
having lost all treatment effect. While the primary analysis assumes that some of subjects ’ 
data might be missing at random for drop -outs, a sensitivity analysis assumes all withdrawals 
were treatment related . Various  other  sensitivity analys es, including multiple imputation , 
time to event , and responder analys es, will be provided to investigate the robustness of the 
primary and secondary analyses  (see respective sections below for more detail ; drop-outs are 
treated as non -responders or having an event of decline in these models ). 
 
Efficacy data missing for an entire outcome scale or for the majority of the scale will not be 
imputed unless stated otherwise. Instead, it will be assumed that the data are close to missing 
at random after accounting for the terms in the model. However, m issing items within a 
subdomain or scale may be upscaled if some items of the subdomain or scale are present; the 
SAP will provide details of the handling of partial data for the efficacy endpoints for each 
scale.  As automated data capturing devices are us ed for all efficacy assessments , the risk of 
missing data of this type is low. For imaging data , this type of missing data is impossible and 
consequently they are not subject to upscaling either . 
Protocol: TRx -237-[ADDRESS_977826] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 96 of 145  
17.4.6  Open-Label, Delayed -Start Analysi s  
“Late” starters, i.e., subjects originally randomized to placebo, will be compared to “early ” 
starters, i.e., those originally randomized to LMTM 16 mg/day or 8  mg/day (pooled, and 
individually for both groups as a sensitivity  analysis ). The last assessment prior to start of 
open -label treatment ( pre-dose at Visit 7) will serve as the baseline assessment for these 
comparisons. The analyses will be based on a similar linear mixed model for repeated 
measures as outlined for the FDA/EMA primary analysis ( see m odel sp ecification in Section s 
17.4.2  and 17.4.3 ) with the aim to investigate whether there is a difference in change in 
primary and MRI imaging endpoints dependent on LMTM treatment history  (certain 
covariates in the model might be dropped if the model does not converge ; see SAP for 
details) .  
 
The comparison  will be implemented through a non -inferiority test. The non-inferiority 
margin for the primary endpoint of ADAS -cog [ADDRESS_977827] of > 5 units (~40% of this 
effect size). Margins for other endpoints which are exploratory to support a disease 
modifying argument will be defin ed in the SAP.  
 
The results will also be presented with the Visit 2 Baseline as baseline , and treat ment  visits 
Week 26 and Week 52 in the open -label, delayed -start phase as Week 78 and Week 104.  
 
17.4.7  Dose  Response Anal yses 
Various dose response analys es will be performed. The primary endpoints and key secondary 
endpoints will be analyzed  using FDA/EMA primary analyses (see model sp ecification in 
Section s 17.4.2  and 17.4.3 ) to show the functional relationship of dose and response on the 
various endpoints as change from baseline to Week 52. This analysis will also be provided 
split by [CONTACT_717280]. For CDR 0.[ADDRESS_977828] as outlined in the SAP.  
 
17.4.8  Responder Anal yses 
Responder analyses will be conducted for the primary and selected secondary endpoints by 
[CONTACT_717281].  
 
For the corresponding imaging/efficacy parameter , a responder will be defined as a subject 
whose change from baseline  is less than or equal to a threshold “T” defined as follows  (these 
analyses will be done separately for the LMTM 16-mg/day versus  placebo and LMTM 
8-mg/day versus  placebo  groups ): 
 
• Let LSM1  be the LSM of change from baseline for the placebo group from the 
respective endpoint analysis  
• Let LSM2 be the LSM of cha nge from baseline for the LMTM group from the 
respective endpoint analysis  
• Then T = (LSM1 + LSM2)/2  
Protocol: TRx -237-[ADDRESS_977829] -[ADDRESS_977830], adjusting for the randomization 
strata. Odds ratios and 95% confidence intervals will be presented.  
 
For each of these analyses, i f there is a significant effect of treatment on an imaging as well 
as another imaging or clinical efficacy parameter, the association between responders across 
these parameters at Week 52 will be assessed by [CONTACT_717282] ’s chi-square test to analyze 
the resulting 2 × 2 table. The number and percent of subjects in each cell of the 2 × 2 table 
will be tabulated along with the p -value from the Pearson ’s chi-square test.  
 
Responder analys es will be used to investigate associations between various endpoints.  
Correlation analys es will complement or replace responder -based analyses of associations in 
some cases.  
 
17.4.9  Time-to-Event Analyses  
Time -to-Event/Time -to-Decline analyses will be performed for a selected subset of endpoints 
as repeated measurements over time are needed. The distributions of time -to-decline in the 
key parameters will be summarized using the Kaplan -Meier method, with onset of decline 
defined as the first of two consecutive measur ements that are worse than the baseline score , 
allowing for a certain margin which will be predefined in the SAP prior to database lock and 
unblinding ; typi[INVESTIGATOR_717151] s are [ADDRESS_977831]. 
Time -to-decline  will be calculated as date of onset of decline – date of randomization + 1.   
 
The time -to-decline analys es are based on visit window. One measurement per visit window 
is selected , including off -treatment measurements. Subjects without any decline will be 
censored at the date of last  assessment, but if a subject missed the scheduled visit, the subject 
is censored at the target day of the scheduled visit. The analysis will be run for the ITT 
population.  
 
Any missing efficacy /imaging  value for a scheduled visit will be treated as a worsening from 
baseline, for that visit. Because of this convention for missing values, it is possible that the 
first of two consecutive measurements that are worse  than the baseline score by [CONTACT_717283] a missed visit. In that case, since there is no date associated with the missed 
visit, the time -to-decline will be calculated based on the scheduled date of the missing visit.  
 
The Cox proportional hazards regression model with effects for treatment group ( two or three 
levels depend ing on whether primary or sensitivity comparison ) and the randomization 
stratification variable s will be used to compare LMTM 8 mg/day  versus placebo  (and LMTM 
16 mg/day versus  placebo , respectively)  by [CONTACT_717284], 95% confidence interval , 
and p -value (for alpha 0.05).  A graph of the Kaplan -Meier estimates will be provided.  
 
There will also be version s of this analysis using actual dates.  
Protocol: TRx -237-[ADDRESS_977832] -[ADDRESS_977833] statements as described in the SAP.   
 
Subgroup analyses will be performed for the primary endpoints and selected secondary 
endpoints  based on the E-MITT /MI-MITT/ PI-MITT  population s (FDA analysis) by [CONTACT_717285].  
If the subgroup consists of less than 10% of subjects in observed cases, only summary 
statistics will be  presented. The subject characteristics that will be included in this type of 
analysis are the following:  
• Baseline diagnosis (probable AD and MCI -AD) 
• MMSE ( 16-19, 20-25, and 26 -27) 
• CDR (0.[ADDRESS_977834] 1 or 2 pooled)  
• AChEI/memantine use ( prior use and never used ) 
• Age group (<75 years and ≥75 years ) 
• Gender  (male  and female ) 
• Race  (white  and non-white ) 
• Geographic region ( North America  and Europe ) 
 
17.4.[ADDRESS_977835] assessment and will follow available 
regulatory guidelines.      
 
[IP_ADDRESS]  Mis-stratification Analysis  
If there are more than 5% of subjects who have been mis -stratified, then the primary analyses 
will be repeated using the actual status at randomization.  
 
[IP_ADDRESS]  All Protocol Version Analysis  
As outlined in Sections 17.3 and 17.4, the MITT and on -treatment populations will be 
restricted further in the primary analysis . A sensitivity will be provided for the respective 
analysis with all data from subjects or all protocol versions included (unrestricted MITT/on -
treatment defin itions).  
 
[IP_ADDRESS]  Analysis of Subjects Who Started A ChEI and/or 
Memantine  
For the FDA analyses, in subjects who initiated treatment with A ChEI and/or memantine at 
any time during the study , data after initiation of such treatment are excluded from the 
primary analyses as they could confound the results . Such subjects will be identified prior to 
Protocol: TRx -237-[ADDRESS_977836] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 99 of 145 unblinding.  For EMA analyses, such subjects are treated as subjects who terminated the study 
at the time of starting A ChEI and/or memantine; a conservative post -withdrawal course is 
assumed for these subjects.  
 
Data for these excluded subjects will be tabulated separately with their observed means, 
standard deviations, standard errors, and minimum and maximum values of selected changes 
in imaging and efficacy assessments . Primary reasons for initiating antidementia therapy will 
be provided. Furthermore, tables will be provided quantifying the number of assessments as 
well as time points that are impacted by [CONTACT_717286].  
 
Sensitivity analyses will be performed including all data for these subjects. Time to event 
(i.e., time to withdrawal in order to start A ChEI and/or memantine) may also be performed if 
more than 10% meet this criterion; if not, the information will be tabulated.  
 
[IP_ADDRESS]  Analysis of the Off-Treatment -On-Study (TOTOS) 
Subjects  
Data for t he TOTOS subjects will be handled in a similar fashion as described in Section  
[IP_ADDRESS] . For the FDA analyses, the TOTOS subjects are included in the analyses (unless 
they initiated A ChEI and/or memantine , in which case data after the initiation of such therapy 
will be excluded ). For the EMA analysis, all TOTOS subjects are treated as subjects who 
terminated the study; a conservative post -withdrawal course is assumed for these subjects.  
 
Data for these subjects will be tabulated  separately  with their observed means, standard 
deviations, standard errors, and minimum and maximum values of selected changes in 
imaging and efficacy assessments; primary reasons for withdrawal of study drug will be 
provided. Furthermore, tables will be provided quantifying the number of assessments as well 
as time points that are impacted by [CONTACT_717286].  
 
Sensitivity analyses will be performed including all data for these subjects.  
 
[IP_ADDRESS]  Imputation Methods  
No data will be imputed in the primary and secondary analysis models unless stated 
otherwise. As sensitivity analyses, two methods for imputation will be explored , as described 
below . 
 
[IP_ADDRESS].[ADDRESS_977837] exactly the same covariates as the respective  models. A total 
of 50 imputed datasets will be generated for this analysis. Each o f the imputed datasets will 
be analyzed using the respective  model with the same covariates. The MIANALYZE 
procedure in SAS will be used to combine results.  
 
Protocol: TRx -237-[ADDRESS_977838] -[ADDRESS_977839]-baseline assessments , additional 
variables such as sex, age, and other baseline values will be employed to allow appropriate  
multiple imputation.  
 
[IP_ADDRESS]  Baseline Severity Rate-correction Analysis  
The FDA  model will include baseline value as an additive covariate . In order to  determine 
whether baseline value influences future assessments, i.e., the rate of progression, a further 
sensitivity analysis which includes the additional term baseline*visit  instead of just baseline  
will be conducted.  
 
[IP_ADDRESS]  Sensitivities for Intervention Effect Analyses  
Further sensitivity analyses are planned to determine the effect of withdrawals on estimation 
of intervention effect (as required by [CONTACT_23357]). These include the alternative assumption that 
the subjects withdrawing from treatment do not retain any treatment  effect; the intervention 
effect I in this case is I=E*(1 -w), where w is the fraction of subjects who w ithdraw for 
potential treatment -related reasons. This is implemented as a contrast statement as well. This 
analysis is only needed if there are more than  two scheduled visits with imaging/efficacy 
assessments , as otherwise this analysis is identical to the EMA  analysis model  specified in 
Section 17.4.[ADDRESS_977840] ew due to a potential 
treatment -related reason.  
 
[IP_ADDRESS]  Polynomial Models  
For the key efficacy /imaging  assessments with more than one scheduled post -Baseline visit, 
maximum likelihood (rather than restricted maximum likelihood) based repeated measures 
models with polynomial time effects with time treated as a continuous variable (number of 
nominal weeks as well as actual study week defined by [CONTACT_717287] 7) will be 
assessed. Tests of the significance of the linear, quadratic , and cubic time effects will be 
carried out in each treatment group. The estimated annualized change in mean values and 
stand ard errors from baseline  to Week 52 will be presented.  
 
[IP_ADDRESS]  Other Population Analys es 
As a sensitivity analysis, the FDA primary analyses and potentially other pre -specified 
endpoints  will be repeated for:  
• The PP population  
• The set of completers ( i.e., all subjects who were on -treatment at Week 52) 
• All visits that are not potentially confounded by [CONTACT_717288] , COVID -19, 
and concomitant medications as identified during the blinded data review meeting  
17.5 Exploratory Analyses  
A number of exploratory analyses will be undertaken, to be specified in the SAP. These could 
include  the following (details will be provided in the SAP) : 
• To compare the treatment groups  on the ADAS -cog 13 
• To compare the treatment groups on a new composite endpoint /composite endpoints  
based on selected item of the Alzheimer’s Disease Assessment Scale, 13 -item version 
Protocol: TRx -237-[ADDRESS_977841] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 101 of 145 (ADAS -cog 13) and the ADCS -ADL 23, analyzed at 9 months and 12 months to 
evaluate its usefulness for future studies (for all subjects and also separately for 
subjects with CDR 0.[ADDRESS_977842] 1 -2 at screening)  
• To compare the treatment groups  on the MMSE  
• To compare the treatment groups  on the CDR sum of boxes  
• Comparison of atrophy in MRI parameters (including putamen, nucleus accumbens, 
and nucleus basalis) according to treatment assignment , as well as the combination of 
treatment assignment with previous treatment status of A ChEIs and/or memantine 
(prior use or never used) in a subgroup analysis; the influence of the baseline volumes 
of putamen, nucleus accumbens, and nucleus basalis will also be investigated for 
selected MRI parameters . Further SPM analyses  may be conducted using all available 
MRI volumetric data to determine regions of significant difference associated with 
treatment  
• Comparison of decline in 18F-FDG-PET SUVR normalized with respect to pons and 
cerebellum in temporal, parietal, and frontal lobes according to treatment assignment , 
as well as the combination of treatment assignment with previous treatment status of 
AChEIs and/or memantine (prior use or never used) in subgroup analyses  
• Determination of decline in SUVR in cerebellum normalized with respect to pons 
according to treatment assignment , as well as the combination of treatment 
assignment with previous treatment status of A ChEIs and/or memantine (prior use or 
never used) in a subgroup analysis  
• Other SUVR regions of interest will also be examined including, but not restricted to, 
inferior temporal gyrus, angular gyrus, anterior and posterior cingulate gyrus, and 
cerebellum  
• SPM analyses (Friston et al., 2007) may be conducted using all available normalized 
cortical 18F-FDG -PET SUVR data  and MRI data to determine regions of significant 
difference associated with treatment without assuming the location and exten t of any 
differences  
• To examine the associations of SPM  approaches using all available normalized 
18F-FDG -PET SUVR  data and volumetric MRI  data with the following clinical 
measures:  
o ADAS -cog 13 
o ADCS -ADL 23 
o Composite Scale s (selected)  
• Comparisons of measures of brain MRI  hyperintensities by [CONTACT_2948] ; subgroup 
analyses by [CONTACT_717289] A ChEIs and/memantine (prior use or never 
used) will also be performed, including for the combined LMTM 8-mg/day  and 
placebo groups  
• Population pharmacokinetics (to be subject to a  section in the SAP or a  separate SAP 
and report)  
• To evaluate the influence of ApoE  genotype (in subjects who provide legally 
acceptable consent) on the primary and selected secondary endpoints  
 
A number of exploratory comparisons with external data may also be performed, to be 
specified in the SAP. These include  comparisons of LMTM 16 mg/day or LMTM 8 mg/day 
on the following : 
• Comp arison of annualized rates of atrophy in a range of brain regions (including 
temporal lobe and  whole brain)  with the estimated decline for subjects with MCI -AD 
and mild AD w ith MMSE in the range of [ADDRESS_977843] 
Protocol: TRx -237-[ADDRESS_977844] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 102 of 145 treatments for AD (AChEIs and/or mem antine) from the ADNI; this will be repeated 
for the entire MMSE range used in this study  
• To compare the primary and selected secondary imaging and efficacy endpoints at 
52 weeks  with pooled mild AD subjects in control groups (subjects receiving LMTM 
at any dose in combination with an A ChEI and/or memantine) from the LMTM 
Phase 3 trials  (Studies TRx-237-005 and TRx-237-015) with baseline MMSE in the 
range of 20-26; this will be repeated for the ent ire MMSE range used in this study  
• Comp arison of decline in tempor al lobe 18F-FDG -PET SUVR  with the estimated 
decline for subjects with mild AD (CDR 0.5  at Screening ) not receiving either of the 
standard treatment s for AD (A ChEIs and/or mem antine) from the ADNI 
• Accounting for and using historic data more generally such as placebo decline or 
treatment effects as priors to inform the analyses of this study.   
17.6 Demographic and Baseline Characteristics  
Demographic variables , baseline characteristics  and medical history will be summarized in 
tables. Medical history will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA) Version 20.1 . The tabular summaries will  present  the numbers and percentages of 
subjects with abnormalities in a given MedDRA System Organ Classification (SOC).  
 
Recently used medications and c oncomitant medications will be coded using the 01March 
2017 version of the WHO drug dictionary. Tabulations will be prepared of all drugs used 
concomitantly (relative to the first dose of study drug) based on WHO Anatomical 
Therapeutic Classification (ATC)  level 1 term, ATC level 3 term , and Preferred Term 
(generic name) with frequency and percentage of subjects in each treatment group  using each 
concomitant medication. Separate tabulation will be made of on -treatment changes in 
antipsychotic medications (to be identified by [CONTACT_717290]), together with the reason(s) for 
such change.  
 
Further information indicating years spent in full -time education and its level before the age 
of 26  years  is to be collected . In addition , main occupation during working life is to be 
provided (see Section 28.3); main occupation will be coded using the Standard Occupational 
Classification, 2010, Volume [ADDRESS_977845] been found to be useful proxies for cognitive reserve (Staff et al., 2004). Exploratory 
analyses will be described in the SAP.  
 
All data, including study eligibility and screening data  (including reason for exclusion) , will 
be listed.  
 
Subjects who are mis -stratified at the time of randomization will be flagged in the listing.  
17.7 Safety Analysis  
Various safety analys es will be conducted for this study. Details will be provided in the SAP. 
The planned safety analyses , including tabulations by [CONTACT_1570],  include:  
• A quantification of the extent of drug exposure  
• Various analyses of AEs (using MedDRA Version 20.1) 
o TEAEs, including by [CONTACT_717291]  
o TEAEs that result in interruption or discontinuation of study drug  
o Selected s ubsets of TEAEs (referred to as TauRx AE Groupi[INVESTIGATOR_14839])  
Protocol: TRx -237-[ADDRESS_977846] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 103 of 145 o Subgroup analyses  
o Time -to-event analyses of TEAEs 
o SAEs  and serious adverse reactions  
o Malignancies other than non-melanoma skin cancers  
• Clinical laboratory evaluations  
• Vital sign analysis  
• Physical and neurological examinations  
 
All safety data will be listed.  
17.[ADDRESS_977847] (including “dose 
equivalent ” for subjects randomized to placebo), will be summarized descriptively by 
[CONTACT_1570]. Mean, modal, and maximum dose will also be summarized over selected 
exposure intervals. In addition, tabular summaries of the proportions of subjects with dose 
interruptions will be prepared for each treatment group.  Listings will encompass dosing, drug 
accountability, and compliance (percentage of tablets taken relative t o intended number) ; any 
doses that are other than that randomized will be flagged.  
 
The plasma  MT and whole blood concentrations (parent MT/LMT, N-desmethyl MT, and 
total MT concentrations , as available) will be listed. The results of p opulation PK and 
exposure -response analyses will be provided in a separate report.  
 
ApoE  genotype will be listed for each subject who consents to this determination. Use of 
these data in exploratory analyses will be described in the SAP.  
17.9 Interim Analysis  
No interim futility or efficacy analysis is planned prior to the completion of the double -blind 
treatment period in which treatment groups will be compared.  
 
Recruitment and discontinuations will, however, be continuously monitored in a blinded 
fashion to ensure that the sample size calculations remain appropriate. The sample sizes may 
be increased but not decreased ; thresholds will be defined in an interim monitoring SAP. 
Specifically:  
• Should the overall dropout for the duration of the study be projected to exceed 25%, 
then the number of subjects to be enrolled may be increased in order to power an 
analysis at 52 weeks.  
• The assumed SD for the change from baseline to Week 52 in the primar y endpoints  
may be re-estimated  at some point during the study’s recruitment period  and the 
sample size required to provide 90% power for the primary endpoints will be re -
estimated . 
• The balance between the three different MMSE stratification groups is determined to 
be approximately 2:3:1 (MMSE 16 -19, 20 -25, and 26 -27) for those randomized to 
Protocol Version  5.0 and above . This value will be closely monitored and controlled 
at study level. Should the balance be deviating from the desired balance, then the 
number of subjects to be enrolled may be increased in order  to rebalance the design 
enriching the MMSE groups that are underrepresented.  
Protocol: TRx -237-[ADDRESS_977848] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 104 of 145 • As indicated in Section 10.2, COVID -[ADDRESS_977849] of the study are responsible for 
ensuring that the study is conducted at their sites in accordance with the approved protocol 
and with the principles contained in the Declaration of Helsinki, the ICH Guidelines for  Good 
Clinical Practice  (GCP )7 and with applicable country and local regulatory requirements and 
laws.  All deviations identified at or by [CONTACT_717292].  See 
Section 10.2 regarding the Sponsor’s ongoing consideration of updates to guidances and 
requirements due to COVID -[ADDRESS_977850] 
rights, trial integrity, and compliance.  
 
The Sponsor ’s designee (s) will be responsible for ensuring that the relevant approval is 
obtained from the local regulatory authority prior to the start of the study . The relevant 
documents will be provided to the investigator. The Sponsor’s designee (s) will forward any 
protocol amendments to the regulatory authority and will ensure that SAEs are reported, and 
that progress reports and details of any serious protocol violations are provided as required.  
 
Each  regulatory authority will be informed should the study be terminated early  consistent 
with local requirements . 
18.1 Approval of the Protocol and Amendments  
Following authorization  by [CONTACT_1034], the final protocol and all related documents ( e.g., 
information sheets and ICFs) will be submitted to the IEC/IRB.  
 
The Sponsor ’s design ee, Syneos Health , will be responsible for ensuring that regulatory and 
IEC/IRB approvals are obtained prior to the start of the study. The relevant documents will be 
provided to the investigator.  
 
Neither the investigator nor the Sponsor will modify this protocol. If modification is 
necessary, either party must first obtain the concurrence of the other. The party initiating a 
 
7 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use  (ICH) 
[homepage on the Internet].  E6 (R2):  Good Clinical Practice:  Consolidated Guideline  (or ICH E6(R1) in 
those juri sdictions where ICH E6(R2) is not yet implemented by [CONTACT_50756] )  
Protocol: TRx -237-[ADDRESS_977851] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 105 of 145 modification will confirm it in writing and the investigator will be responsible for informing 
the IEC/IRB. In case of a substantial amendment, prior approval of the IEC/IRB is required.  
 
The Sponsor or designee is responsible for the submission of a protocol amendment to the 
regulatory authority. In the event of a substantial amendment, prior regulatory approval is 
required  for implementation . 
18.[ADDRESS_977852] Operating Procedures (SOPs) . 
18.[ADDRESS_977853]  (or his/her 
LAR  who is permitted to provide consent in accordance with local legislation ) and study 
partner (s) participating in this stud y. At all study sites, the PI [INVESTIGATOR_717152] a p hysician  (such as a neurologist , psychiatrist ) or other medically qualified 
person  (MD/DO) . 
 
Subjects and/or their LAR (s) must give written (signed and personally  dated) informed 
consent prior to study entry and before any study specific procedures are undertaken . The 
identified study partner (s) for each subject also must provide written consent to his/her own 
participation as outlined below. Where there is a change of study partner , the new study 
partner  must provide written informed consent.  
 
Potential subjects will be assessed for whether they have capacity to understand the ICF and 
give consent.  
 
Where possible, fully informed consent will be obtained from the subject. However, subjects 
entering this study may lack the necessary mental capacity to give fully informed consent. If 
the potential subject is unable to comprehend the ICF, then one or mor e LARs  will be 
required to sign the ICF as required by [CONTACT_277926]/or local law. In this situation, and 
provided that it is permitted by [CONTACT_19666], the subject’s agreement to participate in the 
study will still be obtained to his/her best level of  understanding and recruitment will not 
proceed if the subject refuses or shows signs of significant distress.  
 
Informed consent can be obtained only after it is confirmed that the subject has a likely 
diagnosis of probable AD or MCI -AD and the aims, methods, anticipated benefits, and 
known potential hazards of the study have been explained to and discussed with the potential 
subject and study partner (s) by [CONTACT_093]. As subjects are not allowed to receive 
approved AD medication while in the study, they will be informed of the benefits and risks of 
discontinuing and/or not initiating such therapy, as pertinent . If a subject decides to 
discontinue AD medication in order to enter the study, a letter will be sent to his/her primary 
care physician informing him/her of the subject’s decision.  
 
Protocol: TRx -237-[ADDRESS_977854] -[ADDRESS_977855] and study partner (s) prior to written informed consent being 
obtained. The study partner (s) will also be given an information sheet. The information sheet s 
will make clear that access to the subject’s medical records will be required. It is the 
responsibility of the investigator to ensure that the potential subject and study partner (s) are 
aware of this. The investigator will explain to the potential subject and study partner (s) that 
they are at liberty to refuse to take part in the study or, should they decide to participate, they 
may withdraw from the study at any time. Such a decision  will not impi[INVESTIGATOR_717153]. The potential subject and study partner (s) will be allowed as 
much time as they need to decide whether or not to participate in the study and will be 
provided with a contact [CONTACT_717293].  
 
The study includes sites in North America  and Europe , two geographic regions that maintain 
descriptions of clinical studies on the internet. As required by [CONTACT_1622] , the ICF must contain 
the following text: “A description of this clinical trial will be available on 
http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include 
information that can identify you. At most, the Web site will inclu de a summary of the 
results. You can search this Web site at any time.” Consistent with Europ ean Union law, the 
ICF also indicates that information will be on https://www.clinicaltrialsregister.eu. 
Information regarding other national registries will also be included in the ICF, where 
applicable.  
 
Separate consent may be required by [CONTACT_717294].  
18.[ADDRESS_977856] of the trial at his/her study site and may delegate specific duties 
to appropriately trained members of his/her research team or to other hospi[INVESTIGATOR_33717], e.g., the 
pharmacy. Any delegation must be clearly documented in a study site specific delegation list. 
The PI [INVESTIGATOR_155067] f ollowing:  
• Performing the study in accordance with ICH GCP  
• Ensuring that adequate time and appropriate resources are available to perform the 
study as described in this protocol  
• Ensuring that all persons assisting with the trial are adequately qualified, trained, and 
informed about the protocol, trial -related duties, and functions  
• Maintaining a list of SIs and other appropriately qualified persons to whom duties 
have been delegated  
• Supervising any individual or party to whom the investigator delegates trial -related 
duties and functions conducted at the trial site  
• Signing an Investigator Agreement to confirm acceptance and willingness to comply 
with the study protocol  
• Maintaining adequate control of study drug and appropriate records of drug 
disposition  
• Maintaining adequate records of each subject's participation  
 
Protocol: TRx -237-[ADDRESS_977857] -[ADDRESS_977858] the right to 
interrupt or discontinue study drug for safety reas ons as described in Section 11.4. 
 
The burden/distress associated with participation in this study is addressed in the subject  
information sheet . During the study, the investigators should obtain information from the 
subjects in order to adequately monitor the degree of burden/distress. Subjects are advised 
that they have the right to discontinue study drug and withdraw from the study at any time for 
any reason and should inform the investigators accordingly in order to assist the investigators 
with monitoring activities.  
 
[ADDRESS_977859] strictly maintain the confidentiality of subjects in the trial. For all 
documents and materials submitted to TauRx, its designee, or any electronic system (for 
example, eCRFs, samples, specimens, and other documents ), the investigator must refer to 
subjects by [CONTACT_1209]. The investigator must keep a separate local log of subject 
codes, names, and addresses for all subjects, including those that were screened but not 
enrolled. This local log must never be uploaded to the electronic Trial Master File  (eTMF) .  
 
Collect ing, processing  of, and / or transfe rring data outside the European Economic Area will 
meet the requirements of EU Directive 2016/679 ( General Data Protection Regulation ), with 
appropriate transparency notices included in informed consent documentation . In the United 
States, data will be protected consistent with Health Insurance Portability and Accountability 
Act. 
 
Confidentiality of the records identifying each subject shall be maintained. Representatives of 
the Sponsor , such as monitor(s) or auditor(s), IRB/IEC, and pertinent regulatory authorities 
will be permitted direct access to these records and other source data/documents as 
appropriate.  
 
Details of access to the subjects’ data will be fully described within the subject information 
sheet. The consequence of the subject's withdrawal of consent with regards to the use of data 
will also be described.  
 
For the avoidance of doubt, this protocol does not define or describe any data protection  
obligations. These will be dealt with in relevant vendor contracts and subject -facing 
documentation in compliance with relevant local law . 
 
Protocol: TRx -237-[ADDRESS_977860] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 108 of 145 20 STORED SAMPLES  AND IMAGING DATA  
20.1 Biosamples  
TauRx is interested in identifying biomarkers that correlate to a drug’s mechanism of action 
or the disease state under study. Finding appropriate biomarkers can give clinicians a clearer 
understanding of the most appropriate patients for a particular drug and the most appropriate 
dose for those patients, offering the potential for improved clinical outcomes.  
 
Storage of samples of plasma and whole blood for possible future research related to 
determination of potential biomarker predictors of LMTM response or surrogates of 
treatment response is a mandatory  part of this study, unless country -specific laws and 
regulations prohibit this storage. The samples obtained for genetic testing and the remainder 
of the samples not used for MT concentration determination as  described in Section 15.[ADDRESS_977861] visit for 
the study; any sample remaining at that time will be destroyed. Because of the exploratory 
nature of these analyses and because the results should not change medical management, 
neither subjects nor investigators will rece ive the test results.  
 
TauRx’s research procedures dictate that a research plan be prepared before conducting any 
secondary (future) research on stored samples. The research plan would include objectives of 
the research, scientific rationale for the research, a clear indication that the research is being 
conducted as secondary research, how alternative authorization to use and disclose the data 
from secondary research is to be obtained, a nd how the results are intended to be used. For 
this study, future research could include , but need not be limited to, measurement of plasma 
markers of tau and other protein species, genetic and epi[INVESTIGATOR_717154], or potential surrogate markers of treatment response . Analysis 
of these data could provide an important, minimally invasive biomarker that would guide 
future decisions by [CONTACT_717295].  
20.[ADDRESS_977862] Procedures  
SOPs will be adhered to for all activities relevant to the quality of the study, including 
protocol compliance, data collection, quality control, and data analyses and reporting.  
 
Protocol: TRx -237-[ADDRESS_977863] -[ADDRESS_977864] results and other records needed to 
verify entries on the eCRF.  
 
The investigator (or his/her designated deputy) agrees to cooperate with the monitor and 
other clinical research personnel to ensure that any problems detected in the course of these 
monitoring visits are quickly resolved.  
 
Quality review  of data and/or trial documentation may be carried out by [CONTACT_717296]. Audits of study sites and/or trial processes may be carried out at any 
stage.  
21.[ADDRESS_977865] of COVID -19 on this study , the Sponsor ha s conducted risk assessments to 
identify the potential risk levels and impacts of COVID -19, as well as associated mitigating 
actions for a number of clinical study aspects, including:  direct -to-subject  study drug  
shipments, missed study  visits  and/or clinical assessments, handling of missed post -baseline 
study data, remote site initia tion visits, remote monitoring visits, and remote clinical 
assessme nts (e.g., remote ADAS -cog 13). Vendors have also conducted  risk assessments 
associated with their services to th is study. Risk assessment and m anagement  are ongoing 
process es for this study;  all risks and mitigations are regularly reviewed and managed, and 
the Sponsor will continue to ensure that additi onal risk assessments are carried out and 
documented, in particular for any potential impact due to COVID -19, as the  situation 
develops and as reg ulatory guidances are updated . 
 
A summary of alternate arrangements to clinical monitoring that may be implemented due to 
COVID -19 is provided in Section 10.2.2 . 
 
Protocol: TRx -237-[ADDRESS_977866] -[ADDRESS_977867] be provided before or at site initiation : 
• Protocol and amendments (if applicable) signed and dated by [CONTACT_717297], as well as by [CONTACT_093]  
• Regulatory approval (or in absence of document, evidence that study may proceed)  
• Signed and dated IEC /IRB  approval  
• Approved subject and study partner information sheet s, ICF, and advertisement for 
recruitment (if any)  
• eCRFs  
• Confidentiality agreement(s)  
• Financial disclosure  
• Signed curricula vitae  for personnel who have signed the authorized delegation log 
(including PI, all SIs, and designated assistants)  
• Authorized signature [CONTACT_26500]/delegation list  
• Investigator ’s Brochure with signed and dated Investigator ’s Brochure receipt  
• Signed and dated clinical trial agreement  
• Research and development (or institution) approval, if applicable  
• Signed and dated indemnity/insurance statement (if applicable)  
• Laboratory reference ranges and accreditation for all applicable laboratories (central 
and local, as applicable)  
• Pharmacy agreement (if any)  
• Imaging center agreement (if any)  
• SAE forms  
 
The protocol, its amendments, and any other required documents must be submitted for 
appropriate regulatory review and approval.  
 
The investigator at each study site must generate and maintain adequate records (medical 
records, source documents, and eCRFs) to enable the conduct of this study to be fully 
documented.  The eCRF may serve as the primary collection medium for any data (to be 
agreed with the investigator and documented in the Source Document Agreement). Each 
enrolled subject must have an eCRF completed and this must be reviewed and approved by 
[CONTACT_32595]. 
 
A record must be kept of all subjects consenting for the study and subsequently excluded. 
The reason for non -participation in the study should be recorded.  
 
The documents specified by [CONTACT_91359] ( e.g., copi[INVESTIGATOR_82512], CRF pages, original copi[INVESTIGATOR_717155], reports, drug dispensing logs, correspondence, records of informed consent, 
and other documents pertaining to the conduct of the study) must be kept on file by [CONTACT_150061] a minimum  of [ADDRESS_977868] be informed.  
 
Protocol: TRx -237-[ADDRESS_977869] -[ADDRESS_977870], to the  regulatory authorities . 
 
23 PUBLICATION  
Since this is a multi center  study, the community of investigators and delegated individual 
investigators shall not publish any partial results before the end of the study or before the 
analysis and publication of the results of the entire study.  
 
The investigator and/or institution shall have the right to publish, display, or otherwise 
communicate orally, in writing, or electronically (hereafter a “publication”) the results of 
his/her  work conducted under this protocol after 12 months from a New Drug Application or 
equivalent filing, or earlier only with explicit consent of the Sponsor in advance and in 
writing.  
 
Sites and/or investigators must provide the Sponsor with the opportunity to review the 
contents of any proposed abstract or publication concerning the work, including any results of 
the study, in advance of publication, and agree to delay the publication i f, in the Sponsor’s 
reasonable view, the publication may prejudice the Sponsor’s intellectual property. The 
Sponsor will make every reasonable effort to consider and release each proposed abstract or 
publication within 60 days of submission. The investigat or and/or site will include , where 
possible , comments made by [CONTACT_1034]. Authorship will be determined by [CONTACT_231692]. Access to data will be in accordance with authorship.  
 
[ADDRESS_977871] of this study.  
 
25 ADMINISTRATIVE AND FINANCIAL AGREEMENT  
Agreed costs for each participating study site will be met by [CONTACT_717231]. For each study site, an 
agreement will be prepared and signed off by [CONTACT_717298] ( e.g., National Health Service Trust, University) and by [CONTACT_717299]. Each PI [INVESTIGATOR_717156] a Form FDA 3455 or its 
equivalent to disclose any financial arrangements or interests.  
 
Subjects will be reimbursed by [CONTACT_717231], through the investigator, for reasonable travel costs to 
and from the study site and accommodation in certain circumstances by [CONTACT_717300].  
 
26 STUDY ADMINISTRATION  
This trial will be conducted in compliance with ICH GCP and other applicable regulatory 
requirements.  
 
Protocol: TRx -237-[ADDRESS_977872] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 112 of 145 Vendor s and/or independent contract personnel  will be contracted to manage and monitor the 
trial; to provide services for data management and statistical analysis ; to provide regulatory 
advice and services ; to handle the reporting of  SAEs ; to provide services for laboratory , 
imaging , and PK analysis ; to package and distribute the clinical trial supplies ; and to provide 
QA support and services.  
 
Calibration certification for the following equipment maintained by [CONTACT_717301]: ECG machines, refrigerated centrifuge s, and 
pharmacy temperature loggers.  
  
Protocol: TRx -237-[ADDRESS_977873] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 113 of 145  
27 REFERENCES  
Aduhelm FDA Drug Approval Package, Office of Neurology’s Summary Review 
Memorandum. June 2021.  
 
Al-Hilaly YK, Pollack SJ, Vadukul D, et al. : Alzheimer's disease -like paired helical filament 
assembly from truncated tau protein is independent of disulphide cross -linking. J Mol Biol 
2017; 429:[ADDRESS_977874] JE , et al. : Cysteine -independent inhib ition of Alzheimer's 
disease -like paired helical filament assembly by [CONTACT_717302] -methylthioninium (LMT) . J Mol Biol 
2018; https://doi.org/10.1016/j.jmb.2018.08.[ADDRESS_977875], Dickson D, et al. The diagnosis of mild cognitive impairment due 
to Alzheimer’s disease: Recommendations from the National Institute on Aging -Alzheimer’s 
Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers 
Dement 2011; 7(3):270 -9. 
 
Baddeley TC, McCaffrey JM, Storey J M, et al. Complex disposition of methylthioninium 
redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. 
J Pharmacol Exp Ther 2015; 352 (1):110-18. 
 
Berg L, Miller JP, Storandt M, et al. Mild senile dementia of the Alzheimer type: 2. 
Longitudinal assessment. Ann Neurol 1988;  23(5):477 -84. 
 
Bierer LM, Hof PR, Purohit DP,  et al. Neocortical neurofibrillary tangles correlate with 
dementia severity in Alzheimer's disease. Arch Neurol 1995; 52(1):81 -8. 
 
Birks JS, Harvey R. Donepezil for dementia due to Alzheimer’s disease . Cochrane Database 
of Systematic Reviews , Issue 3, 2004 . Article No. CD001190 . 
 
Bowie P, Branton T, Holmes J. Should the Mini Mental State Examination be used to 
monitor dementia treatments? Lancet 1999;  354(9189):1527 -8. 
 
Braak H, Braak E. Neuropathological staging of Alzheimer -related changes. Acta 
Neuropathol 1991; 82(4): 239 -59. 
 
Courtney C, Farrell D, Gray R, et al.  AD2000 Collaborative Group.  Long -term donepezil 
treatment in 565 patients with Alzheimer’s disease (AD2000): Randomised double -blind 
trial.  Lancet . 2004;363:2105 -15 
 
Fillenbaum  GG, Peterson B, Morris JC. Estimating the validity of the Clinical Dementia 
Rating Scale: the CERAD experience. Aging (Milano) 1996; 8(6):379 -85. 
 
Fitzpatrick AWP, Falcon B, He S, et al. : Cryo -EM structures of tau filaments from 
Alzheimer’s disease. Nature 2017; 547:185 -90. 
 
Protocol: TRx -237-[ADDRESS_977876] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 114 of 145 Folstein MF, Folstein SE, McHugh PR. “Mini -mental State”: A practical method for grading 
the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3):189 -98. 
 
Friston K, Ashburner J, Kiebel S, et al. (eds)  Statistical Parametric Mappi[INVESTIGATOR_007] : The analysis of 
functional brain images . 1st ed. Amsterdam: Academic Press ; 2007.  
 
Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for 
clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer 
Dis Assoc Disord 1997;  11(Suppl 2 ):S33-9.  
 
Galasko D, Schmitt F, Thomas R, et al. Detailed assessment of activities of daily living in 
moderate to severe Alzheimer's disease. J Int Neuropsychol Soc 2005; 11(4):446 -53. 
 
Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau -aggregation 
inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, 
controlled, double -blind, parallel -arm, phase 3 trial. Lancet 2016; 388:2873 -84. 
 
Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br 
J Psychiatry  1982;  140:566 -72.  
 
Lockhart SN, Baker SL, Okamura N, et al. Dynamic PET measures of tau accumulation in 
cognitively normal older adults and Alzheimer’s disease patients measured using 
18F THK -5351. PLoS One 2016; 11(6):e0158460 . 
 
McKhann GM, Knopman DS, Chertkow H, et al. The d iagnosis of dementia d ue to 
Alzheimer’s disease: Recommendations from the National Institute on Aging -Alzheimer’s 
Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers 
Dement 2011; 7(3):263 -9. 
 
Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in 
clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale 
that broaden its scope. The Alzheimer's Disease Cooperative Study.  Alzheimer Dis Assoc 
Disord  1997;11(Suppl 2):S13 –21. 
 
Morris JC, McKeel DW Jr, Fulling K, et al. Validation of clinical diagnostic criteria for 
Alzheimer's disease. Ann Neurol 1988; 24(1):17 -22. 
 
Morris JC, Ernesto C, Schafer K, et al. Clinical Dementia Rating training and reliability in 
multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology 1997;  
48(6):1508 -10. 
 
Mukaetova -Ladinska EB, Garcia -Siera F, Hurt J, et al. Staging of cytoskeletal and β -amyloid 
changes in human isocortex reveals biphasic synaptic protein response during progression of 
Alzheimer's disease. Am J Pathol 2000; 157(2):623 -36. 
 
National Institute for Clinical Excellence (NICE) Technology Appraisal Guidance No 19. 
Guidance for the use of donepezil, rivastig mine and galantamine for the treatment of 
Alzheimer’s disease 2001 , London: NICE.  
 
Protocol: TRx -237-[ADDRESS_977877] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 115 of 145 Olin J, Schneider L. Galantamine for dementia due to Alzheimer’s disease . Cochrane 
Database of Systematic Reviews , Issue 3, 200 2, article No. CD001747 . 
 
Pontecorvo MJ, Devous MD, Sr., Navitsky M, et al.  Relationships between flortaucipir PET 
tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 2017; 140:748 -
63. 
 
Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate -to-severe Alzheimer's 
disease. N Engl J Med 2003; 348(14):1333 -41. 
 
Riedel G, Klein J, Niewiadomska G, et al.  Mechanisms of anticholinesterase interference 
with tau aggregation inhibitor activity in tau -transgenic mouse model.  Curr Alzheimer Res.  
2020;17(3):285 -296. 
 
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J 
Psychiatr y 1984;  141(11):1356 -64. 
 
Schelter BO, Shiells H, Baddeley TC, et al. Concentration -dependent activity of 
hydromethylthionine on cognitive decline and brain atrophy in mild to moderate Alzheimer's 
disease. J Alzheimers Dis 2019;72(3):931 -46 
 
Schneider LS, Dagerman KS, Higgins JP, et al. Lack of evidence for the efficacy of 
memantine in mild Alzheimer disease. Arch Neurol 2011; 68(8):991 -8. 
 
Staff RT1, Murray AD, Deary IJ, et al. What provides cerebral reserve? Brain 2004; 127(Pt 
5):1191 -9. 
 
Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: A comprehensive review. 
J Am Geriatr Soc 1992;  40(9):922 -35. 
 
Wilcock GK, Gauthier S, Frisoni GB, et al. Poten tial of low dose leuco -methylthioninium 
bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer’s 
disease: Cohort analysis as modified primary outcome in a Phase III clinical trial. J 
Alzheimer’s dis 2018; 61:435 -57. 
 
Wischik CM, Lai RY, Harrington CR. Modelling prion -like processing of tau protein in 
Alzheimer’s disease for pharmaceutical development. In: Brain Microtubule Associated 
Proteins: Modifications in Disease. Eds. Avila J, Brandt R, Kosik KS 1997. Amsterdam: 
Harwood Academic Publishers, 185 -241. 
 
Wischik CM, Novak M, Edwards PC, et al. : Structural characterization of the core of the 
paired helical filament of Alzheimer disease. Proc Natl Acad Sci [LOCATION_003] 1988 a; 85:4884 -8. 
 
Wischik CM, Novak M, Thøgersen HC, et al. : Isolation of a fragment of tau derived from the 
core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci [LOCATION_003] 1988b; 
85:4506 -10. 
 
Wischik CM, Staff RT, Wischik DJ,  et al. Tau aggregation inhibition therapy: an exploratory 
Phase 2 study in mild or moderate Alzheimer’s disease. J Alzheimer’s Dis 2015; 44 (2):705-
20. 
Protocol: TRx -237-[ADDRESS_977878] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 116 of 145  
Xia CJ, Makaretz SJ, Caso C, et al. Association of in vivo [18F] tau PET imaging results with 
cortical atrophy and symptoms in typi[INVESTIGATOR_717157]. JAM Neurol 2017; 
74:427 -36.  
Protocol: TRx -237-[ADDRESS_977879] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 117 of 145 28 APPENDICES  
28.1 Disallowed Treatments and Windows  
28.1.1  Disal lowe d Medical Food  / Me dications Beginning 90 Days 
Before Baseline and Durin g the S tudy 
Medical food 
Souvenaid® 
 
Antipsychotic  
Clozapi[INVESTIGATOR_717158]-malarial drugs  
Dapsone  
Primaquine and related antimalarials  
 
Anesthetics  
Benzocaine or other local anesthetics used chronically  
 
Investigational product for cognition  (unless confirmed to have been randomized to placebo)  
 
 
28.1.2  Disal lowe d Medications Beginning 60 Days Before Baseline 
and Durin g the S tudy 
Alzheimer’s disease drugs  
Donepezil  
Galantamine  
Rivastigmine  
Memantine  
 
 
28.1.3  Disal lowe d Treatments Beginning 28 Days Before Baseline 
and Durin g the S tudy 
Investigational drug (other than for cognition), biologic, device, or medical food  
 
  
Protocol: TRx -237-[ADDRESS_977880] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 118 of 145 28.2 Study Blood Assessments  
 
Please see schedule of assessments for timing  of blood sample collections.  
 
Clinical Chemistry  Hematology  
Sodium  Red blood cell (RBC) count  
Potassium  Hemoglobin  
Chloride  Hematocrit  
Bicarbonate  MCV, MCH, MCHC  
Total protein  RBC distribution width  
Albumin  Platelet count  
Calcium  White blood cell (WBC) count  
Phosphorus  WBC Differential (% and  absolute ) 
Glucose  • Neutrophils  
Blood urea nitrogen  • Eosinophils  
Creatinine  • Basophils  
Indirect bilirubin  • Lymphocytes  
Direct bilirubin  • Monocytes  
Total bilirubin  Reticulocytes (absolute and relative)  
Alkaline phosphatase   
Alanine aminotransferase   
Aspartate aminotransferase   
Gamma -glutamyl transferase   
Lactate dehydrogenase   
  
Other Tests   
Serum Pregnancy test   
Vitamin B 12 / Folate   
Haptoglobin   
Thyroid Stimulating Hormone  (TSH)   
Glucose -6-Phosphate Dehydrogenase  (G6PD)  
ApoE  (in subjects who consent for this)   
Blood sample for MT concentration   
 
  
Protocol: TRx -237-[ADDRESS_977881] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 119 of 145  
28.3 Education / Occupation  
28.3.1  Education  
Q: How many years did you spend in full time education before the age of 26?  
 (integer) _ years  
 
Q: How would you best describe your level of education?  
1. Elementary  
2. Some high school / secondary  
3. Completed high school / secondary  
4. Some post high school / secondary education  
5. College education graduate  
6. Post graduate education (including high professional qualification)  
 
28.3.2  Occupation  
 
Q: What was your main occupation during your working life?  
(text)  
 
(Responses will be coded using The Standard Operational Classification, 2010, 
Volume 2 The Coding Index, [LOCATION_006] Office for Natio nal Statistics )  
 
Protocol: TRx -237-[ADDRESS_977882] -003558 -17  
Protocol Version 7.0 CONFIDENTIAL  Page 120 of 145 28.4 Summary of Changes to the Protocol  
28.4.1  Protocol Version 2.0 
The protocol for s tudy TRx -237-039 (Version 1.0 dated 23 Aug 2017) has been revised 
(Version 2.0) to clarify the asse ssments that will be made at v arious visits as follows:  
• The blood will be collected during Visit 2 and Visit 3 (not at Visit 2 or Visit 3).  
• A spelling error  was corrected (dimethyl to desmethyl).  
• Clarification was made that the time of dose  from the previous day will be collected.  
• A redundant paragraph  was removed.  
• Specifications for procedure  of blood collection were removed from the protocol as 
these details will be presented in the laboratory manual.  
• The Appe ndices were renumbered and the t able of contents updated . 
• Minor edits, s uch as  expansion of abbreviations , were made . 
 
The sections affected by  [CONTACT_717303].  
 
Summary of Changes  Affected Section(s) in Revis ed Protocol 
(Version 2.0 ) 
Targeted examinations will be performed 
pre-dose and approximately [ADDRESS_977883] dose of study drug 
(Visit 2); these are to be repeated as needed 
for subjects who remain in the clinic longer 
than 4 hours. Ther eafter, targeted 
examinations are to be performed at each 
subsequent visit  or upon early termination.  • Synopsis, Safety and tolerability  
• Table 10 -1 Schedule of Assessments,  
foot note ‘f’  
• Section 15.2, B ullet #7  
Added the following missing bullet to the 
Synopsis:  
TSH, vitamin B 12, folate, haptoglobin and 
G6PD will be measured at Screening only. 
Standard clinical laboratory testing, 
including hematology, blood chemistry, 
will be performed at Screening and each 
visit thereafter including an early 
termination, if applicable. A blood sample 
for a serum pregnancy test will be collected 
for all women o f childbearing potential at 
Screening and at each subsequent visit, or 
upon early termination.  • Synopsis, Safety and tolerability  
Several updates were made to the various 
statistical analyses planned  • Section 17.8 including subsections  
The blood will be col lected during Visit 2 
and Visit  3 (not at Visit 2 or Visit 3)  • Table 10 -1 Schedule of Assessments,  
foot note  ‘q’ 
A redundant bullet was removed  • Synopsis , Safety and Tolerability  
• Section  15.2 
Spelling changed from dimethyl to 
desmethyl  • Synopsis , safety and tolerability, Bullet #5  
• Section  15.2 Bullet #5  
• Section  15.5.2, line 2  
Protocol: TRx -237-[ADDRESS_977884] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 121 of 145 Summary of Changes  Affected Section(s) in Revis ed Protocol 
(Version 2.0 ) 
The time of dose  from the previous day will 
be collected  • Table 10 -1 Schedule of Assessments,  
foot note  ‘q’ 
• Section 15.4.1 Paragraph 1  
The volume of whole blood, centrifuge 
speed and the number and type of blood 
collection tubes were removed  • Section [IP_ADDRESS]  
The Appendices were renumbered and the 
Table of contents updated  • Table of Contents  
• Appendices 30.3 and 30.3.1  
 
28.4.2  Protocol Version 2.1 
The protocol for s tudy TRx -237-039 (Version 2.0 dated 31 Aug 2017) was updated to make 
administrative change s to provide the latest contact [CONTACT_717304] S ponsor  and the S ponsor’s 
personnel , and the details of the Central Laboratory . 
 
Summary of Changes  Affected Section(s ) in Revised Protocol 
(Version 2.1) 
The address and phone numbers of the 
Sponsor and the S ponsor’s personnel was 
updated.   
 • Cover page  
• Section 3 Protocol Approval  
• Section [ADDRESS_977885] 2017.  • Cover page  
• Headers  
• Footers  
• Section 5 Investigator Signature [CONTACT_717332], address and 
phone numbers were added.  • Section 4 Responsible Personnel  
 
Protocol: TRx -237-[ADDRESS_977886] -003558 -17  
Protocol Version 7.0 CONFIDENTIAL  Page 122 of 145 28.4.3  Protocol Version 3.0 
The protocol for Study TRx -237-039 (Version 2.1 dated 25 October 2017 ) was updated to  
modify  the study design to a 39 -week treatment period  (from 26 weeks)  in subjects with early 
AD (i.e., by [CONTACT_717305] -AD in addition to mild AD) . As a result of 
the addition of a cognitive/functional Composite Scale (to be finalized prior to database lock 
and unblinding)  and a third treatment arm (LMTM 16 mg/day) , the sample size has been 
increased to approximately 3 75 subjects  (from 180 subjects) . Numerous changes have been 
made to the protocol to clarify and/or specify the timing and sequence of assessments.  
 
A summary of the key changes and primary affected sections is provided below (as the 
Synopsis is affected by [CONTACT_717306], it is not listed).   
 
Administrative changes have also been made, such as  adding the  EudraCT number issued for 
this study ( 2017 -003558 -17); updating references to the 2013 (current) version of the 
Declaration of Helsinki , the ICH Integrated Addendum to ICH E6(R2) Guidelines for GCP, 
and GDPR ; and updating parties and contact [CONTACT_717307] 4. 
Additional statistical analyses, including of derived endpoints (such as the Composite Scale)  
and the higher treatment group , are now described . While a brie f summary of planned 
statistical analyses of primary and secondary endpoints is described and a list of possible 
exploratory analyses is included, these will be finalized in a Statistical Analysis Plan prior to 
database lock and unblinding.  These are not described below but are enumerated in a separate 
detailed summary of changes document.  
 
Summary of Changes  Primary Affected Sections in Revised Protocol 
(Version 3.0)  
Background  
The recently adopted [LOCATION_002] Abbreviated 
Names of hydromethylthionine (LMT) and 
hydromethylthionine mesylate (LMTM, drug 
substance) have been added  Section 8.1.[ADDRESS_977887] current version of Investigator’s 
Brochure (v. 20 .0); references have been updated as 
pertinent  Section 8.1.2  Nonclinical Data  
Section 8.1.3  Clinical Data  
Objectives  
A new clinical efficacy scale has been added as a 
gated primary objective; this Composite Scale is to 
be derived from cognitive/functional items selected 
from the ADAS -cog 11 and ADCS -ADL 23  Section 8.2 Rationale  
Section 9.1 Primary Objectives  
Section 15.3.3 Composite Scale  
Section 17  Statistical Analysis  
Section 17.1.2 Primary Efficacy Endpoint  
Section 17.2 Number of Subjects and Sample Size 
Calculation  
Section 17.4.1 Hypothesis  
Section 17.4.7 Subgroup Analyses  
Section [IP_ADDRESS].1 Multiple Imputation  
Section 17.5 Exploratory Analyses  
The secondary clinical endpoint has been changed 
from the ADAS -cog 11 to the ADAS -cog 13 as 
potentially more sensitive to change in subjects with 
milder disease  Section 9.2 Secondary Objectives  
[IP_ADDRESS] Clinical Efficacy Assessments  
15.3.1 ADAS -cog 
17.1.4 Other Secondary Endpoints  
17.5 Exploratory  Analyses  
Protocol: TRx -237-[ADDRESS_977888] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 123 of 145 Summary of Changes  Primary Affected Sections in Revised Protocol 
(Version 3.0)  
The sequence of the secondary objectives has been 
modified and the examination of associations 
between the 18F-FDG -PET regions of interest and the 
Composite Scale and the examination of associations 
between brain MRI endpoints and ADAS -cog 13, 
ADCS -ADL 23, and the Composite Scale have been 
added. Comparison of the LMTM 16 mg/day and 
placebo groups has also been added . Section 9.2 Secondary Objectives  
Section 17.1.3 Secondary Imaging Endpoints  
Section 17.1.4 Other Secondary Endpoints  
Exploratory analyses and exploratory analyses that 
are comparisons with external data are now listed 
only in the Statistical Analysis section.  Section 9.3 (Section removed ) 
Section 9.4  (Section removed ) 
Section 17.5 Exploratory Analyses  
Study Design  
The duration of the study has been increased from 6 
to 9 months; the numbers of visits, schedules of 
safety and efficacy assessments, and statistical 
analyses have also been updated accordingly.   Section 10.[ADDRESS_977889] -randomization 
Assessments  
Section [IP_ADDRESS] Imaging Efficacy Assessments  
Section [IP_ADDRESS] Clinical Efficacy Assessments  
Section [IP_ADDRESS] Safety Assessments  
Section 12.[ADDRESS_977890] has 
been increased from 36 weeks to up to 54  weeks, 
including a Screening period of up to 15  weeks 
(105 days) and a Treatment period of [ADDRESS_977891] treatment arm, LMTM 16 mg/day , has been 
added and the total sample size increased from 180 
subjects (90 each randomized to placebo and LMTM 
8 mg/day ) to 375 subjects (150 each randomized to 
placebo and LMTM 8 mg/day  and 75 randomized to 
LMTM 16 mg/day ). As many as 900 subjects may be 
screened (increased from 360).  Section 10.[ADDRESS_977892] dose of 
study drug, has been deleted; the protocol clarifies 
that investigators are to follow any unresolved 
adverse events to resolution or acceptable 
stabilization cons istent with their medical judgment.  Section 10.[ADDRESS_977893] -randomization 
Assessments  
Section [IP_ADDRESS] Safety Assessments  
Section 11.4 Discontinuations / Withdrawals  
Section 15.4 Safety Assessment and Procedures  
Section 16. 2 Eliciting Adverse Event Information  
Section 16.7 Serious Adverse Event Reporting  
Patient Population  (Inclusion and Exclusion Criteria)  
The patient population has been expanded to include 
subjects with mild cognitive impairment due to 
Alzheimer’s disease (MCI -AD), such that the study 
is now being performed in subjects with early 
Alzheimer’s disease (AD) (inclusive of both mild AD 
and MCI -AD) Section 8.2 Rationale  
Section 9 Objectives  
Section 10.1 General Description  
Section 10.2 Study Population  
Section [IP_ADDRESS] Diagnostic and Cognitive Eligibility 
Assessments  
Section 11.1 Inclusion Criteria  
Protocol: TRx -237-[ADDRESS_977894] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 124 of 145 Summary of Changes  Primary Affected Sections in Revised Protocol 
(Version 3.0)  
Subjects must be able to give their own consent; 
consent by a caregiver on behalf of the subject is no 
longer allowed  Section 9.[ADDRESS_977895] -randomization 
Assessments  
Section 10.4.3  Other Assessments  
Section 11.1  Inclusion Criteria  
Section 15.5.3 Genotypi[INVESTIGATOR_101756] 18.3  Informed Consent  
A PET scan positive for amyloid is now required for 
eligibility (either by [CONTACT_717308])  Section 10.1 General Description  
Section 10.2 Study Population  
Section 10.4.1 Screening Assessments  
Section [IP_ADDRESS] Diagnostic and Cognitive Eligibility 
Assessments  
Section 11.1 Inclusion Criteria  
Section 10.4.1 Screening Assessments  
Section 15.1 Demographic Data/Medical History  
Section 15.2.1 General Considerations  
Section [IP_ADDRESS] 18F-FDG -PET 
Section 18.3 Informed Consent  
The acceptable disease severity based on MMSE has 
been expanded from 20 -25 to 20 -27; randomization 
will now be stratified based on a MMSE of 20 -25 
and 26 -27 (in a 2:1 ratio, monitored and controlled at 
the site level and capped as needed at the study level)  Section 10.[ADDRESS_977896] a score of >0 in one of 
the functional domains (Community Affairs, Home 
and Hobbies, or Personal Care)  Section 10.2 Study Population  
Section 11.1 Inclusion Criteria  
Section 11.3 Re -screening  
Subjects taking an AChEI and/or memantine at 
Screening may now be enrolled, provided they are 
willing to discontinue such medication; the screening 
period in such subjects has been expanded to 15 
weeks to allow for the requisite eligibility 
assessments pri or to the discontinuation of such 
medication (at least 60 days before Baseline  
18F-FDG -PET); if subjects discontinue these 
medications, a letter is to be sent to the primary care 
physicians to inform them of this decision  Section 10.1 General Description  
Section 10.4.1 Screening Assessments  
Section [IP_ADDRESS] Diagnostic and Cognitive Eligibility 
Assessments  
Section 10.4.[ADDRESS_977897] -randomization 
Assessments  
Section 11.1 Inclusion Criteria  
Section 13.1 AChEI and/or Memantine  
As a result of the increased sample size, at least  100 
sites may be required  (increased from 60) and sites 
from geographical regions outside of North America 
and Europe may also be sought  Section 10.1 General Description  
Section 10.2 Study Population  
Section 12.3 Randomization  
Section 17.4.7 Subgroup Analyses  
Additional exclusion criteri a: 
• Any physical disability that would prevent 
completion of study procedures or assessments 
(with examples provided)  
• Use of Souvenaid® within the 90 days prior to 
Baseline  Section 11.2 Exclusion Criteria  
Protocol: TRx -237-[ADDRESS_977898] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 125 of 145 Summary of Changes  Primary Affected Sections in Revised Protocol 
(Version 3.0)  
Modifications of exclusion criteria include:  
• Moderate to severe sleep apnea, even if 
adequately controlled  (previously, subjects who 
were controlled were accepted)  
• Carbamazepi[INVESTIGATOR_145796] (previously, use for 
treatment of restless legs was permitted)  
• G6PD deficiency has been defined based on 
WHO classification (<60% of normal,  i.e., 
<6.1 U/g Hgb)  
• Use of olanzapi[INVESTIGATOR_717159] (the 
only disallowed antipsychotic is clozapi[INVESTIGATOR_050])  
• Need for a cardiology consult in subjects with left 
bundle branch block has been removed  
• The acceptable window for prior use of an 
investigational product for cognition has been 
reduced to 90 days (from 120 days) prior to 
Baseline (rather than Screening)  Section 11.[ADDRESS_977899] treatment arm, all 
subjects will now receive four tablets daily, two in 
the morning and two in the evening, to maintain the 
study blind.  12.2 Study Regimen s 
The study drug wallet now contains 28 tablets (rather 
than 14 tablets)  12.4 Packaging, Labeling, and Storage  
Assessments  
Information regarding education and main 
occupation will now be collected at Screening  Section 15.1 Demographic Data / Medical History  
Section 17.6 Demographic and Baseline 
Characteristics  
Appendix 28.3 Education / Occupation  
In subjects with extended Screening, medical 
assessments for eligibility may need to be repeated if 
initial assessments were more than 42  days prior to 
Baseline  Section 10.4.1 Screening Assessments  
Section [IP_ADDRESS] Other Medical Screening 
Assessments  
Brain MRI hyperintensities will now be quantified  Section [IP_ADDRESS] Imaging Efficacy Assessments  
Section [IP_ADDRESS] MRI  
Section 17.[ADDRESS_977900] sum of boxes (which are obtained 
at Screening) will now also be assessed after 
[ADDRESS_977901] -randomization 
Assessments  
Section [IP_ADDRESS] Clinical Efficacy Assessments  
Section 15.3 Clinical Assessments and Raters  
Section 17.5 Exploratory Analyses  
Whole blood will also be assessed for MT, 
N-desmethyl MT, and total MT concentrations (in 
addition to plasma)  Section 10.[ADDRESS_977902] -randomization 
Assessments  
Section 15.5.1 MT Concentration  
Section [IP_ADDRESS] Procedure for Blood Sample 
Collection  
Section 17.8 Other Data  
A urine sample will be collected at the final visit 
(following all safety and efficacy assessments) for 
determination of color by [CONTACT_2237]; 
results will not be reported to the site  Section 10.1 General Description  
Section 10.4.3 Other Assessments  
Section 15.5.2 Urine Color  
Section 17.8 Other Data  
Other  
Malignancies (with the exception of non -melanoma 
skin cancers) are to be to be reported as ADRs to 
Health Canada   Section 16.9 Malignancies  
Section 17.7 Safety  Analysis  
Protocol: TRx -237-[ADDRESS_977903] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 126 of 145 Summary of Changes  Primary Affected Sections in Revised Protocol 
(Version 3.0)  
Stored samples may be kept for up to 8 years for 
future, as yet unspecified, analyses; consent to such 
storage is mandatory for participation in the study   Section 20 Stored Samples  
 
 
 
Protocol: TRx -237-[ADDRESS_977904] -003558 -17  
Protocol Version 7.0 CONFIDENTIAL  Page 127 of 145 28.4.4  Protocol Version 4.0 
The protocol for Study TRx -237-039 (Version 3.0 dated 31 May 2018 ) has been  updated to 
include administrative changes , as the responsible party for study management, monitoring, 
and pharmacovigilance has changed (previously PAREXEL International, now Syneos 
Health). Additional modifications and clarifications  have been  incorporated  with respect to 
the Sponsor contact [CONTACT_8972],  objectives  and statistical analyses , background, study population, 
informed consent, study  assessments, documentation, data protectio n, and study 
administration.  
 
A summary of the key changes and affected sections is provided below.   
 
Summary of Changes  Affected Sections in Revised Protocol  
(Version 4.0)  
Sponsor Information  
The contact [CONTACT_717309],  
while the operational location is in the [LOCATION_008].  Cover page  
Compliance Statement  
Compliance statement regarding ICH GCP further 
clarified to include ICH  E6(R1) in those jurisdictions 
where ICH  E6(R2) is not yet implemented by [CONTACT_53193].  Reference to the Declaration of 
Helsinki has been clarified to refer to the current 
applicable version.  Section [ADDRESS_977905] Manager, North 
America Medical Monitor, Europe Medical Monitor, and 
Pharmacovigilance, as the responsible party is now 
Syneos Health (previously PAREXEL International); th e 
procedures for safety and regulatory/ethics reporting have 
been updated accordingly.  Additional telephone numbers 
have been added to the list of DSSL 24 -hour Medical 
Contacts, as the study will also be conducted in Italy and 
Spain.  The vendor for recru itment services (ThreeWire) 
has been removed.  Section 4 Responsible Personnel  
Section 16.7 Serious Adverse Event Reporting  
Section 16.9 Malignancies  
Section 16.10 Reporting of Pregnancy  
Section 18 Regulatory and Ethics  
Section 18.1 Approval of the Protocol and 
Amendments  
Objectives  and Statistical Analyses  
The evaluation of  the outcomes described in the Primary 
and Secondary Objectives for LMTM 16 mg/day and 
placebo  has been clarified in Objective No s. 6 and 12 , 
and an evaluation of the outcomes of selected endpoints 
for pooled doses of LMTM 8 mg/day and 16 mg/day 
compared to placebo has been added as Objective No. 13 . 
The various LMTM 8 mg/day as well as LMTM 
16 mg/day and pooled comparisons to placebo are 
described in the SAP . Synopsis  
Section 9.2 Secondary Objectives  
Section 17 Statistical Analysis  
Background  
A new reference has been added regarding c ysteine -
independent inhib ition of Alzheimer's disease -like paired 
helical filament assembly by [CONTACT_717302] -methylthioninium  
(Al-Hilaly et al., 2018) . Section 8.1.[ADDRESS_977906]  
Section 27 References  
The summary of PK data from studies in subjects with 
renal and hepatic impairment has been clarified; results 
have been added from a completed study in healthy older 
volunteers.  Section [IP_ADDRESS] Pharmacokinetics  
Protocol: TRx -237-[ADDRESS_977907] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 128 of 145 Summary of Changes  Affected Sections in Revised Protocol  
(Version 4.0)  
Study Population  
Up to approximately 1500 subjects may be screened for 
the study (increased from 900).  Section 10.[ADDRESS_977908] be a physician  (such as a 
neurologist , psychiatrist ) or other medically qualified 
person .  Section 10.4.[ADDRESS_977909] dose of study drug (during the Screening 
procedures or as part of the Baseline assessments) , rather 
than being limited to Screening.  Synopsis  
Section 10.1 General Description  
Section 10.4.1 Screening Assessments  
Section [IP_ADDRESS] Other Medical Screening 
Assessments  
Section 10.4.[ADDRESS_977910] -randomization 
Assessments  
Section [IP_ADDRESS] Safety Assessments  
Section 15.4 Safety Assessments and Procedures  
Baseline characteristics to be collected include smoking 
history and history of lens implantation.   Section 15.1 Demographic Data/Medical History  
 
Additional instruction for investigators assessing AEs 
during the study includes asking one or more questions to 
evaluate suicidal ideation and behavior at each in -clinic 
visit, as recommended by [CONTACT_941] U.S. FDA . Questions are to 
be addressed to both subjects and their study partners.  Section 16.[ADDRESS_977911] been 
added to clinical chemistry laboratory assessments.  Section 28.2 Study Blood Assessments  
Documentation  
Further details regarding archiving and management of 
the e TMF  are provided.  The requirements for document 
retention and archiving ha ve been clarified to refer to a 
minimum of 25 years after the end of the clinical trial.  Section 7 Abbreviations  
Section 22 Documentation  
Clarification that all deviations identified at or by [CONTACT_717310], and deviations from 
the SAP (if any) will be noted in the clinical study report . Section [ADDRESS_977912] -facing documentation ( e.g., 
in appropriate transparency notices included in informed 
consent documentation) in compliance with relevant local 
laws.  Section 19 Confidentiality and Data Protection  
Study Administration  
Reference to pi[INVESTIGATOR_717160], as the pi[INVESTIGATOR_717161].  Section 26 Study Administration  
 
Protocol: TRx -237-[ADDRESS_977913] -003558 -17  
Protocol Version 7.0 CONFIDENTIAL  Page 129 of 145 28.4.5  Protocol Version 4.1 
The protocol for Study TRx -237-039 (Version 4.[ADDRESS_977914] 2018 ) has been  revis ed in 
this administrative amendment to include an additional Sponsor signatory for  Medical 
Oversight, and to remove references to  specific personnel  for Medical Monitoring 
representation  in North America and Europe.  T he most current Medical Monitoring contact 
[CONTACT_717311] -reference to the Site Contact [CONTACT_717312] . 
 
A summary of the changes and affected section s is provided below.   
 
Summary of Changes  Affected Section s in Revised Protocol  
(Version 4.1)  
Protocol Signatories  
An additional Sponsor signatory has been added for 
TauRx  Medical Oversight.  Section [ADDRESS_977915] been 
removed for personnel responsible for medical 
monitoring ( i.e., the North America Medical Monitor and 
Europe Medical Monitor) .  The most current contact 
[CONTACT_717313] -reference to the 
Site Contact [CONTACT_717314] . Section 4 Responsible Personnel  
 
Protocol: TRx -237-[ADDRESS_977916] -003558 -17  
Protocol Version 7.0 CONFIDENTIAL  Page 130 of 145 28.4.6  Protocol Version 5.0 
The protocol for study TRx -237-039 (Version 4.1 dated  9 November 2018 ) has been  revis ed 
primarily to include the following modifications:  
 
• The study design now includes  two phases , including the double -blind treatment 
period  (now 12  month s, extended from  9 month s) with subjects randomized to 
LMTM 16  mg/day, LMTM 8 mg/day, or placebo , followed by [CONTACT_717315] -label , 
delayed -start treatment period with LMTM 16 mg/day for an additional 52 weeks ; 
study visits and schedules of assessments have been modified accordingly  
 
• The study population now includes subjects with early to mild -moderate AD 
(previously  only early AD ), and t he number of randomized subjects has been 
increased to approximately 450 subjects (previously 375 subjects)  
 
• The primary objectives  for the double -blind treatment period  now pertain to 
comparing LMTM 16 mg/day with placebo for the co -primary endpoints of 
ADAS -cog 11 and ADCS -ADL 23 (difference in temporal lobe 18F-FDG -PET change in 
SUVR and the Composite Scale are no longer primary objectives), and for assessing 
safety and tolerability ; secondary objectives have been modified to include 
comparisons of LMTM 16 mg/day with placebo in whole brain atrophy as measured 
by [CONTACT_9268], to restrict the 18F-FDG -PET endpoints to subjects with CDR 0.5 at 
Screening, and to compare the LMTM dose of 8 mg/day for selected endpoint s 
 
Modifications have also been made to administrative information, criteria for subject 
enrollment and eligibility for the EAP, study drug supplies for the placebo group  (now 
including a urinary discolorant to maintain blinding during the double -blind treatment 
period) , and study assessments. A summary of the key changes and primary affected sections 
is provided below (as the Synopsis is affected by [CONTACT_717306], it is not listed).   
 
Minor revisions have also been  incorporated for clarity; these are not described below but are 
enumerated in a separate detailed summary of changes document.  
 
Summary of Changes  Affected Sections in Revised Protocol  
(Version 5.0)  
Administrative  
The GCP compliance statement has been modified to  
indicate that the study will be conducted in compliance with 
the principles contained in the Declaration of Helsinki, 
rather than include reference to a specific version.  Section 2 GCP Compliance Statement  
Section 5 Investigator Signature [CONTACT_717333] 18 Regulatory and Ethics  
The statistician for the study has been changed to Bjoern 
Schelter, PhD  (Data Analytics and Biostatistics Lead for 
TauRx ). Section [ADDRESS_977917] Leads for this study are now 
Sotereos Gates and Alison Walker (previously Sean 
Neville).  Section [ADDRESS_977918] (DSSL) information is 
also provided by [CONTACT_12783] -reference to the Site Contact [CONTACT_717316].  Section 4 Responsible Personnel  
Protocol: TRx -237-[ADDRESS_977919] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 131 of 145 Summary of Changes  Affected Sections in Revised Protocol  
(Version 5.0)  
For image hypersensitivities, Aberdeen Biomedical Imaging 
Centre has been removed as the data output will be 
provided by [CONTACT_717317], Inc.  Section [ADDRESS_977920] this change ( i.e., MMSE 16 to 27 [inclusive] and 
Global CDR 0.5 to 2 [if 0.5, including a score of >0 in one 
of the functional domains]).  An additional stratification 
level for MMSE severity ( i.e., 16-19) has been added, with 
a target of approximately 2:3:1 for MMSE scores of 16 -19, 
20-25, and 26 -27, respectively.  Cover Page  
Section 10.1 General Description  
Section 10.2 Study Population  
Section 11.1 Inclusion Criteria  
Section 11.3 Re -screening  
Section 12.3 Randomization  
Section 17 Statistical Analysis  
Section 17.2 Number of Subjects and Sample Size 
Calculation  
The study will be conducted in approximately 150 study 
sites in North America and Europe (previously planned to 
be at least [ADDRESS_977921] of World).  Approximately 2000 subjects (previously 
up to 1500 subjects) may be screened.  Section 10.[ADDRESS_977922] a likely diagnosis of AD or MCI -AD prior to 
being offered consent forms.  It is further specified that the 
accuracy of the diag nosis is to be confirmed independently 
by [CONTACT_717318].  Section 10.4.1 Screening Assessments  
Section 11.1 Inclusion Criteria  
Treatment Groups  
The primary treatment group comparison is now LMTM 
16 mg/day versus  placebo, with secondary comparison of 
subjects receiving 8  mg/day versus  placebo.  The rationale 
for revising primary LMTM dosing to 16  mg/day (using 
plasma concentration thresholds based upon a population 
PK model ) and for adding the open -label, delayed -start 
treatment phase is described .  Safety margins for nonclinical 
data were updated to reflect the 16  mg/day dose.   
Supportive data regarding reduction in treatment effects of 
LMTM by [CONTACT_717319].  Section 8.1.2 Nonclinical Data  
Section 8.2 Rationale  
Section 9.1 Primary Objectives  
Section 9.2.1 Double -blind Treatment Period  
Section 10.1 General Description  
Section 12.2 Study Regimens  
The number of randomized subjects has been increased to 
approximately 450  subjects  (previously 375 subjects) , with 
a ratio of 4:1:4 (at the study level) to LMTM 16  mg/day  
(200 subjects),  LMTM 8 mg/day (50  subjects), and placebo  
(200 subjects).  Section 10.1 General Description  
Section 10.2 Study Population  
Section 12.2 Study Regimens  
Section 12.3 Randomization  
Section 17.2 Number of Subjects and Sample Size 
Calculation  
Study Design  
The study design has been modified  to occur in two phases.  
The randomized, double -blind, placebo -controlled portion is 
now a 12 -month (extended from  9-month ) study, including 
five (rather than four) post -randomization visits (Visits 3 
through 7).  Following completion of the double -blind 
treatment period, subjects will continue open -label 
treatment with LMTM 16  mg/day for an additional 
52 weeks, representing a  modified delayed start of 
treatment; the open -label, delayed -start phase will include 
three treat ment visits (Visit  8 [telephone contact], Visit 9, 
and Visit 10).   
 
Prior treatment assignment will not be unblinded; however, 
upon completion of the initial [ADDRESS_977923] -randomization 
Assessments in Double -Blind Treatment Period  
Section 10.4.3 Assessments in the Open -Label, 
Delayed -Start Phase  
Section 12.2 Study Regimens  
Section 12.5 Dispensing  
Section 12.6 Compliance  
Section 12.8 Breaking the Blind for the Double -
Blind Treatment Period  
Protocol: TRx -237-[ADDRESS_977924] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 132 of 145 Summary of Changes  Affected Sections in Revised Protocol  
(Version 5.0)  
locked and unblinded for analysis.  Individual subject 
treatment assignment will not be divulged to subjects or 
individuals involved in the conduct of the ongoing open -
label, treatment phase (except in cases of medical situations 
where it is deemed essential in order to provide appropriate 
care).  Access to the randomization list has also been 
clarified.  Section [ADDRESS_977925] is 
now up to 120 weeks  (rather than 54  weeks ), including a 
Screening period of up to [ADDRESS_977926] 40  months  (rather than 
24 months ), depending on recruitment . Section 10.[ADDRESS_977927] Enrollment and Withdrawal  
The protocol now states that, in the case of subjects with 
reduced decision -making capacity, legally acceptable 
representative(s), consistent with national law, may provide 
(and withdraw) written informed consent.   Section 7 Abbreviations  
Section 10.4.1 Screening Assessments  
Section 11.1 Inclusion Criteria  
Section 11.4.2 Handling of Study Discontinuation / 
Withdrawal  
Section 18.3 Informed Consent  
Clarification that subjects are not to be treated with an 
AChEI and/or memantine within the 60  days prior to 
Baseline assessments, rather than only Baseline 
18F-FDG -PET as previously stated.  Section 10.1 General Description  
Section 10.4.1 Screening Assessments  
Section 11.1 Inclusion Criteria  
Section 13.1 AChEI and/or Memantine  
Re-screening of a subject is allowed to a newly specified 
maximum of two re -screening occasions.  An additional 
acceptable instance for re -screening has been added for 
subjects with Hgb below the lower limit of laboratory 
normal; such subjects may be re -consented and re -screened 
after appropriate management at the discretion of the TauRx 
Medical lead.  Any other criterion not included the list 
would require approval by [CONTACT_717231].  Section 11 .3 Re-Screening  
Criteria for significant head injury no longer specifies a 
specific duration of associated loss of consciousness.  Section 11.2 Exclusion Criterion #3  
Criteria for epi[INVESTIGATOR_717162] a single prior seizure 
>6 months prior to Screening  is considered acceptable . Section 11.2 Exclusion Criterion #4  
Determination of whether or not a Screening Hgb value 
below age/sex appropriate lower limit of normal is 
exclusionary now includes discussion with the Medical 
Monitor, with final decision at the discretion of the Medical 
Oversight Lead.  Section 11.2 Exclusion Criterion #12  
Subjects with moderate to severe sleep apnea are to be 
excluded if the apnea is currently, rather than previously, 
diagnosed; the definition of moderate to severe apnea is 
now included ( e.g., requiring oxygen supplementation).  Section 11.2 Exclusion Criterion #15  
Clarified that active  hepatitis or primary biliary cirrhosis; or 
active  HTLV -III, LAV, mutants/derivatives of such, or 
conditions associated with AIDS or similar, are 
exclusionary.  Section 11.2 Exclusion Criterion #[ADDRESS_977928] been added for exclusions 
regarding cancer diagnosis (e.g., new diagnosis within past 
2 years, or previous [>2  years] diagnosis requiring any 
intervention or treatment within past 2  years).  Section 11.2 Exclusion Criterion #[ADDRESS_977929] open -label visit  may be 
eligible for the EAP (and once entered into the EAP, are 
required to remain off AChEIs  and/or memantine).  Patients Section 10.2 Study Population  
Section 10.6 Definition of End of Study  
Section 11.4.1 Handling of Subjects who 
Discontinue Study Drug  
Protocol: TRx -237-[ADDRESS_977930] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 133 of 145 Summary of Changes  Affected Sections in Revised Protocol  
(Version 5.0)  
who discontinue treatment permanently in this study will 
not be eligible for the EAP.  Section 12.2.[ADDRESS_977931]  
Section 12.1.1 Active Ingredient  
The drug supplies for the placebo group will include tablets 
containing a urinary discolorant, MTC, 4 mg.   To prevent 
inadvertent unblinding due to urinary discoloration, subjects 
randomized to placebo may receive a 4 -mg tablet of  MTC  
as one of the four tablets to be taken daily (the remainder 
being placebo tablets), in order to maintain the treatment 
blind.  Section 8.1.[ADDRESS_977932] (Visit  8).   Section 10.4.[ADDRESS_977933] 0.5; imaging is to occur at Baseline and 
at end of double -blind treatment, i.e., Visit  7/Week  52 (or 
early termination).  For purposes of establishing the 
Baseline assessment, 18F-FDG -PET images are to be 
obtained prior to Visit [ADDRESS_977934] 
dose of AChEI and/or memantine.  Section 9.2.[ADDRESS_977935] -randomization 
Assessments in Double -Blind Treatment Period  
Section [IP_ADDRESS] Imaging Efficacy Assessments in 
Double -Blind Treatment Period  
Section 13.4 Drugs Used to Manage Behavioral 
Disturbance  
Section 13.5 Other Medications  
Section 15. 3.1 General Considerations  
Section 15. 3.3.1 18F-FDG -PET 
Section 17.1.2 Secondary Efficacy Endpoints for 
Double -Blind Treatment Period  
Section 17.3 Analysis Populations  
Section 17.4.6 Dose Response Analyses  
Additional volumetric brain MRIs and cognitive / functional 
assessments (ADAS -cog 13 and ADCS -ADL 23) are to be 
conducted at Visit  7/Week  52, as well as after the additional  
26 and 52  weeks of open -label treatment (Visit  9/Week  78 
and Visit  10/Week  104), or upon early termination in the 
case of the ADAS -cog [ADDRESS_977936]’s last scan was performed <  [ADDRESS_977937] -randomization 
Assessments in Double -Blind Treatment Period  
Section [IP_ADDRESS] Imaging Efficacy Assessments in 
Double -Blind Treatment Period  
Section [IP_ADDRESS] Clinical Efficacy Assessments in 
Double -Blind Treatment Period  
Section 10.4.3 Assessments in the Open -Label, 
Delayed -Start Phase  
Section [IP_ADDRESS] Imaging Efficacy Assessments in 
the Open -Label, Delayed -Start Phase  
Section 15. 3.3.2 MRI  
The estimated total radiation exposure to subjects from the 
amyloid PET scan procedure (if not performed previously)  is 
now provided.  Section 15.3.[ADDRESS_977938] meets the MMSE inclusion criteria, and if the Section 10.1 General Description  
Protocol: TRx -237-[ADDRESS_977939] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 134 of 145 Summary of Changes  Affected Sections in Revised Protocol  
(Version 5.0)  
subject does not qualify with either of these scales, no 
further assessments are to be made and the subject will be 
considered a screen failure.  For enrolled and randomized 
subjects, the MMSE and CDR  sum of boxes  (as exploratory 
clinical efficacy assessments) are to be administered at 
Visit  7 and at the final open -label, delayed -start visit 
(Visit  10), or upon early termination.  Section [IP_ADDRESS] Diagnostic and Cognitive Eligibility 
Assessments  
Section 10.4.[ADDRESS_977940] -randomization 
Assessments in Double -Blind Treatment Period  
Section [IP_ADDRESS] Clinical Efficacy Assessments in 
Double -Blind Treatment Period  
Section 10.4.3 Assessments in the Open -Label, 
Delayed -Start Phase  
Section [IP_ADDRESS] Clinical Efficacy Assessments in the 
Open -Label, Delayed -Start Phase  
Section 15. 2.[ADDRESS_977941] and 
MMSE are now further described in the protocol with 
additional references included . Section 15.2 Assessment of Efficacy (and all 
subsections)  
Section 27 References  
Safety Assessments  
Safety assessments are to occur at each clinic visit during 
double -blind treatment, with additional assessments after 26 
and 52  weeks of open -label treatment (Visit  9/Week  78 and 
Visit  10/Week  104), and as needed to follow up on an AE.  
A telephone contact  [CONTACT_717320] 4  weeks in the 
open -label, delayed -start phase (Visit  8/Week  56).  All 
safety assessments are to be performed by [CONTACT_717321],  with 
certain assessments now specified to be conducted and/or 
reviewed by a medical assessor (physician/MD/DO), 
including targeted physical and neurological examinations, 
clinical laboratory and ECG results, and AEs and 
concomitant medications.   Section 10.1 General Description  
Section [IP_ADDRESS] Other Medical Screening 
Assessments  
Section 10.4.[ADDRESS_977942] -randomization 
Assessments in Double -Blind Treatment Period  
Section [IP_ADDRESS] Safety Assessments in Double -
Blind Treatment Period  
Section 10.4.3 Assessments in the Open -Label, 
Delayed -Start Phase  
Section [IP_ADDRESS] Safety Assessments in the Open -
Label, Delayed -Start Phase  
Section [ADDRESS_977943] 
Restrictions  
Section 15.4 Safety Assessments and Procedures  
Additional ophthalmological examinations in subjects with 
lens implants are to occur at Visits  7 and 10 (or early 
termination) to assess for potential lens discoloration.  It is 
now specified that the examinations are to be conducted by 
[CONTACT_4674],  optometrist, or other suitably qualified 
medical assessor (physician/MD/DO).  Section 10.1 General Description  
Section 10.4.1 Screening Assessments  
Section [IP_ADDRESS] Other Medical Screening 
Assessments  
Section 10.4.[ADDRESS_977944] -randomization 
Assessments in Double -Blind Treatment Period  
Section [IP_ADDRESS] Safety Assessments in Double -
Blind Treatment Period  
Section 10.4.3 Assessments in the Open -Label, 
Delayed -Start Phase  
Section [IP_ADDRESS] Safety Assessments in the Open -
Label, Delayed -Start Phase  
Section 15.4 Safety Assessments and Procedures  
Targeted physical examinations, to be performed by a 
medical assessor, are now specified to include, at a 
minimum, heart and lung auscultation and brief 
neurological assessment guided by [CONTACT_717322]/symptoms/AEs ( e.g., evaluating for potential 
serotonin toxicity).  Section 10.4.[ADDRESS_977945] after screen 
failure will not be recorded for the study.  Emergent AEs 
and SAEs up to the point of screen failure will be followed 
up to resolution at the discretion of the PI.  Section 16.1 Definition of AEs, Period of 
Observation, and Recording of AEs  
Section 16.7 Serious Adverse Event Reporting  
Protocol: TRx -237-[ADDRESS_977946] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 135 of 145 Summary of Changes  Affected Sections in Revised Protocol  
(Version 5.0)  
Other Assessments  
In addition to study visits that are to occur in the morning 
for Visits  2 and 3 to allow for in -clinic dosing and PK blood 
sampling, the protocol now specifies that in -clinic dosing 
and PK sampling are also to occur at morning appointments 
for Visit  7 (aft er 52  weeks on study drug) and Visit  10 (after 
104 weeks of study drug).  Subjects are to be instructed not 
to take their morning dose at home.  Section 10.[ADDRESS_977947] -randomization 
Assessments in Double -Blind Treatment Period  
Section [IP_ADDRESS] Other Assessments in Double -Blind 
Treatment Period  
Section 10.4.3 Assessments in the Open -Label, 
Delayed -Start Phase  
Section [IP_ADDRESS] Other Assessments in Open -Label, 
Delayed -Start Phase  
Section 12.[ADDRESS_977948] -randomization 
Assessments in Double -Blind Treatment Period 
Section [IP_ADDRESS] Other Assessments in Double -Blind 
Treatment Period  
Section 15.5.2 Urine Color (deleted)  
Blood samples for determination of plasma and whole 
blood MT concentrations  will now be 9 -mL blood samples  
collected in 9 -mL vacutainers ( previously  8-mL).  Section [IP_ADDRESS] Procedure for Blood Sample 
Collection  
Objectives and Endpoints / Statistical Analys es 
The primary objectives now pertain to the double -blind 
treatment period only , comparing LMTM 16  mg/day with 
placebo for the co -primary endpoints of ADAS -cog 11 and 
ADCS -ADL 23 (difference in temporal lobe 18F-FDG -PET 
change in SUVR  and the Composite Scale are no longer 
primary objectives),  and for assessing safety and 
tolerability .  Secondary objectives have been modified for 
the double -blind treatment phase to include comparisons of 
LMTM 16 mg/day with placebo in whole brain atrophy as 
measured by [CONTACT_9268], to re strict the 18F-FDG -PET endpoints to 
subjects with CDR 0.5 at Screening, and to compare the 
LMTM dose of 8 mg/day for selected endpoints.  Brain 
MRI remains as a secondary efficacy endpoint, with 
clarification that it will also be used to confirm a lack of 
treatment unblinding.  Section 9.[ADDRESS_977949] been 
added:  determination if there is a difference in disease 
progression on the co -primary clinical endpoints and MRI 
imaging endpoint for subjects who started treatment in the 
double -blind phase and th ose who started in the open -label, 
delayed -start phase ( i.e., “early” and “late” LMTM starters, 
respectively) , and assessment of safety and tolerability of 
LMTM given for up to [ADDRESS_977950] also been Section 17.2 Number of Subjects and Sample Size 
Calculation  
Protocol: TRx -237-[ADDRESS_977951] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 136 of 145 Summary of Changes  Affected Sections in Revised Protocol  
(Version 5.0)  
added for the open -label, delayed -start treatment period of 
the study.  
Clarification is provided that the primary efficacy analyses 
for FDA will be based on the E -MITT, MI -MITT, or 
I-MITT population  (depending on endpoint) , and for EMA 
on the ITT population.  The co -primary efficacy endpoints 
and MRI will be analyzed using a linear mixed model for 
repeated measures with unstructured covariance matrix, and 
18F-FDG -PET analyzed using an ANCOVA, with covariates 
for this model adjusted accordingly.  Section 17 Statistical Analysis  
Section 17.4 Clinical Efficacy and Imaging Analysis  
Section 17.4.2 FDA Analysis  
Evaluat ion of  the influence of ApoE genotype (in subjects 
who provide legally acceptable consent) on the primary and 
selected secondary endpoints  is now an exploratory 
endpoint  (previously a secondary endpoint).  Section 9.2 Secondary Objectives  
Section 17.1.2 Secondary Efficacy Endpoints for 
Double -Blind Treatment Period  
Section 17.5 Exploratory Analyses  
 
No interim futility or efficacy analysis is planned in which 
treatment groups will be compared.   Recruitment and 
discontinuations will, however, be continuously monitored 
in a blinded fashion and projections on future dropouts 
calculated .  In addition, a blinded interim analysis to re -
estimate the assumed SD for the change from Baseline to 
Week 52 in the primary endpoints may be carried out at 
some point during the study’s recruitment period.  Section 17.9 Interim Analysis  
Protocol: TRx -237-[ADDRESS_977952] -003558 -17  
Protocol Version 7.0 CONFIDENTIAL  Page 137 of 145 28.4.7  Protocol Version 5.1 
The protocol for Study TRx -237-039 (Version 5.0 dated  9 July 2019 ) has been  revis ed 
primarily to include modifications to the exclusion criterion  regarding hematological 
abnormalit ies (reverting to the original criterion) , clarifications to background information for 
the study drug and the efficacy objectives /statistical analyses , as well as updates to 
responsible personnel .  A summary of the key changes and affected sections is provided 
below.   
 
Additional revisions are editorial and are intended to correct typographical errors  or add 
further clarification.  
 
Summary of Changes  Affected Sections in Revised Protocol  
(Version 5. 1) 
Responsible Personnel  
Charles River Laboratories Edinburgh Lt d has been added 
to responsible personnel for analysis of MT concentrations 
(cross -validation purposes only).  Section [ADDRESS_977953] Enrollment and Withdrawal  
The provision for discussion of potentially exclusionary low 
screening Hgb values with the Medical Monitor  has been 
removed; Hgb values below age/sex appropriate lower limit 
of the central laboratory normal range  are once again 
exclusionary regardless of etiology.  Synopsis  
Section 11.2 Exclusion Criterion #12  
Section 11.3 Re -screening  
Study Drug  
Clarification has been added that the increased incidences of 
pancreatic islet cell adenoma and adenoma or carcinoma 
(combined)  in male rats, reported in a 2-year carcinogenicity 
study performed by [CONTACT_717323], were 
attributed to MTC by [CONTACT_8415] (as interpreted by [CONTACT_717324]).  Section 8.1.2 Nonclinical Data  
Clarification has been added that t he magnitude of 
concentration -dependent treatment effects was reduced when 
LMTM was given to subjects  who were concurrently using 
(rather than prior  use of ) AChEIs and/or memantine.  Section 8.1 .3.3 Efficacy  
Objectives and Endpoints / Statistical Analys es 
To correct a typographical error in the synopsis regarding 
the first secondary endpoint (the compar ison of  the LMTM 
dose of 16  mg/day with the placebo group in annualized 
rate of whole brain atrophy , rather than temporal and 
parietal lobe atrophy ). Synopsis  
 
To clarify the exploratory analysis for c omparison of 
decline in temporal lobe 18F-FDG -PET SUVR with the 
estimated decline  for subjects with  mild AD  (CDR  0.5); 
reference to the MMSE range has been removed.  The 
analyses will be further described and clarified in the SAP.  Section 17.5 Exploratory Analyses  
 
 
 
Protocol: TRx -237-[ADDRESS_977954] -003558 -17  
Protocol Version 7.0 CONFIDENTIAL  Page 138 of 145 28.4.8  Protocol Version 6.0 
The protocol for Study TRx -237-039 (Version 5.1 dated  05 February 2020 ) has been  revis ed 
to incorporate modifications to the study conduct and monitoring , guidance for continued 
data collection  and analysis , and ongoing risk assessment due to the COVID -[ADDRESS_977955] information for responsible personnel , as well as  
modifications and/or clarifications to investigator responsibilities, study assessments, and 
statistical analyses . Reference to a separate plan has been included for additional analyses to 
be undertaken of the blinded  18F-FDG -PET and MRI data for scientific research and quality 
control purposes . A summary of the key changes and affected sections is provided below.   
 
Additional revisions are editorial and are intended to correct typographical errors and 
editorial inconsiste ncies as well as to add clarification.  
 
Summary of Changes  Affected Sections in Revised Protocol  
(Version 6.0) 
Changes  due to COVID -[ADDRESS_977956] -randomization 
Assessments in Double -Blind Treatment Period  
All MRI  scans are to be performed at approved MRI centers 
using approved scanners; no alternative scanners will be 
accepted ; there is to be no change in scanner for a given 
subject over the course of the study . Guidance will be 
provided for scheduled MRI visits at approved imaging 
centers that may be closed due to COVID -19, including 
acceptable windows outside of the scheduled visit window 
during which MRI scans can still be performed and would 
be accepted for analysis.  Synopsis  
Section 10.[ADDRESS_977957]  
Section  15.3.1 General Considerations  
Section [IP_ADDRESS] MRI  
All 18F-FDG -PET scans are to be performed  at approved 
PET centers  using approved  scanners ; there is  to be  no Synopsis  
Section 10.[ADDRESS_977958]  
Protocol: TRx -237-[ADDRESS_977959] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 139 of 145 Summary of Changes  Affected Sections in Revised Protocol  
(Version 6.0) 
change in scanner for a given subject over the course of the 
study.  Section 15.3.[ADDRESS_977960], either simultaneously or as replacements for 
previous study partners, with no specified maximum.  A 
maximum total of two study partner s participating as 
informants  (i.e., one replacement) would normally be  
permitted for a given subject ; however, up to a total of four 
study partners ( i.e., three replacements) are permitted if  
circumstances change due to C OVID -19. Information 
obtained from study partners participating as informants  
will be appropriately identified to distinguish each 
informant in the event that a given subject has more than 
one study partner providing data for analysis.  Synopsis  
Section 10.[ADDRESS_977961]  
Section 10. 5.1 Screening Assessments  
Section 10. 5.1.1 Diagnostic and Cognitive Eligibility 
Assessments  
Section 11.4.2 Handling of Study Discontinuation / 
Withdrawal  
Section 11.4.[ADDRESS_977962] been added describing the Sponsor’s ongoing 
risk assessment regarding the impact of COVID -[ADDRESS_977963]  
Section 10.2. 2 Changes to Study Monitoring  
Section 10.2. 3 Changes to Statistical Analyses  
Section 17.4.11 Sensitivity Analyses  
Section 17.9 Interim Analysis  
Section 18 Regulatory and Ethics  
Section 21.2 COVID -19 Risk Assessment (new)  
Responsible Personnel  
A DSSL 24-hour medical contact  [CONTACT_717325].  Section 4 Responsible Personnel  
Investigator responsibilities include s upervising any 
individual or party to whom the investigator delegates trial -
related duties and functions conducted at the trial site . Section 18.4 Investigator Responsibilities  
Study Population  
The number of randomized subjects has been increase d: a 
sufficient number of subjects will be recruited such that 
approximately 500 subjects are enrolled; beginning with 
Version  5.0, approximately 450 subjects are to be enrolled 
and randomized in a 4:1:4 ratio (at the study level) to the 
LMTM 16 -mg/day, LMTM 8 -mg/day, and placebo groups.   
The inclusion criterion for an MMSE score of 16 -27 
(inclusive) at Screening  will be  subject to stratification 
requirements . Synopsis  
Section 10.1 General Description  
Section 10. 3 Study Population  
Section 11.1 Inclusion Criteria  
Section 12.2 Study Regimens  
Section 12.3 Randomization  
Section 17.2 Number of Subjects and Sample Size 
Calculation  
Protocol: TRx -237-[ADDRESS_977964] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 140 of 145 Summary of Changes  Affected Sections in Revised Protocol  
(Version 6.0) 
Imaging  
If subjects have  an acceptable MRI  scan or PET scan (the 
latter only in subjects who have a screening CDR of 0. 5) 
already completed during the original Screening window, the 
scan does not require repetition . Section 10.2.[ADDRESS_977965]  
Section [IP_ADDRESS]  Diagnostic and Cognitive Eligibility 
Assessments  
Section 11.3 Re -screening  
Section [IP_ADDRESS] 18F-FDG -PET 
Reference is included to a separate plan and data transfer 
agreement that will capture standard procedures for 
additional exploratory analyses  to be  undertaken  to 
characterize  the blinded  18F-FDG -PET and MRI data for 
scientific research and quality control purposes , which are 
separate from the study objectives.   
 
Section  20.2 Imaging Data (new)  
 
Added consistent wording regarding baseline 18F-FDG -PET 
scan in subjects who have a screening CDR of  0.5. Synopsis  
Section  10.1 General Description  
Section [IP_ADDRESS] Imaging Efficacy Assessments in 
Double -Blind Treatment Period  
Section 11.3 Re -screening  
Section 13.1 AChEI and/or Memantine  
Section [IP_ADDRESS] 18F-FDG -PET 
 
Safety  
Permanent discontinuation due to decreased creatinine 
clearance is only required in subjects if renal concerns arise . Section 11.4.[ADDRESS_977966] result from Screening 
assessments (prior to treatment) is to be added to the 
subject’s medical history, unless deemed clinically 
significant by [CONTACT_717262] (MD/DO) in which case 
it will be recorded as an AE.  Section 15.[ADDRESS_977967] -randomization 
Assessments in Double -Blind Treatment Period  
Section [IP_ADDRESS] Other Assessments in Double -Blind 
Treatment Period  
Section 10.5.3 Assessments in the Open -Label, 
Delayed -Start Phase  
Section [IP_ADDRESS] Other Assessments in Open -Label, 
Delayed -Start Phase  
Section 15.5.[ADDRESS_977968] 0.5 at Screening (LMTM 
16 mg/day versus  placebo, and LMTM 8 mg/day versus  
placebo ) will now only be analyzed if a predefined threshold 
is reached for a sufficient number of subjects providing data 
as specified in the SAP . Synopsis  
Section 9.2.1 Double -Blind Treatment Period  
Section 17.1.2 Secondary Efficacy Endpoints for 
Double -Blind Treatment Period  
Protocol: TRx -237-[ADDRESS_977969] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 141 of 145 Summary of Changes  Affected Sections in Revised Protocol  
(Version 6.0) 
Upon completion of the initial 52 -week, double -blind, 
placebo -controlled treatment period, the database will be 
locked and unblinded for analysis, and an interim report will 
be prepared describing the complete efficacy and safety 
analyses of the double -blind phase; individual subject prior 
treatment assi gnment will not be divulged to subjects or 
individuals involved in the operational conduct of the 
ongoing open -label, treatment phase . Section 10.1 General Description  
Section 10.7 Definition of End of Study  
Section 12.8 Breaking the Blind for Double -Blind 
Treatment Period  
Section 17.9 Interim Analysis  
Due to the introduction of MTC spi[INVESTIGATOR_717163] 5.0, the respective MITT populations 
will be restricted to subjects randomized to Protocol 
Versions 5.0 and above for the primary and key secondary 
analyses as per the SAP. The  full MITT populations will be 
analyzed for these as a sensitivity analysis. Details will be 
provided in the SAP.  Section 17.3 Analysis Populations  
Section 17.4 Clinical Efficacy and Imaging Analysis  
It is now indicated that t he SAP will specify estimands to 
provide a more comprehensive assessment of the 
performance and efficacy of the drug accounting for various 
factors  (importantly, drop -outs). Section 17.4.[ADDRESS_977970] ( LOCF ) imputation has 
been removed from  the statistical analyses . Section 17.4.[ADDRESS_977971] 
(LOCF) Imputation  (deleted)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol: TRx -237-[ADDRESS_977972] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 142 of 145 28.4.9  Protocol Version 7.0 
The protocol for Study TRx -237-039 (Version 6.0 dated 09 October 2020) has been revised 
to incorporate changes to responsible personnel; updates to the background information to 
reflect the most current version of the Investigator’s Brochure; clarification  of assessments 
and drug dispensing for Visit 7 of double -blind treatment (also Baseline/Day  1 of open -label 
phase); addition of lens discoloration as an AESI and further instruction regarding timing of 
slit lamp examinations; clarification that MT concent ration sampling will not continue for the 
off-treatment on -study (TOTOS) group; and further description of composite scores and 
endpoints. Additional statistical analysis updates include sensitivity and subgroup analyses, 
and further detail provided for pr imary endpoints, all in response to potential impacts of 
COVID -19; the primary efficacy hypotheses have been clarified ; and the primary estimand  
and five components of interest are now described.   
 
A summary of the key changes and affected sections is provided below.  
 
Additional revisions are editorial and are intended to correct typographical errors and 
editorial inconsistencies as well as to add clarification.  
 
Summary of Changes  Affected Sections in Revised Protocol  
(Version 7.0)  
Signatories / Responsible Personnel  
Modified address for Sponsor Medical Oversight signatory.  Section [ADDRESS_977973] has been changed from DSSL 
to Emergency Scientific and Medical Services Global 
(ESMS Global).  Section 4 Responsible Personnel  
The Central Laboratory has been changed from Covance, 
Inc. to Labcorp Central Laboratory Services (e.g., Labcorp 
Central Laboratory Services LP in the Americas and 
Labcorp Central Laboratory Services S. à r.l in Europe).  Section [ADDRESS_977974]  
Section 10.5.1 Screening Assessments  
Section 15.5.2 Genotypi[INVESTIGATOR_717164], Inc. is now responsible for Statistical 
Analysis of Pharmacokinetic Data rather than the Institute 
for Clinical Pharmacodynamics, with corresponding 
addresses and telephone number added for Certara’s New 
Jersey and Amsterdam locations.    Section [ADDRESS_977975], Inc. continuing to 
be responsible for data management and Cytel Inc. now 
responsible for statistics (corresponding address and 
telephone number added for Cytel Inc.).   Section [ADDRESS_977976] current version of the Investigator’s 
Brochure (Version 23.0), including updates to nonclinical 
and clinical data as well as the study drug terminology. The 
discussion of drugs currently available to treat AD has been 
updated to include the recent FDA accelerated approval of 
Aduhelm (aducanumab).  Synopsis  
Section [ADDRESS_977977]  
Section 8.1.2 Nonclinical Data  
Section [IP_ADDRESS] Pharmacokinetics  
Section [IP_ADDRESS] Efficacy  
Section [IP_ADDRESS] Safety  
Section 8.2 Rationale  
Section 12.1.1 Active Ingredient  
Section 13.2 Drugs with Serotonergic Potential  
Protocol: TRx -237-[ADDRESS_977978] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 143 of 145 Summary of Changes  Affected Sections in Revised Protocol  
(Version 7.0)  
Section 13.3 CYP and P -gp Substrates  
Section 13.6 Dietary Tyramine  
Section 13.8 Folate and Vitamin B 12 
Section 15.5.1 MT Concentration  
Section 17.8 Other Data  
Section 27 References  
Study Visits and Drug Dispensing  
Clarification provided that Visit 7 of the double -blind 
treatment period is also Baseline/Day  [ADDRESS_977979] -randomization 
Assessments in Double -Blind Treatment Period  
Section 10.5.3 Assessments in the Open -Label, 
Delayed -Start Phase  
Section 12.2 Study Regimens  
Section 12.5 Dispensing  
Section 15.2.1 Raters  
Section 17 Statistical Analyses  
Section 17.4.6 Open -Label, Delayed -Start Analysis  
Efficacy  
Composite Scores (and additional Composite Endpoints [if 
any]) derived from the ADAS -cog 13 and the ADCS -ADL 23 
will be defined in the SAP prior to sign off and database 
lock/unblinding, with at least one designed to be sensitive to 
early stages of the disease as well as one that is less/not 
impacted by [CONTACT_4113] -19. Synopsis  
Section 15.2.2 Instruments  
Section [IP_ADDRESS] Composite Scale (s) 
Section 17.[ADDRESS_977980] dose of study drug (Screening/Baseline), at 
Visit 7, and at Visit 10/early termination to check for lens 
discoloration. In addition, this examination is now to be 
performed if subjects have cataract surgery/lens 
implantation at any point during study participation  (as soon 
as possible after the surgery), as well as in response to 
visual complaints if suggestive of lens discoloration . Synopsis  
Section 15.4 Safety Assessments and Procedures  
Section 16.11.2 Lens Discoloration  
A new section added  for lens discoloration, which is now a 
pre-specified AESI (in addition to hemolytic anemia). If a 
lens discoloration is identified by [CONTACT_283705], it 
is to be recorded as an AESI in the AE eCRF; however , no 
specific action is required for study drug.  Lens discoloration 
has been  removed from the list of examples of SAEs that 
are not life -threatening, as it should be reported as an AESI 
unless SAE reporting criteria are later met . Section 16.[ADDRESS_977981] 
Abnormalities  
Section 16.11.2 Lens Discoloration  
Clarification that adverse events of malignancies other than 
non-melanoma  skin cancers are to be reported to Syneos 
Health (regardless of causality or whether they meet the 
criteria for serious).  Section 16.[ADDRESS_977982] has 
discontinued study drug but continues to attend study visits 
off-treatment (the TOTOS group), blood samples will not 
continue to be collected for measurement of MT 
concentrations.  Synopsis  
Section 10.5.[ADDRESS_977983] -randomization 
Assessments in Double -Blind Treatment Period  
Section 10.5.3 Assessments in the Open -Label, 
Delayed -Start Phase  
Section 11.4.1 Handling of Subjects Who Discontinue 
Study Drug  
Protocol: TRx -237-[ADDRESS_977984] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 144 of 145 Summary of Changes  Affected Sections in Revised Protocol  
(Version 7.0)  
Section 15.5.1 MT Concentration  
Statistical Analyses  
Further detail provided that if >5% of all assessments (over 
all subjects and visits) of a given primary endpoint are 
impacted by [CONTACT_4113] -19 (based on the eCRF COVID -[ADDRESS_977985] Assessment), the impacted assessment will be 
excluded and upscaled when the respective primary 
endpoint is analyzed.  Section 10.2. 3 Changes to Statistical Analyses  
Other sensitivity analyses were added and include:  
subgroup analysis of endpoint ascertainment (in -clinic, 
remote) with subjects assigned to the subgroup with most 
visits done, excluding (in -clinic) Baseline and Week 52 
visits; analysis of ADAS -cog 11 to include only subset of 
items (for all visits) which are administered remotely by 
[CONTACT_165164]; analysis of ADCS -ADL 23 to 
exclude items affected by [CONTACT_4113] -19 restrictions; and 
analysis of composite scale designed as COVID -[ADDRESS_977986] requiring both co -primary endpoints to meet statistical 
significance at the 5% two -sided level of significance for 
the global null hypothesis to be rejected.   Section 17.4.1 Hypothesis  
For the ITT (EMA) analysis, no data will be imputed, 
unless specified in selected sensitivity/exploratory 
endpoints.    Section 17.4.3 ITT (EMA) Analysis  
The Estimands section has been expanded, with the primary 
estimand  now defined and constructed in line with ICH E9 
(R1) addendum. The five components for the estimand of 
interest are as follows:  treatment, population, patient -level 
outcomes/variables, population -level summary, and 
intercurrent events (ICE).   Section 17.4.4 Estimands  
 
  
Protocol: TRx -237-[ADDRESS_977987] -003558 -17  
Protocol Version 7.1 CONFIDENTIAL  Page 145 of 145 28.4.10  Protocol Version 7.1 
 
Summary of Changes  Affected Sections in Revised Protocol  
(Version 7.1)  
Signatories / Responsible Personnel  
The Global Project Manager has been changed to Marta 
Medina, with corresponding telephone numbers and email 
address added.  Section 4 Responsible Personnel  
Bjoern Schelter job title has been updated from Data 
analytics and Biostatistic lead to Chief Analytics Officer  Section 3 Protocol Approval  
Vendor Bioclinica removed for Magnetic Resonance 
Imaging (MRI ); suitably qualified vendor added  Section 4 Responsible Personnel  
Study Design  
Removed sentence - an interim report will be prepared 
describing the complete efficacy and safety analyses of the 
double blind phase.  Section 10.1 General Description  
Study Assessments  
Aberdeen Biomedical Imaging centre  removed as vendor. 
Removed sentence any further processing by [CONTACT_717326] a separate report.  Section [IP_ADDRESS] 18F-FDG -PET 
Section [IP_ADDRESS] MRI  
 